0001818382-22-000180.txt : 20221110 0001818382-22-000180.hdr.sgml : 20221110 20221110085604 ACCESSION NUMBER: 0001818382-22-000180 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Humacyte, Inc. CENTRAL INDEX KEY: 0001818382 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851763759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39532 FILM NUMBER: 221375190 BUSINESS ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-313-9633 MAIL ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200716 10-Q 1 huma-20220930.htm 10-Q huma-20220930
000181838212-312022Q3FALSE00018183822022-01-012022-09-300001818382us-gaap:CommonStockMember2022-01-012022-09-300001818382huma:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150Member2022-01-012022-09-3000018183822022-11-04xbrli:shares00018183822022-09-30iso4217:USD00018183822021-12-31iso4217:USDxbrli:shares00018183822022-07-012022-09-3000018183822021-07-012021-09-3000018183822021-01-012021-09-300001818382us-gaap:CommonStockMember2021-12-310001818382us-gaap:AdditionalPaidInCapitalMember2021-12-310001818382us-gaap:RetainedEarningsMember2021-12-310001818382us-gaap:CommonStockMember2022-01-012022-03-310001818382us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100018183822022-01-012022-03-310001818382us-gaap:RetainedEarningsMember2022-01-012022-03-3100018183822022-03-310001818382us-gaap:CommonStockMember2022-03-310001818382us-gaap:AdditionalPaidInCapitalMember2022-03-310001818382us-gaap:RetainedEarningsMember2022-03-310001818382us-gaap:CommonStockMember2022-04-012022-06-300001818382us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000018183822022-04-012022-06-300001818382us-gaap:RetainedEarningsMember2022-04-012022-06-3000018183822022-06-300001818382us-gaap:CommonStockMember2022-06-300001818382us-gaap:AdditionalPaidInCapitalMember2022-06-300001818382us-gaap:RetainedEarningsMember2022-06-300001818382us-gaap:CommonStockMember2022-07-012022-09-300001818382us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001818382us-gaap:RetainedEarningsMember2022-07-012022-09-300001818382us-gaap:CommonStockMember2022-09-300001818382us-gaap:AdditionalPaidInCapitalMember2022-09-300001818382us-gaap:RetainedEarningsMember2022-09-3000018183822020-12-310001818382us-gaap:CommonStockMember2020-12-310001818382us-gaap:AdditionalPaidInCapitalMember2020-12-310001818382us-gaap:RetainedEarningsMember2020-12-310001818382us-gaap:CommonStockMember2021-01-012021-03-310001818382us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100018183822021-01-012021-03-310001818382us-gaap:RetainedEarningsMember2021-01-012021-03-3100018183822021-03-310001818382us-gaap:CommonStockMember2021-03-310001818382us-gaap:AdditionalPaidInCapitalMember2021-03-310001818382us-gaap:RetainedEarningsMember2021-03-310001818382us-gaap:CommonStockMember2021-04-012021-06-300001818382us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000018183822021-04-012021-06-300001818382us-gaap:RetainedEarningsMember2021-04-012021-06-3000018183822021-06-300001818382us-gaap:CommonStockMember2021-06-300001818382us-gaap:AdditionalPaidInCapitalMember2021-06-300001818382us-gaap:RetainedEarningsMember2021-06-300001818382us-gaap:CommonStockMember2021-07-012021-09-300001818382us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001818382us-gaap:RetainedEarningsMember2021-07-012021-09-3000018183822021-09-300001818382us-gaap:CommonStockMember2021-09-300001818382us-gaap:AdditionalPaidInCapitalMember2021-09-300001818382us-gaap:RetainedEarningsMember2021-09-30huma:segment0001818382us-gaap:CashAndCashEquivalentsMember2021-12-310001818382us-gaap:CashAndCashEquivalentsMember2022-09-300001818382us-gaap:ShortTermInvestmentsMember2021-12-310001818382us-gaap:ShortTermInvestmentsMember2022-09-300001818382us-gaap:GovernmentContractsConcentrationRiskMemberhuma:RevenueFromGrantsMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-30xbrli:pure0001818382us-gaap:GovernmentContractsConcentrationRiskMemberhuma:RevenueFromGrantsMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001818382us-gaap:GovernmentContractsConcentrationRiskMemberhuma:RevenueFromGrantsMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300001818382us-gaap:GovernmentContractsConcentrationRiskMemberhuma:RevenueFromGrantsMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300001818382huma:RevenueFromGrantsMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-09-300001818382huma:RevenueFromGrantsMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001818382us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001818382us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001818382us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001818382us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001818382us-gaap:WarrantMember2022-07-012022-09-300001818382us-gaap:WarrantMember2022-01-012022-09-300001818382us-gaap:WarrantMember2021-01-012021-09-300001818382us-gaap:WarrantMember2021-07-012021-09-3000018183822021-08-260001818382huma:AHACFoundersMember2021-08-262021-08-260001818382huma:EarnoutSharesMember2021-08-26huma:tranche0001818382huma:ContingentConsiderationTrancheOneMemberhuma:EarnoutSharesMember2021-08-260001818382huma:ContingentConsiderationTrancheTwoMemberhuma:EarnoutSharesMember2021-08-260001818382huma:EarnoutSharesMember2021-08-262021-08-260001818382us-gaap:PrivatePlacementMember2021-08-262021-08-260001818382us-gaap:PrivatePlacementMember2021-08-260001818382huma:AHACMember2021-08-250001818382huma:AHACMember2021-08-262021-08-260001818382huma:CommonShareholdersMember2021-08-262021-08-2600018183822021-08-262021-08-260001818382huma:AHACMember2021-08-260001818382us-gaap:AccruedLiabilitiesMember2021-01-012021-12-310001818382us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001818382us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001818382us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001818382us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001818382us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-09-300001818382us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-09-300001818382us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-09-300001818382us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-09-300001818382us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001818382us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001818382us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001818382us-gaap:FairValueMeasurementsRecurringMember2022-09-300001818382us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001818382us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001818382us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001818382us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001818382us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001818382us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001818382us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001818382us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001818382us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001818382us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001818382us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001818382us-gaap:FairValueMeasurementsRecurringMember2021-12-310001818382huma:ContingentEarnoutLiabilityMember2022-06-300001818382huma:ContingentEarnoutLiabilityMember2021-06-300001818382huma:ContingentEarnoutLiabilityMember2021-12-310001818382huma:ContingentEarnoutLiabilityMember2020-12-310001818382huma:ContingentEarnoutLiabilityMember2022-07-012022-09-300001818382huma:ContingentEarnoutLiabilityMember2021-07-012021-09-300001818382huma:ContingentEarnoutLiabilityMember2022-01-012022-09-300001818382huma:ContingentEarnoutLiabilityMember2021-01-012021-09-300001818382huma:ContingentEarnoutLiabilityMember2022-09-300001818382huma:ContingentEarnoutLiabilityMember2021-09-300001818382huma:PrivatePlacementWarrantsMember2022-06-300001818382huma:PrivatePlacementWarrantsMember2021-06-300001818382huma:PrivatePlacementWarrantsMember2021-12-310001818382huma:PrivatePlacementWarrantsMember2020-12-310001818382huma:PrivatePlacementWarrantsMember2022-07-012022-09-300001818382huma:PrivatePlacementWarrantsMember2021-07-012021-09-300001818382huma:PrivatePlacementWarrantsMember2022-01-012022-09-300001818382huma:PrivatePlacementWarrantsMember2021-01-012021-09-300001818382huma:PrivatePlacementWarrantsMember2022-09-300001818382huma:PrivatePlacementWarrantsMember2021-09-300001818382huma:ContingentEarnoutLiabilityMemberus-gaap:MeasurementInputExpectedTermMember2022-09-30utr:Y0001818382huma:ScientificEquipmentMember2022-09-300001818382huma:ScientificEquipmentMember2021-12-310001818382us-gaap:ComputerEquipmentMember2022-09-300001818382us-gaap:ComputerEquipmentMember2021-12-310001818382us-gaap:SoftwareDevelopmentMember2022-09-300001818382us-gaap:SoftwareDevelopmentMember2021-12-310001818382us-gaap:FurnitureAndFixturesMember2022-09-300001818382us-gaap:FurnitureAndFixturesMember2021-12-310001818382us-gaap:LeaseholdImprovementsMember2022-09-300001818382us-gaap:LeaseholdImprovementsMember2021-12-310001818382us-gaap:ConstructionInProgressMember2022-09-300001818382us-gaap:ConstructionInProgressMember2021-12-310001818382huma:ScientificEquipmentNotPlacedIntoServiceMember2021-12-310001818382huma:TermLoanAgreementMemberhuma:SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember2021-03-300001818382huma:TermLoanAgreementMemberhuma:SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember2022-01-012022-09-300001818382huma:TermLoanAgreementMember2021-03-312021-03-310001818382huma:TermLoanAgreementMember2021-10-132021-10-130001818382huma:TermLoanAgreementMember2022-09-300001818382huma:TermLoanAgreementMemberus-gaap:PrimeRateMember2022-01-012022-09-300001818382huma:TermLoanAgreementMemberus-gaap:PrimeRateMember2022-09-300001818382huma:TermLoanAgreementMember2022-01-012022-09-300001818382huma:TermLoanAgreementMemberhuma:DebtInstrumentPrepaymentFeePeriodOneMember2022-01-012022-09-300001818382huma:TermLoanAgreementMemberhuma:DebtInstrumentPrepaymentFeePeriodTwoMember2022-01-012022-09-300001818382huma:TermLoanAgreementMemberhuma:DebtInstrumentPrepaymentFeePeriodThreeMember2022-01-012022-09-300001818382huma:TermLoanAgreementMemberus-gaap:WarrantMember2021-03-300001818382huma:TermLoanAgreementMemberus-gaap:WarrantMember2021-10-130001818382huma:SVBLoanPayableMember2022-09-300001818382huma:PaycheckProtectionProgramMember2020-04-302020-04-300001818382huma:PaycheckProtectionProgramMember2021-04-012021-06-300001818382us-gaap:CommonStockMember2021-08-262021-08-26huma:Vote0001818382huma:CommonStockReservedForContingentConsiderationSharesMember2022-09-300001818382us-gaap:EmployeeStockOptionMember2022-09-300001818382huma:IssuanceOfOptionsUnderStockPlanMember2022-09-300001818382huma:SharesAvailableForGrantUnderESPPMember2022-09-300001818382us-gaap:WarrantMember2022-09-300001818382huma:HumacyteIncMember2022-09-300001818382huma:HumacyteIncMember2021-12-310001818382huma:PrivatePlacementWarrantsMember2022-09-300001818382huma:PrivatePlacementWarrantsMember2021-12-310001818382huma:PublicWarrantsMember2022-09-300001818382huma:PublicWarrantsMember2021-12-310001818382huma:MergerAgreementMemberhuma:AssumptionOfPubliclyTradedSecuritiesMemberus-gaap:WarrantMemberhuma:PublicWarrantsMember2021-08-262021-08-260001818382us-gaap:PrivatePlacementMemberhuma:MergerAgreementMemberus-gaap:WarrantMemberhuma:PrivatePlacementWarrantsMember2021-08-262021-08-260001818382huma:PublicWarrantsMember2021-08-260001818382huma:PublicWarrantsMember2021-08-262021-08-260001818382huma:PrivatePlacementWarrantsMember2021-08-260001818382huma:PrivatePlacementWarrantsMember2022-07-012022-09-300001818382huma:PrivatePlacementWarrantsMember2022-01-012022-09-300001818382huma:PrivatePlacementWarrantsMember2021-01-012021-09-300001818382huma:PrivatePlacementWarrantsMember2021-07-012021-09-300001818382huma:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputSharePriceMember2022-09-300001818382huma:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-12-310001818382huma:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2022-09-300001818382huma:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2021-12-310001818382huma:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-09-300001818382huma:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001818382us-gaap:MeasurementInputPriceVolatilityMemberhuma:PrivatePlacementWarrantsMember2022-09-300001818382us-gaap:MeasurementInputPriceVolatilityMemberhuma:PrivatePlacementWarrantsMember2021-12-310001818382us-gaap:MeasurementInputRiskFreeInterestRateMemberhuma:PrivatePlacementWarrantsMember2022-09-300001818382us-gaap:MeasurementInputRiskFreeInterestRateMemberhuma:PrivatePlacementWarrantsMember2021-12-310001818382us-gaap:MeasurementInputExpectedDividendRateMemberhuma:PrivatePlacementWarrantsMember2022-09-300001818382us-gaap:MeasurementInputExpectedDividendRateMemberhuma:PrivatePlacementWarrantsMember2021-12-310001818382huma:EarnoutSharesMemberus-gaap:MeasurementInputExpectedTermMember2021-08-260001818382us-gaap:MeasurementInputSharePriceMember2022-09-300001818382us-gaap:MeasurementInputSharePriceMember2021-12-310001818382us-gaap:MeasurementInputPriceVolatilityMember2022-09-300001818382us-gaap:MeasurementInputPriceVolatilityMember2021-12-310001818382us-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001818382us-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001818382us-gaap:MeasurementInputExpectedDividendRateMember2022-09-300001818382us-gaap:MeasurementInputExpectedDividendRateMember2021-12-310001818382us-gaap:MeasurementInputExpectedTermMember2022-09-300001818382us-gaap:MeasurementInputExpectedTermMember2021-12-310001818382huma:LongTermIncentivePlan2021Member2022-09-300001818382us-gaap:EmployeeStockMember2022-09-300001818382huma:LongTermIncentivePlan2021Member2022-01-012022-09-300001818382us-gaap:EmployeeStockMember2022-01-012022-09-3000018183822021-08-252021-08-25huma:plan0001818382huma:OmnibusIncentivePlan2015Member2022-09-300001818382huma:StockOptionPlan2005Member2022-09-300001818382us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001818382us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-09-300001818382srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001818382us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001818382us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001818382us-gaap:EmployeeStockOptionMemberhuma:LongTermIncentivePlan2021Member2022-09-300001818382us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001818382us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001818382us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001818382us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001818382us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001818382us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001818382us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001818382us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-3000018183822021-01-012021-12-310001818382huma:DecellularizedTissueEngineeringPatentRightsMemberhuma:LicenseAgreementMemberhuma:DukeUniversityMember2022-01-012022-09-300001818382huma:SmallDiameterVesselsPatentRightsMemberhuma:LicenseAgreementMemberhuma:YaleUniversityMember2014-02-012014-02-280001818382huma:LicenseAgreementMemberhuma:YaleUniversityMemberhuma:BVPPatentRightsMember2019-08-012019-08-310001818382huma:LicenseAgreementMemberhuma:YaleUniversityMemberhuma:TubularProsthesesPatentRightsMember2019-08-012019-08-310001818382huma:LicenseAgreementMemberhuma:YaleUniversityMember2022-01-012022-09-300001818382huma:RegulatoryMilestoneMemberhuma:LicenseAgreementMemberhuma:YaleUniversityMember2022-01-012022-09-300001818382huma:LicenseAgreementMemberhuma:YaleUniversityMemberhuma:CommercialMilestoneMember2022-01-012022-09-300001818382huma:FreseniusMedicalCareMember2018-06-012018-06-300001818382huma:FreseniusMedicalCareMember2021-08-262021-08-260001818382huma:FreseniusMedicalCareMember2021-08-012021-08-310001818382huma:FreseniusMedicalCareMember2021-08-310001818382huma:FreseniusMedicalCareMember2021-02-162021-02-160001818382huma:LicenseExpensesMember2022-07-012022-09-300001818382huma:LicenseExpensesMember2021-07-012021-09-300001818382huma:LicenseExpensesMember2022-01-012022-09-300001818382huma:LicenseExpensesMember2021-01-012021-09-300001818382huma:OtherRelatedPartyExpensesMember2022-07-012022-09-300001818382huma:OtherRelatedPartyExpensesMember2021-07-012021-09-300001818382huma:OtherRelatedPartyExpensesMember2022-01-012022-09-300001818382huma:OtherRelatedPartyExpensesMember2021-01-012021-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________________________________________________________________________________________
FORM 10-Q
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______.
Commission File Number: 001-39532
___________________________________________________________________________________________________
Humacyte, Inc.
(Exact name of registrant as specified in its charter)
___________________________________________________________________________________________________
Delaware
85-1763759
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)
2525 East North Carolina Highway 54
Durham, NC27713
(Address of principal executive offices)(Zip code)
(919) 313-9633
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
___________________________________________________________________________________________________
Securities registered pursuant to 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareHUMAThe Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50HUMAWThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of November 4, 2022, 103,118,461 shares of common stock, par value $0.0001, were issued and outstanding.


Humacyte, Inc.
Quarterly Report on Form 10-Q
Table of Contents
Page No.
2

FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) are statements that are not historical facts and involve a number of risks and uncertainties. These statements include, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used therein, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, our management.
Forward-looking statements may include, for example, statements about:
our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines;
our plans and ability to obtain marketing approval from the U.S. Food and Drug Administration (“FDA”) and other regulatory authorities, including the European Medicines Agency, for our bioengineered human acellular vessels (“HAVs”) and other product candidates;
our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials, including for our ongoing V005 Phase II/III clinical trial and V007 Phase III clinical trial;
the outcome of our ongoing discussions with the FDA concerning the design of our ongoing V005 Phase II/III clinical trial, including determination of trial size, and the scope of any approved indication for our HAVs;
our anticipated growth rate and market opportunities;
the potential liquidity and trading of our securities;
our ability to raise additional capital in the future;
our ability to use our proprietary scientific technology platform to build a pipeline of additional product candidates;
the characteristics and performance of our HAVs;
our plans and ability to commercialize our HAVs and other product candidates, if approved by regulatory authorities;
the expected size of the target populations for our product candidates;
the anticipated benefits of our HAVs relative to existing alternatives;
our assessment of the competitive landscape;
the degree of market acceptance of HAVs, if approved, and the availability of third-party coverage and reimbursement;
our ability to manufacture HAVs and other product candidates in sufficient quantities to satisfy our clinical trial and commercial needs;
our expectations regarding our strategic partnership with Fresenius Medical Care Holdings, Inc. (“Fresenius Medical Care”) to sell, market and distribute our 6 millimeter HAV for certain specified indications and in specified markets;
the performance of other third parties on which we rely, including our third-party manufacturers, our licensors, our suppliers and the organizations conducting our clinical trials;
our ability to obtain and maintain intellectual property protection for our product candidates as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others;
3

our ability to maintain the confidentiality of our trade secrets, particularly with respect to our manufacturing process;
our compliance with applicable laws and regulatory requirements, including FDA regulations, healthcare laws and regulations, and anti-corruption laws;
our ability to attract, retain and motivate qualified personnel and to manage our growth effectively;
our future financial performance and capital requirements;
our ability to implement and maintain effective internal controls;
the impact of the COVID-19 pandemic on our business, including our manufacturing efforts, and our preclinical studies and clinical trials; and
the impact of the overall global economy and increasing interest rates and inflation on our business.
We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Quarterly Report and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (the “SEC”), including, but not limited to, those described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in this Quarterly Report and our Annual Report on Form 10-K for the year ended December 31, 2021, which we filed with the SEC on March 29, 2022. We disclaim any obligation, except as specifically required by law, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
4

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
Humacyte, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands except for share and per share amounts)
September 30,
2022
December 31,
2021
ASSETS
Current assets
Cash and cash equivalents$163,731 $217,502 
Short-term investments8,000 8,000 
Accounts receivable31 176 
Prepaid expenses and other current assets2,850 3,662 
Total current assets174,612 229,340 
Finance lease right-of-use assets, net19,888 21,432 
Operating lease right-of-use assets, net693 727 
Property and equipment, net31,026 35,034 
Total assets$226,219 $286,533 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable$3,255 $2,094 
Accrued expenses7,959 6,757 
SVB loan payable, current portion4,286  
Finance lease obligation, current portion2,185 1,981 
Deferred payroll tax173 173 
Operating lease obligation, current portion48 45 
Total current liabilities17,906 11,050 
Contingent Earnout Liability45,011 103,660 
SVB loan payable, net of current portion24,286 27,361 
Finance lease obligation, net of current portion19,442 21,109 
Operating lease obligation, net of current portion645 682 
Common stock warrant liabilities257 497 
Total liabilities107,547 164,359 
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $0.0001 par value; 20,000,000 shares designated as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021
  
Common stock, $0.0001 par value; 250,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 103,098,768 and 103,003,646 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively
10 10 
Additional paid-in capital541,480 536,737 
Accumulated deficit(422,818)(414,573)
Total stockholders' equity118,672 122,174 
Total liabilities and stockholders’ equity$226,219 $286,533 
The accompanying notes are an integral part of these financial statements.
5

Humacyte, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands except for share and per share amounts)
For the
 Three Months Ended September 30,
For the
 Nine Months Ended September 30,
2022202120222021
Grant revenue$31 $241 $1,565 $1,086 
Operating expenses:
Research and development17,337 15,386 48,303 45,091 
General and administrative6,188 5,398 17,050 15,576 
Total operating expenses23,525 20,784 65,353 60,667 
Loss from operations(23,494)(20,543)(63,788)(59,581)
Other income (expense), net:
Interest income883 3 1,215 6 
Change in fair value of Contingent Earnout Liability(962)(9,768)58,649 (9,768)
Change in fair value of common stock warrant liabilities(67)(2)240 (2)
Gain on PPP loan forgiveness   3,284 
Interest expense(1,641)(1,204)(4,561)(2,952)
Transaction costs expensed (49) (49)
Total other income (expense), net(1,787)(11,020)55,543 (9,481)
Net loss and comprehensive loss$(25,281)$(31,563)$(8,245)$(69,062)
Net loss per share attributable to common stockholders, basic and diluted$(0.25)$(0.72)$(0.08)$(3.69)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted103,031,980 43,950,856 103,014,009 18,728,471 
The accompanying notes are an integral part of these financial statements.
6

Humacyte, Inc.
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(unaudited)
(in thousands except for share amounts)

Redeemable Convertible
Preferred Stock
Common StockAdditional
Paid-in Capital
Accumulated
Deficit
Total Stockholders'
Equity
Shares  Amount  Shares  Amount
Balance as of December 31, 2021
 $ 103,003,646 $10 $536,737 $(414,573)$122,174 
Proceeds from the exercise of stock options— — 926 — 1 — 1 
Stock-based compensation— — — — 1,547 — 1,547 
Net loss— — — — — (19,832)(19,832)
Balance as of March 31, 2022 $ 103,004,572 $10 $538,285 $(434,405)$103,890 
Proceeds from the exercise of stock options— — 2,231 — 11 — 11 
Stock-based compensation— — — — 1,491 — 1,491 
Net income— — — — — 36,868 36,868 
Balance as of June 30, 2022 $ 103,006,803 $10 $539,787 $(397,537)$142,260 
Proceeds from the exercise of stock options— — 91,965 — 217 — 217 
Stock-based compensation— — — — 1,476 — 1,476 
Net loss— — — — — (25,281)(25,281)
Balance as of September 30, 2022
 $ 103,098,768 $10 $541,480 $(422,818)$118,672 

7

Humacyte, Inc.
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) - (continued)
(unaudited)
(in thousands except for share amounts)

Redeemable Convertible
Preferred Stock
Common StockAdditional
Paid-in Capital
Accumulated
Deficit
Total Stockholders'
(Deficit) Equity
SharesAmount Shares Amount
Balance as of December 31, 202069,613,562 $420,989 5,822,396 $1 $37,778 $(388,096)$(350,317)
Proceeds from the exercise of stock options— — 116,149 — 206 — 206 
Stock-based compensation— — — — 2,528 — 2,528 
Issuance of warrants in conjunction with debt— — — — 2,360 — 2,360 
Net loss— — — — — (20,301)(20,301)
Balance as of March 31, 202169,613,562 $420,989 5,938,545 $1 $42,872 $(408,397)$(365,524)
Proceeds from the exercise of stock options— — 5,204 — 30 — 30 
Stock-based compensation— — — — 2,930 — 2,930 
Net loss— — — — — (17,198)(17,198)
Balance as of June 30, 202169,613,562 $420,989 5,943,749 $1 $45,832 $(425,595)$(379,762)
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing(69,613,562)(420,989)69,613,562 7 420,982 — 420,989 
The Merger and related PIPE financing, net of transaction costs and acquired liabilities— — 27,346,449 2 209,478 — 209,480 
Public warrants assumed upon the Merger, net of transaction costs— — — — 13,912 — 13,912 
Contingent Earnout Liability recognized upon closing of the reverse recapitalization— — — — (159,432)— (159,432)
Proceeds from the exercise of stock options— — 99,624 — 360 — 360 
Stock-based compensation— — — — 1,877 — 1,877 
Net loss— — — — — (31,563)(31,563)
Balance as of September 30, 2021 $ 103,003,384 $10 $533,009 $(457,158)$75,861 

The accompanying notes are an integral part of these financial statements.
8

Humacyte, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
For the
Nine Months Ended September 30, 2022,
20222021
Cash flows from operating activities
Net loss$(8,245)$(69,062)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense4,552 4,650 
Stock-based compensation expense4,514 7,335 
Change in fair value of Contingent Earnout Liability(58,649)9,768 
Change in fair value of common stock warrant liabilities(240)2 
Amortization expense1,544 1,545 
Non-cash operating lease costs34 31 
Amortization of SVB debt discount1,211 628 
Accrued interest on PPP loan obligation 11 
Gain on PPP loan forgiveness (3,284)
Payment of liabilities assumed in Merger (12,363)
Changes in operating assets and liabilities:
Accounts receivable145 (127)
Prepaid expenses and other current assets812 (2,002)
Accounts payable984 757 
Accrued expenses1,202 2,401 
Operating lease obligation(34)(32)
Net cash used in operating activities(52,170)(59,742)
Cash flows from investing activities
Purchase of short-term investments (certificates of deposit)(8,000) 
Proceeds from maturity of short-term investments (certificates of deposit)8,000  
Purchase of property and equipment(367)(175)
Net cash used in investing activities(367)(175)
Cash flows from financing activities
Proceeds from the exercise of stock options 229 596 
Payment of finance lease principal (1,463)(1,277)
Proceeds from Merger and PIPE financing, net of offering costs paid  242,400 
Payment of transaction costs related to Merger  (941)
Proceeds from SVB loan  19,659 
Payment of deferred offering costs  
Net cash (used in) provided by financing activities (1,234)260,437 
Net (decrease) increase in cash and cash equivalents (53,771)200,520 
Cash and cash equivalents at the beginning of the period 217,502 39,929 
Cash and cash equivalents at the end of the period $163,731 $240,449 
Supplemental disclosure
Cash paid for interest on SVB loan $1,867 $642 
Supplemental disclosure of noncash activities:
Purchase of property and equipment in accounts payable$198 $ 
Issuance of warrants in conjunction with debt$ $2,360 
Unpaid liabilities assumed in connection with Merger$ $2,228 
Unpaid transaction costs in connection with Merger$ $3,004 
Conversion of redeemable convertible preferred stock into common stock in connection with the reverse capitalization$ $420,989 
Contingent Consideration Liability recognized upon the closing of the reverse recapitalization$ $159,432 
The accompanying notes are an integral part of these financial statements.
9

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

1. Organization and Description of Business
Organization
Humacyte, Inc. and subsidiary (the “Company”) is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company is leveraging its technology platform to develop proprietary product candidates for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
On August 26, 2021 (the Closing Date), Alpha Healthcare Acquisition Corp. (AHAC) consummated a merger pursuant to a Business Combination Agreement, dated as of February 17, 2021 (the “Merger Agreement”), by and among Humacyte, Inc., a Delaware Corporation (“Legacy Humacyte”), AHAC and Hunter Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly owned subsidiary of AHAC. As contemplated by the Merger Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte continuing as the surviving corporation and as a wholly owned subsidiary of AHAC (such transactions, the “Merger,” and, collectively with the other transactions described in the Merger Agreement, the “Reverse Recapitalization”). On the Closing Date, AHAC changed its name to Humacyte, Inc. (“New Humacyte”) and Legacy Humacyte changed its name to Humacyte Global, Inc. The Merger is accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and under this method of accounting, AHAC is treated as the acquired company for financial reporting purposes and Legacy Humacyte is treated as the acquirer. Operations prior to the Merger are those of Legacy Humacyte.
Refer to Note 3 — Reverse Recapitalization for further details of the Merger.
Liquidity and Going Concern
Since its inception in 2004, the Company has generated no product revenue and has incurred operating losses and negative cash flows from operations in each year. To date, the Company has financed its operations primarily through the sale of equity securities and convertible debt, proceeds from the Reverse Recapitalization, borrowings under loan facilities and, to a lesser extent, through governmental and other grants. At September 30, 2022 and December 31, 2021, the Company had an accumulated deficit of $422.8 million and $414.6 million, respectively. The Companys operating losses were $63.8 million and $59.6 million for the nine months ended September 30, 2022 and 2021, respectively. Net cash flows used in operating activities were $52.2 million and $59.7 million during the nine months ended September 30, 2022 and 2021, respectively. Substantially all of the Companys operating losses resulted from costs incurred in connection with the Companys research and development programs and from general and administrative costs associated with the Companys operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates.
As of September 30, 2022, the Company had cash and cash equivalents and short-term investments of $171.7 million. The Company believes its combined cash and cash equivalents and short-term investments on hand will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, for at least 12 months from the issuance date of these interim financial statements.
10

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Impact of COVID-19
The COVID-19 pandemic has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in-place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on the Companys business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Companys business and operations are uncertain. The COVID-19 pandemic may affect the Companys ability to initiate and complete preclinical studies, delay its clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on its business and operations. The pandemic has already caused significant disruptions in the financial markets and may continue to cause such disruptions, which could impact the Companys ability to raise additional funds to support its operations. Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Companys business and operations.
To date, there have been no material financial impacts or impairment losses in the carrying values of the Companys assets as a result of the pandemic and the Company is not aware of any specific related event or circumstance that would require it to revise the estimates reflected in these financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact the Companys business, results of operations and financial condition, including current and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, the emergence of new virus variants, and the duration and intensity of the related economic impact of the pandemic.
2. Summary of Significant Accounting Policies
Basis of Presentation
The Company has prepared the accompanying financial statements in conformity with U.S. GAAP. The Companys condensed consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement. Operations prior to the Merger are those of Legacy Humacyte.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in the financial statements include stock-based compensation costs, right-of-use assets, accruals for research and development activities, contingent earnout liability, fair value of common stock warrants, redeemable convertible preferred stock and income taxes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
Unaudited Interim Condensed Consolidated Financial Statements
The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements and, in managements opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Companys financial position as of September 30, 2022 and its results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or any other period. The December 31, 2021 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.
11

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 and the related notes included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022 (the “Annual Report”), which provides a more complete discussion of the Company’s accounting policies and certain other information. There have been no significant changes to the significant accounting policies disclosed in Note 2 of the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in the Companys Annual Report.
Segments
The Company operates and manages its business as one reportable and operating segment. The Company is developing proprietary, bioengineered, acellular human tissues, advanced tissue constructs and organ systems that are designed to be used in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The Companys chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments consisting of certificates of deposit (“CDs”). Total cash balances exceeded insured balances by the Federal Deposit Insurance Corporation (“FDIC”) as of September 30, 2022 and December 31, 2021. The Company has cash equivalents that are invested in highly rated money market funds that are invested only in obligations of the U.S. government and its agencies.
As of both September 30, 2022 and December 31, 2021, the Company had approximately $10.0 million in CDs. These cash deposits are deposited at a bank that is a member of the Certificate of Deposit Account Registry Service (“CDARS”), in which large deposits are divided into smaller amounts and placed with other FDIC insured banks which are also members of the CDARS network. Those members issue CDs in amounts under $250,000, so that the entire deposit balance is eligible for FDIC insurance. As of both September 30, 2022 and December 31, 2021, the Company classified $2.0 million of its certificates of deposit as cash and cash equivalents and $8.0 million of its certificates of deposit as short-term investments on its condensed consolidated balance sheets.
During the three and nine months ended September 30, 2022 and 2021, 100% of the Company’s total revenue relates to an award it received from the Department of Defense (“DoD”) in August 2017. As of September 30, 2022 and December 31, 2021, 100% of the Company’s accounts receivable relates to the DoD grant.
Net Loss per Share Attributable to Common Stockholders
Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive.
The potential shares of common stock that were excluded from the computation of diluted net loss per share for each period because including them would have had an antidilutive effect were as follows:
Three and Nine Months Ended
September 30,
20222021
Exercise of options under stock plan6,722,422 6,399,888 
Warrants to purchase common stock5,588,506 5,465,204 
12

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The 15,000,000 Contingent Earnout Shares, as defined in Note 3, are excluded from the anti-dilutive table for all periods presented, as such shares are contingently issuable until the share price of the Company exceeds specified thresholds that have not yet been achieved, or upon the occurrence of a change in control.
Other Risks and Uncertainties
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, the success of clinical trials and other studies for its product candidates, including for its ongoing V005 Phase II/III clinical trial and V007 Phase III clinical trial, the regulatory approval and commercialization of its HAVs and other product candidates, the expected size of the target populations for the Companys product candidates, the degree of market acceptance of the HAVs, if approved, the availability of third-party coverage and reimbursement, development by competitors of new technological innovations, the ability to manufacture HAVs and other product candidates in sufficient quantities, expectations regarding the Companys strategic partnerships, dependence on third parties, key personnel and the ability to attract and retain qualified employees, protection of proprietary technology and confidentiality of trade secrets, compliance with governmental regulations, the impact of the COVID-19 pandemic, the Companys implementation and maintenance of effective internal controls, and the ability to secure additional capital to fund operations and the commercial success of its product candidates.
Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Companys commercialization efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales, and the Company may depend on certain strategic relationships to distribute its products, including the Companys strategic partnership with Fresenius Medical Care, to sell, market and distribute its 6 millimeter HAV for certain specified indications outside the United States.
Recently Adopted Accounting Pronouncements
In May 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, “Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). The FASB issued this update to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring after the effective date of the amendments. The Company adopted ASU 2021-04 as of January 1, 2022. The adoption of this ASU had no impact on the Companys financial statements and related disclosures.
In November 2021, the FASB issued ASU No. 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”) to improve financial reporting by requiring annual disclosures that increase the transparency of transactions with a government accounted for by applying a grant or contribution model by analogy, including (i) the types of transactions, (ii) an entity’s accounting for those transactions, and (iii) the effect of those transactions on an entity’s financial statements. ASU 2021-10 is effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021, and an entity can elect to apply the amendments in this guidance prospectively or retrospectively. The Company adopted ASU 2021-10 effective January 1, 2022, and does not expect a material impact to its annual consolidated financial statement disclosures.
13

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
3. Reverse Recapitalization
On August 26, 2021, Merger Sub, a wholly-owned subsidiary of AHAC, merged with Legacy Humacyte, with Legacy Humacyte surviving as a wholly-owned subsidiary of AHAC. At the effective time of the Merger:
each outstanding share of Legacy Humacyte common stock was converted into approximately 0.26260 shares of New Humacyte’s common stock, par value $0.0001 per share (“Common Stock”);
each outstanding share of preferred stock of Legacy Humacyte was cancelled and converted into the aggregate number of shares of Common Stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately 0.26260; and
each outstanding option or warrant to purchase Legacy Humacyte common stock was converted into an option or warrant, as applicable, to purchase a number of shares of Common Stock equal to the number of shares of Legacy Humacyte common stock subject to such option or warrant multiplied by approximately 0.26260, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.26260;
in each case, rounded down to the nearest whole share.
In addition, upon the closing of the Merger (the “Closing”), 2,500,000 Class B shares of AHAC (the “Founder Shares”) automatically converted into shares of Common Stock on a one-for-one basis.
Former holders of the Legacy Humacyte common stock and Legacy Humacyte preferred stock are eligible to receive up to an aggregate of 15,000,000 additional shares of Common Stock (the “Contingent Earnout Shares”) in the aggregate, comprised of two equal tranches of 7,500,000 shares per tranche if the volume-weighted average closing sale price of the Common Stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period. At the Closing on August 26, 2021, the Company recorded a liability (“Contingent Earnout Liability”) of $159.4 million, based on the estimated fair value of the 15,000,000 Contingent Earnout Shares with a corresponding reduction of additional paid-in capital in the equity section of the Company’s condensed consolidated balance sheet.
Concurrently with the execution of the Merger Agreement, AHAC entered into subscription agreements (the “Subscription Agreements”) with certain investors (the “PIPE Investors”). Pursuant to the Subscription Agreements, the PIPE Investors purchased an aggregate of 17,500,000 shares of Common Stock (the “PIPE Shares”) in a private placement at a price of $10.00 per share for an aggregate purchase price of $175 million (the “PIPE Financing”). The PIPE Financing was consummated in connection with the Closing.
The number of shares of Common Stock outstanding immediately following the consummation of the Merger was:
Shares
Common stock of AHAC, outstanding prior to Merger10,355,000 
Less redemption of AHAC shares(3,008,551)
Common stock of AHAC7,346,449 
AHAC Founder Shares2,500,000 
New Humacyte shares issued to PIPE Investors17,500,000 
Issuance of common stock upon reverse recapitalization and PIPE Financing27,346,449 
New Humacyte shares issued in Merger to Legacy Humacyte stockholders75,656,935 (1)
Total shares of Common Stock immediately after Merger103,003,384 
________________
(1)Includes 69,613,562 shares of Common Stock issued upon conversion of Legacy Humacyte’s redeemable convertible preferred stock.
14

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, AHAC was treated as the acquired company for financial reporting purposes and Legacy Humacyte was treated as the acquirer. This determination was primarily based on the fact that subsequent to the Merger, the Legacy Humacyte stockholders held a majority of the voting rights of the combined company, Legacy Humacyte comprised all of the ongoing operations of the combined company, Legacy Humacyte comprised a majority of the governing body of the combined company, and Legacy Humacyte’s senior management comprised all of the senior management of the combined company. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Humacyte issuing shares for the net assets of AHAC, accompanied by a recapitalization. The net assets of AHAC were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the Merger are those of Legacy Humacyte.
In connection with the Merger, the Company received $242.4 million in proceeds from the Merger and related PIPE Financing. The Company incurred $3.9 million of transaction costs, consisting of banking, legal, and other professional fees, of which $3.9 million was recorded as a reduction of proceeds to additional paid-in capital, and less than $0.1 million related to the Private Placement Warrants, which are classified as liabilities in the condensed consolidated balance sheets, was expensed in the condensed consolidated statements of operations and comprehensive loss during the three months ended September 30, 2021. All transaction costs were paid as of December 31, 2021. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Of the $15.2 million of liabilities assumed from AHAC, $0.1 million was included in accrued expenses as of December 31, 2021, and there were no unpaid liabilities as of September 30, 2022.
4. Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) 820, Fair Value Measurement and Disclosures, establishes a hierarchy whereby inputs to valuation techniques used in measuring fair value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy based on reliability of inputs, as follows:
Level 1 — Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.
Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.
The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company.
15

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Company’s assets and liabilities that were measured at fair value on a recurring basis were as follows:
($ in thousands)
Fair Value Measured as of September 30, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents (money market funds)$160,370 $ $ $160,370 
Cash equivalents (certificates of deposit) 2,014  2,014 
Short-term investments (certificates of deposit) 8,000  8,000 
Total financial assets$160,370 $10,014 $ $170,384 
Liabilities:
Contingent Earnout Liability$ $ $45,011 $45,011 
Private Placement Warrants liability  257 257 
Total financial liabilities$ $ $45,268 $45,268 
($ in thousands)
Fair Value Measured as of December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents (money market funds)$208,821 $ $ $208,821 
Cash equivalents (certificates of deposit) 2,000  2,000 
Short-term investments (certificates of deposit) 8,000  8,000 
Total financial assets$208,821 $10,000 $ $218,821 
Liabilities:
Contingent Earnout Liability$ $ $103,660 $103,660 
Private Placement Warrants liability  497 497 
Total financial liabilities$ $ $104,157 $104,157 
The following tables present a summary of the changes in the fair value of the Company’s Level 3 financial instruments:
($ in thousands)Contingent Earnout Liability
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Fair value as of beginning of period$(44,049)$ $(103,660)$ 
Contingent Earnout Liability recognized upon the closing of the reverse recapitalization (159,432) (159,432)
Change in fair value included in other income (expense), net(962)(9,768)58,649 (9,768)
Fair value as of end of period$(45,011)$(169,200)$(45,011)$(169,200)
16

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Private Placement Warrants
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
Fair value as of beginning of period$(190)$ $(497)$ 
Private placement warrant liability acquired as part of the Merger (553) (553)
Change in fair value included in other income (expense), net(67)(2)240 (2)
Fair value as of end of period$(257)$(555)$(257)$(555)
The fair value of the Contingent Earnout Liability and Private Placement Warrants (as defined in Note 8 — Stockholders’ Equity (Deficit)) liability are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy.
In determining the fair value of the Contingent Earnout Liability, the Company used the Monte Carlo simulation value model using a distribution of potential outcomes on a monthly basis over a 10-year period prioritizing the most reliable information available. The assumptions utilized in the calculation were based on the achievement of certain stock price milestones, including the current Common Stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8 — Stockholders’ Equity (Deficit)). Contingent earnout payments involve certain assumptions requiring significant judgment and actual results can differ from assumed and estimated amounts.
In determining the fair value of the Private Placement Warrants liability, the Company used the Monte Carlo simulation valuation model to estimate the fair value utilizing assumptions including the current Company stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8 — Stockholders’ Equity (Deficit)).
The Company’s money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheets, which approximates their fair value based on Level 2 inputs. The carrying values of other receivables, accounts payable and accrued expenses as of September 30, 2022 and December 31, 2021 approximated their fair values due to the short-term nature of these items.
5. Property and Equipment, Net
Property and equipment, net consist of the following:
($ in thousands)September 30,
2022
December 31,
2021
Scientific equipment(1)
$27,926 $27,641 
Computer equipment232 155 
Software335 335 
Furniture and fixtures1,000 988 
Leasehold improvements26,355 26,355 
Construction in progress170  
56,018 55,474 
Accumulated depreciation(24,992)(20,440)
Property and equipment, net$31,026 $35,034 
___________________________
(1)As of December 31, 2021, includes $3.6 million related to scientific equipment not depreciated until being placed in service during the third quarter of 2022.
17

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Depreciation expense totaled $1.5 million and $4.6 million for the three and nine months ended September 30, 2022, respectively, and $1.5 million and $4.7 million for the three and nine months ended September 30, 2021, respectively. All long-lived assets are maintained in the United States.
6. Accrued Expenses
Accrued expenses consisted of the following:
($ in thousands)September 30,
2022
December 31,
2021
Accrued external research, development and manufacturing costs$2,673 $2,520 
Accrued employee compensation and benefits5,023 3,943 
Accrued professional fees263 294 
Total$7,959 $6,757 
7. Debt
On March 30, 2021, the Company entered into a term loan agreement with Silicon Valley Bank (“SVB”) and SVB Innovation Credit Fund VIII, L.P., as amended in June 2021 and September 2021 (the “Loan Agreement”), which provides a term loan facility of up to $50.0 million with a maturity date of March 1, 2025. The Companys obligations under the Loan Agreement are secured by substantially all of its assets except for its intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. If a minimum liquidity amount is not maintained, 50% of the outstanding principal and interest will become cash collateralized. As of September 30, 2022, the Company was in compliance with all covenants. The Company may use the proceeds of borrowings under the Loan Agreement as working capital and to fund its general business requirements.
The Loan Agreement provides that the term loans will be distributed in tranches. The initial term loan tranche of $20.0 million was drawn on March 31, 2021, and on October 13, 2021, the Company borrowed an additional $10.0 million under the Loan Agreement. Borrowings under the Loan Agreement are accounted for net of issuance costs which are being accreted to interest expense over the term of the loan using the effective interest method. As of September 30, 2022, two subsequent $10.0 million term loan tranches will be eligible to be drawn at the request of the Company during specified draw periods prior to May 15, 2023, the first tranche subject to submission by the Company of its first Biologics License Application (“BLA”) to the FDA for its HAV prior to March 31, 2023, and the second tranche subject to the first approval from the FDA of any BLA for the HAV prior to March 31, 2023 and the Company having borrowed the first remaining tranche.
Borrowings bear interest at the greater of 7.5% or the Wall Street Journal Prime Rate plus 4.25% (10.50% as of September 30, 2022). Interest only payments on the principal amount outstanding are due monthly beginning in the first month after the loan is dispersed. Repayment of principal may begin as soon as July 1, 2023 under the level of borrowing outstanding at September 30, 2022, and no later than April 1, 2024 if the remaining two loan tranches are drawn. The term loans may only be prepaid in full, and such prepayment requires 30 days advance notice and was subject initially to a prepayment fee of 3.00% that was decreased to 2.00% after March 30, 2022 (with a further decrease to 1.00% after March 30, 2023). The Company is not obligated to pay a prepayment fee if the Company makes a prepayment after March 30, 2024.
In connection with the Loan Agreement, the Company granted warrants to the lenders to purchase shares of Common Stock at an exercise price of $10.28 per share, of which 287,704 warrants were immediately exercisable. The warrants are classified within stockholders equity, as the settlement of the warrants is indexed to the Common Stock. The Company recognized the fair value of the warrants immediately exercisable within stockholders equity using a Black-Scholes valuation model at issuance.
18

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
At issuance, the Company initially determined that the funding of an additional tranche was not probable, and therefore no value was ascribed to the remaining 123,302 warrants that were only exercisable upon the funding of the first additional tranche. As a result of the Company’s additional $10.0 million borrowings under the Loan Agreement on October 13, 2021, the warrants to purchase the additional 123,302 shares of Common Stock became exercisable at an exercise price of $10.28 per share and the value of the warrants was recorded as of that date. The additional warrants are classified within stockholders’ equity using a Black-Scholes valuation model, as the settlement of the warrants is indexed to the Common Stock.
As of September 30, 2022, the fair value of warrants ($3.3 million), a 5% final payment fee ($1.5 million) and debt issuance costs ($0.3 million) are being accreted to interest expense over the term of the loan using the effective interest method.
SVB loan payable and net discount or premium balances are as follows:
($ in thousands)September 30,
2022
Principal amount of SVB loan payable$30,000 
Final payment amount of SVB loan payable1,500 
Net premium associated with accretion of final payment and other debt issuance costs(2,928)
SVB loan payable, current and noncurrent28,572 
Less SVB loan payable, current portion(4,286)
SVB loan payable, noncurrent portion$24,286 
Future minimum payments of principal on the Companys outstanding variable rate borrowings as of September 30, 2022 are as follows:
Year ending December 31:
($ in thousands)
2022 (remainder)
$ 
20238,571 
202417,143 
20254,286 
Total future payments$30,000 
On April 30, 2020, the Company received loan proceeds in the amount of approximately $3.3 million under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act. All or a portion of this loan and any accrued interest was eligible to be forgiven after a twenty-four week period as long as the borrower used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintained its payroll levels. On May 25, 2021, the PPP loan was forgiven and the Company recognized a gain from loan extinguishment in the amount of $3.3 million during the three months ended June 30, 2021.
8. Stockholders Equity (Deficit)
Redeemable Convertible Preferred Stock
Immediately prior to the Merger, Legacy Humacyte had outstanding series A redeemable convertible preferred stock, series B redeemable convertible preferred stock, series C redeemable convertible preferred stock and series D redeemable convertible preferred stock, which are collectively referred to as redeemable convertible preferred stock.
In connection with the Merger, all previously issued and outstanding redeemable convertible preferred stock was converted into an equivalent number of shares of Common Stock of the Company on a one-for-one basis, then multiplied by the exchange ratio pursuant to the Merger Agreement and the amounts were reclassified as additional paid-in capital.
19

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Common Stock
On August 26, 2021, the Merger and related PIPE Financing was consummated and the Company issued 27,346,449 shares of Common Stock for proceeds of $242.4 million. The Company incurred $3.9 million of transaction costs, consisting of banking, legal, and other professional fees. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Immediately following the Merger, there were 103,003,384 shares of Common Stock outstanding with a par value of $0.0001 per share.
As of September 30, 2022, the Companys Second Amended and Restated Certificate of Incorporation authorized the Company to issue 250,000,000 shares of Common Stock. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares then outstanding or reserved for issuance) by the affirmative vote of the holders of a majority of the capital stock of the Company entitled to vote and may require a separate class vote of the Common Stock.
The holders of Common Stock are entitled to receive dividends from time to time as may be declared by the Companys board of directors. Through September 30, 2022, no dividends have been declared.
The holders of Common Stock are entitled to one vote for each share held with respect to all matters voted on by the common stockholders of the Company.
In the event of a reorganization of the Company, after payment to the preferred stockholders of their liquidation preferences, holders of Common Stock are entitled to share ratably in all remaining assets of the Company.
As of September 30, 2022, the Company had reserved Common Stock for future issuances as follows:
September 30,
2022
Common stock reserved for Contingent Earnout Shares15,000,000 
Exercise of options under stock plans6,722,422 
Issuance of options under stock plans7,312,585 
Shares available for grant under ESPP1,030,033 
Warrants to purchase Common Stock5,588,506 
35,653,546 
Preferred Stock
The Companys Second Amended and Restated Certificate of Incorporation provides the Companys board of directors with the authority to issue preferred stock, par value $0.0001 per share, in one more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were 20,000,000 shares designated as preferred stock and none were outstanding as of September 30, 2022 and December 31, 2021.
20

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Warrants
The Company had the following common stock warrants outstanding as of September 30, 2022 and December 31, 2021:
Common Stock Warrants Outstanding
Legacy Humacyte Common Stock Warrants411,006 
Private Placement Warrants177,500 
Public Warrants5,000,000 
Total Common Stock Warrants5,588,506 
See Note 7 — Debt for a discussion of common stock warrants issued in conjunction with the Companys Loan Agreement in 2021 (such warrants, “Legacy Humacyte Common Stock Warrants”). There were no issuances, exercises or expirations of warrants during the nine months ended September 30, 2022. During the nine months ended September 30, 2021 there were 32,961 of warrants exercised that were issued in conjunction with a long-term debt agreement repaid in a prior reporting period. There were no expirations of warrants during the nine months ended September 30, 2021.
In connection with the Merger, the Company assumed 5,000,000 publicly-traded warrants (Public Warrants) and 177,500 private placement warrants issued to AHAC Sponsor LLC (the Sponsor), Oppenheimer & Co. Inc. and Northland Securities, Inc, in connection with AHACs initial public offering (Private Placement Warrants and, together with the Public Warrants, the Common Stock Warrants). The Common Stock Warrants entitle the holder to purchase one share of Common Stock at an exercise price of $11.50 per share. The Company evaluated the Common Stock Warrants to determine the appropriate financial statement classification upon the consummation of the Merger. The Common Stock Warrants are not mandatorily redeemable and are considered to be freestanding instruments as they are separately exercisable into common shares. As such, the Common Stock Warrants were not classified as liabilities under FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company then evaluated the Common Stock Warrants under FASB ASC Topic 815, Derivatives and Hedging.
Public Warrants
The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the Public Warrants may be eligible for a cashless exercise. The Public Warrants may only be exercised for a whole number of shares and will expire five years after the completion of the Merger. The Public Warrants became exercisable 30 days after the completion of the Merger.
The Public Warrants are considered to be “indexed to the Company’s own stock”. The agreement provides that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of the Companys Common Stock, all holders of the Common Stock Warrants (both the Public Warrants and the Private Placement Warrants) would be entitled to receive cash for all of their Common Stock Warrants. As the Company has a single class of Common Stock, a qualifying cash tender offer of more than 50% of the Companys Common Stock will always result in a change in control and would not preclude permanent equity classification of the Public Warrants. Based on this evaluation, the Company concluded that the Public Warrants meet the criteria to be classified within stockholders equity. The Public Warrants were initially recognized as equity on the Closing Date at a fair value of $2.80 per share.
Private Placement Warrants
The Private Placement Warrants are non-redeemable for cash so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
21

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The agreement governing the Common Stock Warrants includes a provision, the application of which could result in a different settlement value for the Private Placement Warrants depending on their holder. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on the Common Stock, the Private Placement Warrants are not considered to be indexed to the Companys own stock and therefore are not classified in stockholders equity. As the Private Placement Warrants meet the definition of a derivative, the Company recorded these warrants as liabilities on the condensed consolidated balance sheet at fair value, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date.
The Private Placement Warrants were initially recognized as a liability on the Closing Date, at a fair value of $0.6 million, and the liability was remeasured to an estimated fair value of $0.5 million as of December 31, 2021. See Note 4 — Fair Value Measurements for a summary of the change in the fair value of the Private Placement Warrants during the three and nine months ended September 30, 2022 and 2021. The remeasurement of the Private Placement Warrant liability to a fair value of $0.3 million as of September 30, 2022 resulted in a non-cash loss of $0.1 million and a non-cash gain of $0.2 million for the three and nine months ended September 30, 2022, respectively, compared to a non-cash loss of less than $0.1 million for each of the three and nine months ended September 30, 2021. The remeasurement of the Private Placement Warrant liability is classified within Change in fair value of common stock warrant liabilities in the condensed consolidated statements of operations and comprehensive loss.
The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model:
September 30,
2022
December 31,
2021
Market price of public stock$3.26$7.25
Exercise price$11.50$11.50
Expected term (years)3.914.65
Expected share price volatility94.5 %61.0 %
Risk-free interest rate4.16 %1.21 %
Estimated dividend yield0 %0 %
Contingent Earnout Liability
Following the Closing, former holders of Legacy Humacyte common and preferred shares may receive up to 15,000,000 additional shares of Common Stock in the aggregate, in two equal tranches of 7,500,000 shares of Common Stock per tranche. The first and second tranches are issuable if the closing volume weighted average price (VWAP) per share of Common Stock quoted on Nasdaq (or the exchange on which the shares of Common Stock are then listed) is greater or equal to $15.00 and $20.00, respectively, over any 20 trading days within any 30 consecutive trading day period.
Upon the Closing, the contingent obligation to issue Contingent Earnout Shares was accounted for as a liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the Common Stock. The Contingent Earnout Shares are subsequently remeasured at each reporting date with changes in fair value recorded as a component of other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss. The estimated fair value of the total Contingent Earnout Shares at the Closing on August 26, 2021 was $159.4 million based on a Monte Carlo simulation valuation model using a distribution of potential outcomes on a monthly basis over a ten-year period using the most reliable information available. The estimated fair value of the total Contingent Earnout Shares at December 31, 2021 was $103.7 million.
22

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
See Note 4 — Fair Value Measurements for a summary of the change in the fair value of the Contingent Earnout Liability during the three and nine months ended September 30, 2022. The remeasurement of the Contingent Earnout Liability to a fair value of $45.0 million as of September 30, 2022 resulted in a non-cash loss of $1.0 million and a non-cash gain of $58.6 million for the three and nine months ended September 30, 2022, respectively, compared to a non-cash loss of $9.8 million for each of the three and nine months ended September 30, 2021. The remeasurement of the Contingent Earnout Liability is classified within Change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss. The assumptions utilized in the calculations of fair value were based on the achievement of certain stock price milestones, including the current Common Stock price, expected volatility, risk-free rate, expected term and expected dividend yield.
Assumptions used in the valuations are described below:
September 30,
2022
December 31,
2021
Current stock price$3.26$7.25
Expected share price volatility89.0 %85.8 %
Risk-free interest rate3.83 %1.52 %
Estimated dividend yield0.0 %0 %
Expected term (years)10.0010.00
9. Stock-based Compensation
At Closing, the 2021 Long-Term Incentive Plan, (the “2021 Plan”), and the 2021 Employee Stock Purchase Plan, (the “ESPP”), became effective. As of September 30, 2022, 7,312,585 and 1,030,033 shares of Common Stock were available under the 2021 Plan and ESPP, respectively. The 2021 Plan and ESPP provide that on January 1 of each year commencing January 1, 2022, the 2021 Plan and the ESPP reserve will automatically increase in an amount equal to the lesser of (a) 5% and 1%, respectively, of the number of shares of the Companys Common Stock outstanding on December 31 of the preceding year and (b) a number of shares of Common Stock determined by the Companys board of directors. In December 2021, the Company’s board of directors determined that there would be no automatic increase in the number of shares reserved under the 2021 Plan or the ESPP on January 1, 2022.
Under the 2021 Plan, the Company can grant non-statutory stock options (“NSOs”), incentive stock options (“ISOs), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, performance awards and other forms of awards. Under the ESPP, when and if implemented, eligible employees will be permitted to purchase shares of the Company’s Common Stock at the lower of 85% of the closing trading price per share of the Company’s Common Stock on the first day of the offering or 85% of the closing trading price per share on the exercise date, which will occur on the last day of each offering.
Prior to the Closing, Legacy Humacyte had two equity incentive plans, the 2015 Omnibus Incentive Plan, as amended (the “2015 Plan”), and the 2005 Stock Option Plan (the “2005 Plan”). As a result of the Merger, no further awards may be granted under either the 2015 Plan or the 2005 Plan. All awards previously granted and outstanding as of the effective date of the Merger were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2021 Plan or the 2015 Plan that are forfeited, cancelled or reacquired by the Company prior to vesting, that expire or that are paid out in cash rather than shares will become available for grant and issuance under the 2021 Plan. As of September 30, 2022, 5,233,533 and 504,254 shares of Common Stock remain reserved for outstanding options issued under the 2015 Plan and 2005 Plan, respectively.
The Companys stock option plans allow for the grant of awards that the Company believes aid in aligning the interests of award recipients with those of its stockholders. The Companys board of directors or compensation committee determines the specific terms of equity incentive grants, including the exercise price per share and vesting period for option awards. Option awards are granted with an exercise price equal to the fair market value of the Companys Common Stock at the date of grant.
23

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Company has granted options that include either a service-based or performance-based vesting condition, or both, and a 10-year contractual term. The service-based vesting condition for the plans is generally satisfied over 36 to 48 months from the date of grant. The performance-based vesting conditions are satisfied upon the attainment of certain product development milestones. The Company recognizes stock-based compensation expense based on the grant date fair value of the awards measured using the Black-Scholes option pricing model. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying Common Stock on the date of grant. Forfeitures are accounted for as they occur.
Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur.
Option awards under the Companys option plans generally provide for accelerated vesting of the unvested portions of any option award in the event of an involuntary termination, as such term is defined in the relevant stock option agreement, of a grantees employment during the period that commences 30 days prior to the effective date of a corporate transaction and that ends 12 months following the effective date of such transaction. Additionally, the Companys board of directors may, in its sole discretion, accelerate the vesting of any unvested stock options in the event of a corporate transaction.
The Company estimated the fair value of the stock options on the date of grant using the following assumptions in the Black-Scholes option-pricing model:
Three Months Ended September 30,Nine Months Ended September 30,
2022
2021 (1)
20222021
Estimated dividend yield0 %— 0 %0 %
Expected share price volatility (weighted average and range, if applicable)
89.3% (89.2% to 89.4%)
— 
93.3% (89.0% to 100.0%)
91.4% (91.0% to 92.1%)
Risk-free interest rate (weighted average and range, if applicable)
3.58% (3.46% to 3.65%)
— 
2.96% (1.89% to 3.65%)
0.68% (0.62% to 1.02%)
Expected term of options (in years)6.25— 6.256.00
__________________________
(1)The Company did not grant any stock options during the three months ended September 30, 2021.
Fair Value of Common Stock. Prior to the Merger, as the Companys common stock was not publicly traded, the fair value of the shares of its common stock underlying the options was determined by the Companys board of directors with input from management, after considering independent third-party valuation reports. Subsequent to the Merger, the fair value of the Common Stock has been determined based on the closing price of the shares on the Nasdaq market.
Expected Term. The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.
24

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Expected Volatility. The expected volatility was determined based on a blended approach using the historical share volatility of the Company’s Common Stock and that of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company has a limited trading history. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies.
Risk-Free Interest Rate. The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options.
Expected Dividend Yield. The Company has not paid dividends on its Common Stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero.
At September 30, 2022, there were 7,312,585 options remaining available for grant under the 2021 Plan. The Company has sufficient authorized and unissued shares to issue Common Stock in satisfaction of any awards available for grant under the 2021 Plan.
The following tables show a summary of stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021, and remaining unrecognized cost as of September 30, 2022 and December 31, 2021:
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
Research and development$216 $486 $682 $1,837 
General and administrative1,260 1,391 3,832 5,498 
Total$1,476 $1,877 $4,514 $7,335 
($ in thousands)September 30,
2022
December 31,
2021
Unrecognized stock-based compensation cost$10,234 $13,346 
Expected weighted average period compensation costs to be recognized (years)2.02.3
A summary of option activity under the Companys stock option plans during the nine months ended September 30, 2022 is presented below:
Number of SharesWeighted
Average Exercise
Price Per Share
Weighted
Average
Remaining
Contractual Term
(years)
Aggregate
Intrinsic Value
(in thousands)
Options outstanding at December 31, 2021
6,711,192 $7.48 5.3$8,276 
Granted675,077 $5.00 
Exercised(95,122)$2.41 
Forfeited(568,725)$8.69 
Options outstanding at September 30, 2022
6,722,422 $7.20 5.2$1,438 
Vested and exercisable, September 30, 2022
4,408,060 $6.41 3.3$1,438 
Vested and expected to vest, September 30, 2022
6,722,422 $7.20 5.2$1,438 
25

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
10. Income Taxes
The Companys tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate and, if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. No such adjustment was made as of September 30, 2022. The Companys effective federal tax rate for the three and nine months ended September 30, 2022 and 2021 was 0%, primarily as a result of estimated tax losses for the fiscal year to date offset by the increase in the valuation allowance in the net operating loss carryforwards.
The Company did not record any income tax expense or benefit during the three and nine months ended September 30, 2022 and 2021. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Companys ability to realize these assets. All losses before income taxes arose in the United States.
11. Commitments and Contingencies
Patent License Agreements
Duke University
In March 2006, the Company entered into a license agreement with Duke University (“Duke”), which was subsequently amended in 2011, 2014, 2015, 2018, 2019 and January 2022. Under this license agreement, Duke granted the Company a worldwide, exclusive, sublicensable license to certain patents related to decellularized tissue engineering, referred to as the patent rights, as well as a non-exclusive license to use and practice certain know-how related to the patent rights. The relevant licensed patent on decellularization of tissue expired in 2021. The Company has agreed to use commercially reasonable efforts to develop, register, market and sell products utilizing the patent rights, referred to as the licensed products. Any services provided to a third party utilizing licensed products are referred to as licensed services. The Company has also agreed to meet certain benchmarks in its development efforts, including as to development events, clinical trials, regulatory submissions and marketing approval, within specified timeframes. Under the license agreement, Duke retains the right to use the patent rights for its own educational and research purposes, and to provide the patent rights to other non-profit, governmental or higher-learning institutions for non-commercial purposes without paying royalties or other fees.
In connection with the Companys entry into the license agreement, the Company granted equity consideration to Duke in the form of 52,693 shares of the Companys common stock. Under the license agreement, the Company also agreed to pay Duke:
a low single-digit percentage royalty on eligible sales of licensed products and licensed services, plus a low double-digit percentage of any sublicensing revenue;
an annual minimum royalty beginning in 2012, which increases in the calendar year immediately following the first commercial sale of licensed products or licensed services (whichever occurs first); and
an additional amount in license fees, as certain milestones are met.
The license agreement remains effective until the later of (i) the last of the patent rights expires or (ii) four years after the Companys first commercial sale, unless terminated earlier. Either party may terminate the agreement for fraud, willful misconduct or illegal conduct, or uncured material breach. Duke may terminate the agreement if the Company becomes insolvent. Duke may also terminate the license, convert the license into a non-exclusive license or seek assignment of any sublicense if the Company fails to reach diligence milestones within the applicable time period. If the Company abandons any claim, patent or patent application, its rights under the license with respect to such patent rights will be terminated in the territory in which the Company abandons such rights. The Company may terminate the license agreement unilaterally upon three months prior notice to Duke. The Company agrees to indemnify Duke against certain third-party claims. Payments to Duke under the license agreement were immaterial during the periods presented.
26

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Yale University
In February 2014, the Company entered into a license agreement with Yale University (“Yale”) that granted the Company a worldwide license to the patents related to coatings for small-diameter vessels to inhibit clotting. The license granted under the agreement is exclusive in the field of engineered vascular tissues and tissues and extracellular matrix-based implants used for vascular repair, reconstruction and replacement (provided that all uses are vascular tissues within the range of 1 12mm in diameter), except that it is subject to Yales non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.
In August 2019, the Company entered into a license agreement with Yale, that granted the Company a worldwide license to the patents related to Bioartificial Vascular Pancreas (“BVP”). The license granted under the agreement is exclusive in the field of engineered vascular tissues that deliver pancreatic islet cells to patients, except that it is subject to Yales non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.
In August 2019, the Company entered into a license agreement with Yale that granted the Company a worldwide license to the patents related to tubular prostheses. The license granted under the agreement is exclusive in the field of engineered urinary conduits, engineered tracheas/airways, and engineered esophagi, except that it is subject to Yales non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.
The Company has agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. The Company is also obligated to provide Yale periodically an updated and revised copy of its plan for each license, which must indicate progress of its development and commercialization. The Company may also sublicense the Companys rights without Yales prior written consent, but such sublicense is subject to certain conditions.
In connection with its entry into the license agreement, the Company paid Yale upfront cash fees. The Company has also agreed to pay Yale:
annual maintenance fees, increasing between the first anniversary of the agreement until the fifth anniversary for the coating and BVP licenses and until the fourth anniversary for the tubular prostheses license up to a maximum of less than $0.1 million per year;
milestone payments upon achievement of certain regulatory and commercial milestones of $0.2 million and $0.6 million, respectively;
a low single-digit percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and
a low double-digit percentage of sublicensing income.
If the Company or any of its future sublicensees bring a patent challenge against Yale or assists another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties.
27

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The agreements expire on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Yale may terminate the agreements if the Company fails to (i) provide written diligence reports, (ii) provide commercially reasonable diligence plans, (iii) implement the plans in accordance with the obligations under the agreements, or (iv) reach certain research and development milestones within the scheduled timeframe set forth in the agreements; however, any such termination right would be limited in scope to the country to which such failure relates. Yale may also terminate for the Companys non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of the Companys products or insolvency. The Company may terminate the license agreements (i) on 90 days prior written notice to Yale, provided the Company is not in breach of the license agreements and has made all required payments to Yale thereunder and (ii) on written notice to Yale following an uncured material breach. With respect to the license agreements related to small-diameter vessels and BVP, the Companys rights under the license agreements will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, the Company does not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive licenses to non-exclusive licenses if the Company declines to initiate certain infringement or interference proceedings with respect to the licensed patents. The Company has agreed to indemnify Yale against certain third-party claims. Payments to Yale under the license agreement were immaterial during the periods presented.
Legal Matters
The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Companys business, financial condition, results of operations, or cash flows.
Indemnification
To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Companys request in such capacity. The indemnification period covers all pertinent events and occurrences during the directors or officers service. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is not specified in such arrangements; however, the Company has director and officer insurance coverage that is intended to reduce its exposure and enable the Company to recover a portion of any potential future amounts the Company could be required to make. To date, the Company has not incurred any costs as a result of such obligations and has not accrued any liabilities related to such obligations in the condensed consolidated financial statements.
12. Related Party Transactions
Fresenius Medical Care investments and distribution agreement
In June 2018, the Company completed a $150 million financing transaction pursuant to which Fresenius Medical Care purchased shares of series D redeemable convertible preferred stock that at the Closing of the Merger converted into 15,812,735 shares of the Companys common stock. In August 2021, Fresenius Medical Care invested $25 million as part of the PIPE Financing and received an additional 2.5 million shares of the Companys common stock.
In addition, the Company entered into a distribution agreement with Fresenius Medical Care in June 2018 which, as amended as of February 16, 2021, granted Fresenius Medical Care and its affiliates exclusive rights to develop outside the United States and European Union (the “EU”) and commercialize outside of the United States the Companys 6 millimeter x 42 centimeter HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter or configuration of the foregoing), for use in vascular creation, repair, replacement or construction, including renal replacement therapy for dialysis access, the treatment of peripheral arterial disease, and the treatment of vascular trauma, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients. Within the United States, Fresenius Medical Care will collaborate with the Company in its commercialization of the product in the field, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic analyses.
28

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Company is responsible for developing and seeking regulatory approval for the distribution product in the field in the United States. For countries outside the United States, the parties agreed to use commercially reasonable efforts to satisfy certain agreed minimum market entry criteria for the distribution product in the field in such country. For the EU, once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory approval for the distribution product in the field in the applicable country, the Company agreed to use commercially reasonable efforts to obtain such regulatory approval (other than pricing approval), and Fresenius Medical Care agreed to use commercially reasonable efforts to obtain the corresponding pricing approval. For the rest of the world (i.e., outside the United States and the EU), once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory and pricing approval for the distribution product in the field in the applicable country, Fresenius Medical Care agreed to use commercially reasonable efforts to obtain such approvals, and the Company agreed to use commercially reasonable efforts to support Fresenius Medical Care in its efforts.
Under the distribution agreement, the Company grants an exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to commercialize the distribution product in the field outside the United States, subject to the Companys retained rights to carry out its obligations under the distribution agreement. The Company also grants a non-exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to develop the distribution product in accordance with the terms of the distribution agreement. In addition, the Company grants to Fresenius Medical Care, among other things, a perpetual, irrevocable, non-exclusive sublicensable license under the patents and know-how that primarily relate to the distribution product or its manufacture and that were created, conceived or developed solely or jointly by or on behalf of Fresenius Medical Care in the performance of its activities under the distribution agreement.
The distribution agreement provides that the Company will own all know-how and patents that primarily relate to the distribution product or its manufacture that are created, conceived or developed by or on behalf of either party in the performance of activities under the distribution agreement. Ownership of all other know-how, patents, materials and other intellectual property created, conceived or developed during the performance of activities under the distribution agreement will be determined in accordance with U.S. patent laws for determining inventorship.
The Company is obligated to make payments to Fresenius Medical Care based on a share of aggregate net sales by or on behalf of the Company of the distribution product in the United States in the field. Such revenue-share payments will be a percentage of net sales in the low double digits, without regard to the calendar year in which such net sales are attributable, until such time that the Company has paid to Fresenius Medical Care a certain total amount, at which time the revenue-share will decrease to a percentage of net sales in the mid-single digits. The amounts that Fresenius Medical Care will be obligated to pay the Company under the distribution agreement for sales of the distribution product in the field outside of the United States will vary. Fresenius Medical Care agreed to pay the Company initially, on a country-by-country basis for sales outside of the United States, the amount equal to the average cost of manufacturing the Companys distribution product plus a fixed dollar amount per unit. Following a specified period, on a country-by-country basis outside of the United States, Fresenius Medical Care will pay the Company a fixed percentage of net sales for each unit sold in such country, such that the Company will receive more than half of such net sales.
The distribution agreement will generally continue on a country-by-country basis until the later of (a) the tenth anniversary of the launch date of the distribution product in the relevant country or (b) the expiration of the last-to-expire valid claim of specified patents in such country. Each party is permitted to terminate the distribution agreement for insolvency of, or, under certain circumstances, including various cure periods, material breach by the other party. Subject to a cure period, Fresenius Medical Care may also terminate the distribution agreement in its entirety or on a country-by-country basis (i) for certain withdrawals of regulatory approval or (ii) for termination or expiration of any of our in-licenses that is necessary for the exercise of Fresenius Medical Cares rights, or the satisfaction of its obligations, under the distribution agreement. In addition, Fresenius Medical Care may terminate the distribution agreement for convenience on a country-by-country basis upon not less than 12 months written notice to the Company, although Fresenius Medical Care is not permitted to give such notice prior to the end of the second year following launch of the distribution product in such country. Each party is required to indemnify one another for certain third-party claims.
29

Humacyte, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Arrangements with Yale University
The Company’s President and Chief Executive Officer, Laura Niklason M.D., PhD., serves as an Adjunct Professor in Anesthesia at Yale University. As of September 30, 2022 and December 31, 2021, the Company was a party to license agreements with Yale University as described in Note 11 Commitments and Contingencies, above.
The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021:
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
License expenses$ $ $50 $85 
Other8 2 16 83 
Total8 2 66 168 

30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (“Quarterly Report”) and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021 (“Annual Report”), filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022. In addition, you should read the “Risk Factors” and “Information Regarding Forward-Looking Statements” sections of this Quarterly Report and our Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Unless the context indicates otherwise, references in this Quarterly Report to the “Company,” “Humacyte,” “we,” “us,” “our” and similar terms refer to Humacyte, Inc. (formerly known as Alpha Healthcare Acquisition Corp.) and its consolidated subsidiaries (including Humacyte Global, Inc.) following the Merger (defined below); references to “Legacy Humacyte” refer to Humacyte, Inc. prior to the Merger; and references to “AHAC” refer to Alpha Healthcare Acquisition Corp. prior to the Merger.
Overview
We are pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. We believe our technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. We are leveraging our novel, scalable technology platform to develop proprietary product candidates for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
We are initially using our proprietary, scientific technology platform to engineer and manufacture human, acellular vessels (“HAVs”). Our investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. We are developing a portfolio, or “cabinet”, of HAVs with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including use in vascular trauma; arteriovenous (“AV”) access for hemodialysis, peripheral arterial disease (“PAD”); and coronary artery bypass grafting (“CABG”). In addition, we are developing our HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes (our biovascular pancreas). We will continue to explore the application of our technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus and other novel cell delivery systems.
We believe there is substantial clinical demand for safe and effective vascular conduits to replace and repair blood vessels throughout the body. Vascular injuries resulting from trauma are common in civilian and military populations, frequently resulting in the loss of either life or limb. Existing treatment options in the vascular repair, reconstruction and replacement market include the use of autologous vessels and synthetic grafts, which we believe suffer from significant limitations. For example, the use of autologous veins to repair traumatic vascular injuries can lead to significant morbidity associated with the surgical wounds created for vein harvest and prolonged times to restore blood flow to injured limbs leading to an increased risk of amputation and infection. Synthetic grafts are often contraindicated in the setting of vascular trauma due to higher infection risk that can lead to prolonged hospitalization and limb loss. Given the competitive advantages our HAVs are designed to have over existing vascular substitutes, we believe that HAVs have the potential to become the standard of care and lead to improved patient outcomes and lower healthcare costs.
We are currently conducting Phase II and Phase III trials of our 6 millimeter HAV across two therapeutic indications, vascular trauma and AV access for hemodialysis, as well as continuing long-term follow up of patients in our Phase II PAD studies. We were granted Fast Track designation by the FDA for our 6 millimeter HAV for use in AV access for hemodialysis in 2014. We also received the first Regenerative Medicine Advanced Therapy (“RMAT”) designation from the FDA, for the creation of vascular access for performing hemodialysis, in March 2017. In addition, in 2018 our HAV product candidate was assigned a priority designation by the Secretary of Defense under Public Law 115-92, enacted to expedite the FDA’s review of products that are intended to diagnose, treat or prevent serious or life-threatening conditions facing American military personnel. Upon completion of our Phase III trials, we intend to submit a Biologics License Application (“BLA”) to the FDA for an indication in vascular trauma in mid-2023.
31

We have generated no product revenue and incurred operating losses and negative cash flows from operations in each year since our inception in 2004. As of September 30, 2022 and December 31, 2021, we had an accumulated deficit of $422.8 million and $414.6 million, respectively, and working capital of $156.7 million and $218.3 million, respectively. Our operating losses were approximately $23.5 million and $63.8 million for the three and nine months ended September 30, 2022, respectively, and $20.5 million and $59.6 million for the three and nine months ended September 30, 2021, respectively. Net cash flows used in operating activities were $52.2 million and $59.7 million during the nine months ended September 30, 2022 and 2021, respectively. Substantially all of our operating losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to incur substantial operating losses and negative cash flows from operations for the foreseeable future as we advance our product candidates.
As of September 30, 2022, we had cash and cash equivalents and short-term investments of $171.7 million. We believe our cash and cash equivalents and short-term investments on hand will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, for at least 12 months from the date of this Quarterly Report. See Note 1 — Organization and Description of Business in the notes to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information regarding this assessment.
Our need for additional capital will depend in part on the scope and costs of our development and commercial manufacturing activities. To date, we have not generated any revenue from the sale of commercialized products. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. Until such time, if ever, we expect to finance our operations through the use of existing cash and cash equivalents and short-term investments, the sale of equity or debt, borrowings under credit facilities, or through potential collaborations, other strategic transactions or government and other grants. Adequate capital may not be available to us when needed or on acceptable terms. If we are unable to raise capital, we could be forced to delay, reduce, suspend or cease our research and development programs or any future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition. See “Risk Factors” for additional information.
We expect to continue to incur significant expenses and to increase operating losses for at least the next several years. We anticipate that our expenses will increase substantially as we seek to:
obtain marketing approval for our 6 millimeter HAV for vascular repair, reconstruction and replacement, including for vascular trauma and AV access for hemodialysis;
commercialize the HAV via U.S. market launches in vascular trauma and hemodialysis AV access;
scale out our manufacturing facility to the extent required to satisfy potential demand following any receipt of marketing approval;
continue our preclinical and clinical development efforts;
maintain, expand and protect our intellectual property portfolio;
add operational, financial and management information systems and personnel to support, among other things, our product development and commercialization efforts and operations; and
continue operating as a public company, which includes higher costs associated with hiring additional personnel, director and officer insurance premiums, audit and legal fees, and expenses for compliance with public company reporting requirements under the Securities Exchange Act of 1934 (the “Exchange Act”) and rules implemented by the SEC and The Nasdaq Stock Market LLC (“Nasdaq”).
Merger and Public Company Costs
On August 26, 2021 (the “Closing Date”), Legacy Humacyte and AHAC consummated a merger pursuant to that certain Business Combination Agreement, dated as of February 17, 2021 (the “Merger Agreement”), by and among Legacy Humacyte, AHAC and Hunter Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly owned subsidiary of AHAC. As contemplated by the Merger Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte continuing as the surviving corporation and as a wholly owned subsidiary of AHAC (the “Merger”). On the Closing Date, AHAC changed its name to Humacyte, Inc. and Legacy Humacyte changed its name to Humacyte Global, Inc. Operations prior to the Merger included in this Quarterly Report are those of Legacy Humacyte.
32

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (1) each outstanding share of common stock of Legacy Humacyte (“Legacy Humacyte common stock”) was cancelled and converted into the right to receive approximately 0.26260 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and (2) each outstanding share of preferred stock of Legacy Humacyte (“Legacy Humacyte preferred stock”) was cancelled and converted into the aggregate number of shares of Common Stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by approximately 0.26260, resulting in the issuance of a total of 75,656,935 shares of Common Stock. Prior holders of shares of Legacy Humacyte common stock and Legacy Humacyte preferred stock also received the contingent right to receive certain Contingent Earnout Shares (as defined below), for each share owned by each such Legacy Humacyte stockholder that was outstanding immediately prior to the closing of the Merger (the “Closing”). In addition, certain investors purchased an aggregate of 17,500,000 shares of Common Stock (such investors, the “PIPE Investors”) in a private placement that closed concurrently with the Closing for an aggregate purchase price of $175 million (the “PIPE Financing”). Additionally, at the Closing, 2,500,000 shares of AHAC’s Class B common stock (“Founder Shares”) automatically converted into shares of Common Stock on a one-for-one basis.
Following the Closing Date, former holders of Legacy Humacyte common stock and Legacy Humacyte preferred stock may receive up to 15,000,000 additional shares of Common Stock (“Contingent Earnout Shares”) in the aggregate in two equal tranches if the volume-weighted average closing sale price of our Common Stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period.
Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement.
Impact of COVID-19
The COVID-19 pandemic, which began in December 2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in-place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on our business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the COVID-19 pandemic, including any existing or potential variants of the virus which causes COVID-19, and its effects on our business and operations are uncertain. The COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay our clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on our business and operations. The pandemic has already caused significant disruptions in the financial markets and may continue to cause such disruptions, which could impact our ability to raise additional funds to support our operations. Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on our business and operations.
To date, the COVID-19 pandemic has not resulted in material financial impacts or impairment losses in the carrying values of our assets and we are not aware of any specific related event or circumstance that would require us to revise the estimates reflected in our financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including current and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, the emergence of new virus variants, and the duration and intensity of the related economic impact of the COVID-19 pandemic.
Components of Results of Operations
Revenue
To date, we have not generated revenue from the sale of any products. All of our revenue has been derived from government and other grants. Since inception we have been awarded grants from the California Institute of Regenerative Medicine (“CIRM”), the National Institutes of Health (“NIH”), and the Department of Defense (“DoD”), to support our development, production scaling and clinical trials of our product candidates. We may generate revenue in the future from government and other grants, payments from future license or collaboration agreements and, if any of our product candidates receive marketing approval, from product sales. We expect that any revenue we generate will fluctuate from quarter to quarter. If we fail to complete the development of, or obtain marketing approval for, our product candidates in a timely manner, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.
33

Research and Development Expenses
Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, developing our manufacturing process and activities related to regulatory filings for our product candidates. We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:
salaries and related overhead expenses for personnel in research and development functions, including stock-based compensation and benefits;
fees paid to consultants and clinical research organizations (“CROs”), including in connection with our clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work and statistical compilation and analysis;
allocation of facility lease and maintenance costs;
depreciation of leasehold improvements, laboratory equipment and computers;
costs related to purchasing raw materials and producing our product candidates for clinical trials;
costs related to compliance with regulatory requirements;
costs related to our manufacturing development and expanded-capabilities initiatives; and
license fees related to in-licensed technologies.
The majority of our research and development resources are currently focused on our Phase II and III clinical trials for our 6 millimeter HAV and other work needed to obtain marketing approval for our 6 millimeter HAV for use for vascular repair, reconstruction and replacement, including vascular trauma and AV access in hemodialysis in the United States. We have incurred and expect to continue to incur significant expenses in connection with these and our other clinical development efforts, including expenses related to regulatory filings, trial enrollment and conduct, data analysis, patient follow up and study report generation for our Phase II and Phase III clinical trials. We do not allocate all of our costs by each research and development program for which we are developing our cabinet of HAVs, as a significant amount of our development activities broadly support multiple programs that use our technology platform. We plan to further increase our research and development expenses for the foreseeable future as we continue the development of our proprietary scientific technology platform and our novel manufacturing paradigm.
The successful development of our preclinical and clinical product candidates is highly uncertain. At this time, we cannot estimate with any reasonable certainty the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our preclinical or clinical product candidates or the period, if any, in which material net cash inflows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our product candidates, including:
the scope, rate of progress, expense and results of our preclinical development activities, our ongoing clinical trials and any additional clinical trials that we may conduct, and other research and development activities;
successful patient enrollment in and the initiation and completion of clinical trials;
the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (“FDA”) and non-U.S. regulators;
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
development of clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that it or its third-party manufacturers are able to successfully manufacture our product;
obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
significant and changing government regulations;
34

launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others;
the degree of market acceptance of any product candidates that obtain marketing approval; and
maintaining a continued acceptable safety profile following approval, if any, of our product candidates.
A change in the outcome of any of these variables could lead to significant changes in the costs and timing associated with the development of our product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate being required to conduct in order to complete the clinical development of any of our product candidates, or if we experience significant delays in the enrollment or the conduct of any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs for employees in executive, finance, human resources, commercialization, and administrative support functions, which also include stock-based compensation expenses and benefits for such employees. Other significant general and administrative expenses include facilities costs, professional fees for accounting and legal services and expenses associated with obtaining and maintaining patents.
We expect our general and administrative expenses will continue to increase for the foreseeable future to support our expanded infrastructure and increased costs of operating as a public company and as we prepare for our anticipated commercial launch of the HAV. These increases are expected to include increased employee-related expenses, increased sales and marketing expenses, and increased director and officer insurance premiums, audit and legal fees, and expenses for compliance with public company reporting requirements under the Exchange Act and rules implemented by the SEC, as well as Nasdaq rules.
Other Income (Expense), Net
Total other income (expense), net consists of (i) the change in fair value of the Contingent Earnout Liability that was accounted for as a liability as of the date of the Merger, and is remeasured to fair value at each reporting period, resulting in a non-cash gain or loss, (ii) interest income earned on our cash and cash equivalents and short-term investments, (iii) interest expense incurred on our Loan Agreement, finance leases, and our PPP loan during the periods each were outstanding, (iv) a change in fair value of private placement common stock warrant liabilities related to the Private Placement Warrants, which we assumed in connection with the Merger, and which are subject to remeasurement to fair value at each balance sheet date resulting in a non-cash gain or loss, (v) a non-cash gain on PPP loan forgiveness during the nine months ended September 30, 2021, and (vi) during the nine months ended September 30, 2021, legal, accounting, and underwriting fees and other costs directly related to the consummation of the Merger that were associated with the aforementioned warrant liabilities.
35

Results of Operations
Comparison of the Three Months Ended September 30, 2022 and 2021
Three Months Ended September 30,Change
($ in thousands)20222021$%
Revenue$31 $241 $(210)(87)%
Operating expenses:  
Research and development17,337 15,386 1,951 13 %
General and administrative6,188 5,398 790 15 %
Total operating expenses23,525 20,784 2,741 13 %
Loss from operations(23,494)(20,543)(2,951)14 %
Other income (expense), net  
Change in fair value of Contingent Earnout Liability(962)(9,768)8,806 (90)%
Interest expense(1,641)(1,204)(437)36 %
Other income (expense), net816 (48)864 *
Total other expense, net(1,787)(11,020)9,233 (84)%
Net loss$(25,281)$(31,563)$6,282 (20)%
* Not meaningful
Grant Revenue
For the three months ended September 30, 2022 and 2021, revenue was less than $0.1 million and approximately $0.2 million, respectively, and related to our grant from DoD. The decrease in revenue of $0.2 million, or 87%, relates to the timing of reimbursement of certain allowable costs related to our grant from DoD, currently estimated to total approximately $6.8 million over the life of the grant.
Research and Development Expenses
The following table discloses the breakdown of research and development expenses:
Three Months Ended September 30,Change
($ in thousands)20222021$%
External services$4,542 $3,801 $741 19 %
Materials and supplies3,131 2,947 184 %
Payroll and personnel expenses6,448 5,775 673 12 %
Other research and development expenses3,216 2,863 353 12 %
$17,337 $15,386 $1,951 13 %
Research and development expenses increased by $2.0 million, or 13%, from $15.4 million for the three months ended September 30, 2021 to $17.3 million for the three months ended September 30, 2022. The increase was primarily driven by expenses to support our expanded research and development initiatives, including (i) increased salaries and benefits of $0.9 million, (ii) a $0.7 million increase in external services, (iii) a $0.4 million increase in other research and development expenses including software costs, professional fees and facility maintenance, and (iv) a $0.2 million increase in the purchase of materials and supplies to be used in the development of our commercial-scale manufacturing process and other research and development initiatives, partially offset by a $0.3 million decrease in non-cash stock compensation expense.
36

General and Administrative Expenses
General and administrative expenses were $6.2 million and $5.4 million for the three months ended September 30, 2022 and 2021, respectively. The increase in general and administrative expenses during this period of $0.8 million, or 15%, was primarily driven by expenses associated with the transition to public company status and company growth, including (i) a $0.4 million increase in salaries and benefits due to higher headcount, including the initial members of the planned commercial launch team, (ii) a $0.3 million increase in external services and (iii) a $0.2 million increase in professional fees, partially offset by a $0.1 million decrease in non-cash stock compensation expense.
Total Other Expense, net
Total other expense, net was $1.8 million and $11.0 million for the three months ended September 30, 2022 and 2021, respectively. The decrease in expense of $9.2 million primarily resulted from a $8.8 million reduction in the non-cash loss related to the remeasurement of the Contingent Earnout Liability as of September 30, 2022 compared to September 30, 2021 and a $0.9 million increase in interest income, partially offset by a $0.4 million increase in interest expense primarily related to our loan facility with Silicon Valley Bank.
Comparison of the Nine Months Ended September 30, 2022 and 2021
Nine Months Ended September 30,Change
($ in thousands)20222021$%
Revenue$1,565 $1,086 479 44 %
Operating expenses:
Research and development 48,303 45,091 3,212 %
General and administrative 17,050 15,576 1,474 %
Total operating expenses 65,353 60,667 4,686 %
Loss from operations (63,788)(59,581)(4,207)%
Other income (expense), net:
Change in fair value of Contingent Earnout Liability 58,649 (9,768)68,417 *
Interest expense (4,561)(2,952)(1,609)55 %
Gain on PPP loan forgiveness — 3,284 (3,284)(100)%
Other income (expense), net 1,455 (45)1,500 *
Total other income (expense), net 55,543 (9,481)65,024 *
Net loss $(8,245)$(69,062)$60,817 (88)%
* Not meaningful
Grant Revenue
For the nine months ended September 30, 2022 and 2021, revenue was approximately $1.6 million and $1.1 million, respectively, and related to our grant from DoD. The increase in revenue of $0.5 million, or 44%, relates to the timing of reimbursement of certain allowable costs related to our grant from DoD, currently estimated to total approximately $6.8 million over the life of the grant.
37

Research and Development Expenses
The following table discloses the breakdown of research and development expenses for the periods indicated:
Nine Months Ended September 30,Change
($ in thousands)20222021$%
External services$12,202 $11,534 $668 %
Materials and supplies8,706 8,141 565 %
Payroll and personnel expenses18,000 17,003 997 %
Other research and development expenses9,395 8,413 982 12 %
$48,303 $45,091 $3,212 %
Research and development expenses increased from $45.1 million for the nine months ended September 30, 2021 to $48.3 million for the nine months ended September 30, 2022. The increase of $3.2 million, or 7%, was primarily driven by expenses to support our expanded research and development initiatives, including (i) increased salaries and benefits of $2.2 million, (ii) a $1.0 million increase in other research and development expenses including facility maintenance, travel and software costs, (iii) a $0.7 million increase in external services including the support of clinical studies, and (iv) a $0.6 million increase in the purchase of materials and supplies to be used in the development of our commercial-scale manufacturing process and other research and development initiatives, partially offset by a $1.2 million decrease in non-cash stock compensation expense.
General and Administrative Expenses
General and administrative expenses were $17.1 million and $15.6 million for the nine months ended September 30, 2022 and 2021, respectively. The increase in general and administrative expenses during this period of $1.5 million, or 9%, was primarily driven by expenses associated with the transition to public company status and company growth, including (i) a $1.2 million increase in salaries and benefits and recruiting costs primarily due to higher headcount, including the initial members of the planned commercial launch team, (ii) increased professional fees of $0.7 million primarily related to increased legal and audit fees, (iii) a $0.5 million increase in insurance costs, (iv) a $0.4 million increase in external services, and (v) a $0.3 million increase in other general and administrative expenses, partially offset by a $1.7 million decrease in non-cash stock compensation expense primarily due to higher costs in 2021 resulting from restructuring of the management team to accommodate the transition to being a public company.
Total Other Income (Expense), net
Total other income, net was $55.5 million for the nine months ended September 30, 2022, compared to total other expense, net of $9.5 million for the nine months ended September 30, 2021. The increase in income of $65.0 million primarily resulted from (i) a $58.6 million non-cash gain related to the remeasurement of the Contingent Earnout Liability as of September 30, 2022, compared to a $9.8 million non-cash loss during the nine months ended September 30, 2021, (ii) a $1.2 million increase in interest income, and (iii) a $0.2 million non-cash gain related to the remeasurement of our private placement warrant liability, partially offset by (i) a $3.3 million gain on PPP loan forgiveness we recognized during the nine months ended September 30, 2021 and (ii) a $1.6 million increase in interest expense primarily related to our loan facility with Silicon Valley Bank, which commenced in March 2021.
Liquidity and Capital Resources
Sources of Liquidity
To date, we have financed our operations primarily through the sale of equity securities and convertible debt, proceeds from the Merger and related PIPE Financing, borrowings under loan facilities and, to a lesser extent, through grants from governmental and other agencies. Since our inception, we have incurred significant operating losses and negative cash flows. As of September 30, 2022 and December 31, 2021, we had an accumulated deficit of $422.8 million and $414.6 million, respectively.
38

As of September 30, 2022 and December 31, 2021, we had cash and cash equivalents and short-term investments of $171.7 million and $225.5 million, respectively. We believe our cash and cash equivalents and short-term investments will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements for at least 12 months from the date of this Quarterly Report. See Note 1 — Organization and Description of Business to our accompanying unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information regarding our assessment. We believe that our longer-term working capital, planned research and development, capital expenditures and other general corporate funding requirements will be satisfied through the sale of equity, debt, borrowings under credit facilities or through potential collaborations with other companies, other strategic transactions or government or other grants. Our liquidity plans are subject to a number of risks and uncertainties, including those described in the sections entitled “Forward-Looking Statements” and “Risk Factors” in this Quarterly Report and our Annual Report.
As of September 30, 2022 and December 31, 2021, we had working capital of $156.7 million and $218.3 million, respectively. As of September 30, 2022, we had $30.0 million outstanding principal and $20.0 million of contingent borrowing capacity under our Loan Agreement. We do not currently have any committed external source of funds beyond the Loan Agreement.
Material Cash Requirements
Our known material cash requirements include: (1) the purchase of supplies and services that are primarily for research and development; (2) debt repayments (for additional information, see below and Note 7 — Debt to our unaudited condensed consolidated financial statements contained elsewhere in this Quarterly Report); (3) employee wages, benefits, and incentives; and (4) financing and operating lease payments (for additional information see below). We have also entered into contracts with CROs primarily for clinical trials. These contracts generally provide for termination upon limited notice, and therefore we believe that our non-cancellable obligations under these agreements are not material. Moreover, we may be subject to additional material cash requirements that are contingent upon the occurrence of certain events, for example, legal contingencies, uncertain tax positions, and other matters.
As of September 30, 2022, we had non-cancellable purchase commitments of $16.8 million for supplies and services that are primarily for research and development. We have existing license agreements with Duke University and Yale University and have a distribution agreement with Fresenius Medical Care. The amount and timing of any potential milestone payments, license fee payments, royalties and other payments that we may be required to make under these agreements are unknown or uncertain at September 30, 2022. For additional information regarding our agreement with Fresenius Medical Care, and our agreements with Duke University and Yale University, see Note 12 — Related Party Transactions and Note 11 — Commitments and Contingencies, respectively, to our unaudited condensed consolidated financial statements contained elsewhere in this Quarterly Report.
Debt
In March 2021, we entered into the Loan Agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., as amended in June and September 2021, which provides a term loan facility of up to $50.0 million, with a maturity date of March 1, 2025. The initial term loan tranche of $20.0 million was funded upon the closing of the Loan Agreement, and on October 13, 2021, we borrowed an additional $10.0 million under the Loan Agreement. The additional $20.0 million becomes accessible in two tranches of $10.0 million each contingent on the achievement of certain business and clinical development milestones. As a result of the additional borrowing in October 2021, the commencement of repayment of principal was deferred until no earlier than July 2023 and potentially later if the remaining tranches are drawn. As of September 30, 2022, principal of $30.0 million was outstanding under the Loan Agreement and we were in compliance with all covenants in all material respects. Assuming no additional borrowings under the Loan Agreement, we expect to make interest payments of approximately $5.3 million under the Loan Agreement from October 1, 2022 through March 1, 2025, approximately $3.1 million of which we expect to pay within one year of September 30, 2022.
Our obligations under the Loan Agreement are secured by substantially all of our assets, except for our intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. We may use the proceeds of borrowings under the Loan Agreement as working capital and to fund our general business requirements.
39

Borrowings under the Loan Agreement bear interest at a rate of 7.5% or the sum of the Wall Street Journal Prime Rate plus 4.25%, whichever is greater (10.50% as of September 30, 2022). In addition, the lenders were granted warrants to purchase common stock. Interest-only payments on the principal amount outstanding are due monthly beginning in the first month after the loan is dispersed. We are required to repay principal beginning on July 1, 2023, unless we draw the remaining two loan tranches, in which case repayment of the outstanding principal amount will begin no later than April 1, 2024. Additionally, we are obligated to pay to the lenders a final payment fee of $1.5 million upon the maturity of the loan.
Our contractual obligations under the Loan Agreement as of September 30, 2022 include $4.3 million of cash payments related to principal within one year and $25.7 million of principal payments within one to three years.
In April 2020, we received loan proceeds in the amount of approximately $3.3 million under the PPP. The loan and accrued interest were forgivable after a 24-week period as long as we used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintained our payroll levels. On May 25, 2021, the Small Business Administration approved the forgiveness of the outstanding amount of the PPP loan and we recognized a gain from loan extinguishment in the amount of $3.3 million during the three months ended June 30, 2021.
Leases
Our finance lease relates to our headquarters facility containing our manufacturing, research and development and general and administrative functions, which was substantially completed in June 2018 and leased through May 2033, and our operating lease relates to the land lease associated with our headquarters. Our future contractual obligations under our lease agreements as of September 30, 2022 are as follows:
($ in thousands)TotalLess than
1 year
1 – 3 years
3 – 5 years
More than
5 years
Finance leases
$30,107 $3,941 $8,181 $7,433 $10,552 
Operating leases
1,021 105 211 211 494 
ATM Facility
On September 1, 2022, the Company entered into an agreement for the sale from time to time up to $80.0 million of shares of Common Stock pursuant to a sales agreement (the “ATM Facility”). As of September 30, 2022, the Company has not conducted any sales of Common Stock under the ATM Facility.
Future Funding Requirements
We expect to incur significant expenses in connection with our ongoing activities as we seek to (i) continue clinical development of our 6 millimeter HAV for use in vascular trauma and hemodialysis AV access and submit biologics license applications for FDA approval, (ii) if marketing approval is obtained, to launch and commercialize our HAVs for hemodialysis AV access and vascular repair in the U.S. market, including subsequent launches in key international markets, (iii) advance our pipeline in major markets, including PAD Phase III trials and continue preclinical development and advance to planned clinical studies in CABG and biovascular pancreas for diabetes, and (iv) scale out our manufacturing facility as required to satisfy potential demand if our HAVs receive marketing approval. We will need additional funding in connection with these activities.
Our future funding requirements, both short-term and long-term, will depend on many factors, including:
the progress and results of our clinical trials and interpretation of those results by the FDA and other regulatory authorities;
the cost, timing and outcome of regulatory review of our product candidates, particularly for marketing approval of our HAVs in the United States;
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our additional product candidates;
the cost and timing of our future commercialization activities, including product manufacturing, marketing and distribution for our HAVs if approved by the FDA, and any other product candidate for which we receive marketing approval in the future;
40

the amount and timing of revenues, if any, that we receive from commercial sales of any product candidates for which we receive marketing approval;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and
the costs of operating as a public company, including hiring additional personnel as well as increased director and officer insurance premiums, audit and legal fees, and expenses for compliance with public company reporting requirements under the Exchange Act and rules implemented by the SEC and Nasdaq.
Until such time, if ever, as we are able to successfully develop and commercialize one or more of our product candidates, we expect to continue financing our operations through the sale of equity, debt, borrowings under credit facilities or through potential collaborations with other companies, other strategic transactions or government or other grants. Adequate capital may not be available to us when needed or on acceptable terms. We do not currently have any committed external source of funds beyond the Loan Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures. Debt financing would also result in fixed payment obligations. If we are unable to raise capital, we could be forced to delay, reduce, suspend or cease our research and development programs or any future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition.
Our principal use of cash in recent periods has been primarily to fund our operations, including the clinical and preclinical development of our product candidates. Our future capital requirements, both short-term and long-term, will depend on many factors, including the progress and results of our clinical trials and preclinical development, timing and extent of spending to support development efforts, cost and timing of future commercialization activities, and the amount and timing of revenues, if any, that we receive from commercial sales.
See the section of this Quarterly Report entitled “Risk Factors” for additional risks associated with our substantial capital requirements.
41

Cash Flows
The following table shows a summary of our cash flows for each of the periods shown below:
Nine Months Ended September 30,
($ in thousands)20222021
Net loss$(8,245)$(69,062)
Non-cash adjustments to reconcile net loss to net cash used in operating activities(1):
(47,034)20,686 
Payment of liabilities assumed in Merger— (12,363)
Changes in operating assets and liabilities:3,109 997 
Net cash used in operating activities(52,170)(59,742)
Net cash used in investing activities(367)(175)
Net cash (used in) provided by financing activities(1,234)260,437 
Net (decrease) increase in cash and cash equivalents$(53,771)$200,520 
Cash and cash equivalents at the beginning of the period$217,502 $39,929 
Cash and cash equivalents at the end of the period$163,731 $240,449 
___________________________
(1) Includes depreciation, amortization related to our leases and our debt discount, stock-based compensation expense, the change in fair value of our Contingent Earnout Liability and our common stock warrant liabilities, and in 2021 includes a gain on PPP loan forgiveness.
Cash Flow from Operating Activities
The decrease in net cash used in operating activities from the nine months ended September 30, 2021 to the nine months ended September 30, 2022 was primarily due to $12.4 million in payments of liabilities acquired in the Merger during the nine months ended September 30, 2021, partially offset by increased spending on pre-clinical, clinical and pre-commercial activities as well as payroll and personnel expenses.
Cash Flow from Investing Activities
Net cash used in investing activities for the nine months ended September 30, 2022 and 2021 primarily consisted of the purchases of laboratory equipment.
Cash Flow from Financing Activities
The decrease in net cash provided by financing activities for the nine months ended September 30, 2022 was primarily due to $242.4 million of proceeds received in August 2021 in connection with the Merger, including proceeds from the trust account that we obtained in connection with the closing of the Merger, as well as from the PIPE Financing, along with $19.7 million of net proceeds in connection with draws under our loan facility with Silicon Valley Bank in March 2021.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in SEC rules and regulations.
Critical Accounting Estimates
Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of our unaudited condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and disclosure of contingent liabilities. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates based on different assumptions, judgments, or conditions.
42

An accounting estimate or assumption is considered critical if both (a) the nature of the estimate or assumption involves a significant level of estimation uncertainty, and (b) the impact within a reasonable range of outcomes of the estimate and assumption is material to our financial condition. There have been no material changes to our critical accounting policies and estimates as compared to those disclosed in our audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020, included in our Annual Report.
Emerging Growth Company and Smaller Reporting Company Status
We are an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies until it is no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We expect to use the extended transition period and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies, unless we choose to early adopt a new or revised accounting standard. This may make it difficult or impossible to compare our financial results with the financial results of another public company because of the potential differences in accounting standards used.
Additionally, we are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K under the Exchange Act (“Regulation S-K”). Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company if (1) the market value of Common Stock held by non-affiliates is less than $250 million as of the last business day of the second fiscal quarter, or (2) our annual revenues in our most recent fiscal year completed before the last business day of its second fiscal quarter are less than $100 million and the market value of Common Stock held by non-affiliates is less than $700 million as of the last business day of the second fiscal quarter.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We qualify as a smaller reporting company, as defined by Item 10 of Regulation S-K and, thus, are not required to provide the information required by this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
As of September 30, 2022, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2022.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

43

PART II – OTHER INFORMATION
Item 1. Legal Proceedings
The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows.
Item 1A. Risk Factors
Our risk factors are disclosed in Part I, Item 1A of our Annual Report. There have been no material changes during the nine months ended September 30, 2022 from or updates to the risk factors discussed in Part I, Item 1A, Risk Factors of our Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
None.
44

Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
Exhibit
Number
Description
10.1
31.1*
31.2*
32.1**
32.2**
101*
The following materials from Humacyte, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited), (iii) Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited), (v) Notes to Condensed Consolidated Financial Statements (unaudited), and (vi) Cover Page.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
** This exhibit is being furnished rather than filed, and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.
45

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 10th day of November, 2022.
HUMACYTE, INC.
Date: November 10, 2022
By: /s/ Laura E. Niklason, M.D., Ph.D.
Name:  Laura E. Niklason, M.D., Ph.D.
Title:President and Chief Executive Officer
By: /s/ Dale A. Sander
Name:  Dale A. Sander
Title:Chief Financial Officer, Chief Corporate Development Officer and Treasurer
46
EX-31.1 2 huma-20220930x10qxex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Laura E. Niklason, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Humacyte, Inc. for the quarter ended September 30, 2022;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 10, 2022
By:/s/ Laura E. Niklason
Name:Laura E. Niklason, M.D., Ph.D.
Title:President and Chief Executive Officer

EX-31.2 3 huma-20220930x10qxex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Dale A. Sander, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Humacyte, Inc. for the quarter ended September 30, 2022;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 10, 2022
By: /s/ Dale A. Sander
Name:Dale A. Sander
Title:Chief Financial Officer, Chief Corporate Development Officer and Treasurer

EX-32.1 4 huma-20220930x10qxex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION
In connection with the Quarterly Report on Form 10-Q of Humacyte, Inc. (the “Company”) for the quarter ended September 30, 2022 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Laura E. Niklason, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 10, 2022
By:/s/ Laura E. Niklason
Name:Laura E. Niklason, M.D., Ph.D.
Title:President and Chief Executive Officer

EX-32.2 5 huma-20220930x10qxex322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION
In connection with the Quarterly Report on Form 10-Q of Humacyte, Inc. (the “Company”) for the quarter ended September 30, 2022 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Dale A. Sander, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 10, 2022
By:/s/ Dale A. Sander
Name:Dale A. Sander
Title:Chief Financial Officer, Chief Corporate Development Officer and Treasurer

EX-101.SCH 6 huma-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Reverse Recapitalization link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Reverse Recapitalization (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Stockholders' Equity (Deficit) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Summary of Significant Accounting Policies - Segments (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Reverse Recapitalization - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Reverse Recapitalization - Common Stock Outstanding Immediately Following the Consummation of the Merger (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Fair Value Measurements - Changes in Fair Value of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Debt - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Debt - SVB Loan Payable and Net Discount or Premium Balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Debt - SVB Loan Payable and Net Discount or Premium Balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Debt - Future Minimum Payments of Principal (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Stockholders' Equity (Deficit) - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Stockholders' Equity (Deficit) - Common stock for future issuances (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Stockholders' Equity (Deficit) - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Stockholders' Equity (Deficit) - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Stockholders' Equity (Deficit) - Warrants Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Stockholders' Equity (Deficit) - Public Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Stockholders' Equity (Deficit) - Private Placement Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Stockholders' Equity (Deficit) - Contingent Earnout Liability (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Stock-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Stock-based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Stock-based Compensation - Remaining Unrecognized Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Related Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Related Party Transactions - Related Party Expenses (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 huma-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 huma-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 huma-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Unpaid liabilities assumed in connection with Merger Unpaid Liabilities Assumed in Connection with Merger Amount of unpaid liabilities assumed in connection with Merger. Business Acquisition [Axis] Business Acquisition [Axis] Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares) Temporary Equity Stock Issued During Period Shares Conversion Merger And Related Pipe Financing Temporary Equity Stock Issued During Period Shares Conversion Merger And Related Pipe Financing Related Party Transactions [Abstract] Principal amount of SVB loan payable Total future payments Long-Term Debt, Gross Proceeds from maturity of short-term investments (certificates of deposit) Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Entity Address, Postal Zip Code Entity Address, Postal Zip Code Finance lease right-of-use assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Property, Plant and Equipment [Abstract] Minimum fixed rate on variable rate Debt Instrument, Interest Rate, Minimum Fixed Rate On Variable Rate Debt Instrument, Interest Rate, Minimum Fixed Rate On Variable Rate Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding 2024 Long-Term Debt, Maturity, Year Two Short-term investments (certificates of deposit) Investments, Fair Value Disclosure Contingent Earnout Liability Business Combinations Policy [Policy Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Property and equipment, gross Property, Plant and Equipment, Gross Related party expenses Related Party Transaction, Expenses from Transactions with Related Party Income Taxes Income Tax Disclosure [Abstract] Warrants immediately exercisable (in shares) Class of Warrant or Right, Warrants Exercisable Immediately Represents the number of warrants immediately exercisable. Contingent Earnout Liability Contingent Earnout Liability Contingent Earnout Liability [Member] Represents the information pertaining to contingent earnout liability. Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Financing transaction Proceeds from Issuance or Sale of Equity Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation expense Depreciation License Agreement License Agreement [Member] Represents the pertaining information to license agreement. Proceeds from debt instruments Proceeds from Issuance of Debt Proceeds from the exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Accrued interest on PPP loan obligation Interest Expense, Debt, Excluding Amortization Yale University Yale University [Member] Represents the information pertaining to yale university. Share-Based Payment Arrangement [Abstract] Asset Acquisition [Table] Asset Acquisition [Table] Collaborative Arrangement, Milestone Payments [Axis] Collaborative Arrangement, Milestone Payments [Axis] Collaborative Arrangement, Milestone Payments Founder shares converted to common stock (in shares) Shares acquired (in shares) Stock Issued During Period, Shares, Acquisitions Debt Instrument, Prepayment Fee, Period One Debt Instrument, Prepayment Fee, Period One [Member] Debt Instrument, Prepayment Fee, Period One Beginning balance (in shares) Ending balance (in shares) Temporary Equity, Shares Outstanding Net loss Net income (loss) Net loss Net Income (Loss) Attributable to Parent Measurement Input Type [Domain] Measurement Input Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Securities that were not included in the computation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Information [Line Items] Document Information [Line Items] Summary of Future Minimum Payments of Principal Schedule of Maturities of Long-Term Debt [Table Text Block] Equity Component [Domain] Equity Component [Domain] Total financial assets Assets, Fair Value Disclosure Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Founder shares conversion ratio Reverse Recapitalization, Founder Shares Conversion, Ratio The ratio of the conversion of founder shares to common stock upon closing of business combination. Amortization expense Finance Lease, Right-of-Use Asset, Amortization Related Party [Domain] Related Party [Domain] Plan Name [Axis] Plan Name [Axis] Other Other Related Party Expenses [Member] Represents the information pertaining to other research and development expenses. Number of days warrants become exercisable after the completion of merger Number of Days Warrants Become Exercisable After the Completion of Merger The number of days warrants become exercisable after the completion of merger. Estimated dividend yield Measurement Input, Expected Dividend Rate [Member] Supplemental disclosure Supplemental Cash Flow Information [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Debt Instrument, Prepayment Fee, Period [Domain] Debt Instrument, Prepayment Fee, Period [Domain] Debt Instrument, Prepayment Fee, Period [Domain] Number of operating segments Number of Operating Segments Plan Name [Domain] Plan Name [Domain] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] ESPP Employee Stock [Member] Weighted average remaining contractual term, outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Contingent Consideration Tranches [Axis] Contingent Consideration Tranches [Axis] Represents the contingent consideration tranches number. Award Type [Axis] Award Type [Axis] Contingent Consideration by Type [Domain] Contingent Consideration Type [Domain] Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating lease obligation, current portion Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Related Party Transaction [Domain] Related Party Transaction [Domain] Transaction costs expensed Reverse Recapitalization, Transaction Costs Expensed This element represents costs incurred to effect a reverse recapitalization which have been expensed during the period, including banking, legal, and other professional fees. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Private Placement Warrants Private Placement Warrants [Member] Represents the information pertaining to private placement warrants. Lender Name [Axis] Lender Name [Axis] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Liability Class [Axis] Liability Class [Axis] Legal Entity [Axis] Legal Entity [Axis] SVB loan payable, noncurrent portion Long-Term Debt, Excluding Current Maturities Cash equivalents (certificates of deposit) Certificates of Deposit [Member] Total liabilities Liabilities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] The Merger and related PIPE financing, net of transaction costs and acquired liabilities Stock Issued During Period, Value, New Issues Number of tranches of contingent earnout shares Reverse Recapitalization, Contingent Consideration, Liability, Number of Tranches The number of tranches of shares of combined entity that equity holders of acquiring entity are entitled to upon occurrence of triggering events. Humacyte, Inc. Humacyte, Inc. [Member] Represents Humacyte, Inc. Redeemable convertible preferred Stock Increase (Decrease) in Temporary Equity [Roll Forward] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding BVP Patent Rights BVP Patent Rights [Member] BVP Patent Rights Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fresenius Medical Care Fresenius Medical Care [Member] Represents information pertaining to Fresenius Medical Care. Scientific equipment, not placed into service Scientific Equipment, Not Placed Into Service [Member] Scientific Equipment, Not Placed Into Service Scientific equipment Scientific Equipment [Member] N/A Schedule Of Property And Equipment Property, Plant and Equipment [Table Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Collaborative Arrangement, Milestone Payments [Domain] Collaborative Arrangement, Milestone Payments [Domain] Collaborative Arrangement, Milestone Payments [Domain] Assets: Assets, Fair Value Disclosure [Abstract] Debt Debt Disclosure [Text Block] Shares issued under agreement (in shares) Collaborative Arrangement, Shares Issued Represents the number of shares issued in connection with License agreement. Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accrued expenses Increase (Decrease) in Accrued Liabilities Concentration Risk [Table] Concentration Risk [Table] Number of securities issued or issuable (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Earnout Shares Earnout Shares [Member] Earnout Shares 2025 Long-Term Debt, Maturity, Year Three Revenue Benchmark Revenue Benchmark [Member] Document Period End Date Document Period End Date Transaction costs recorded in APIC Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Fair Value per share on Closing Date (in dollars per share) Fair Value per Share on Closing Date Fair value per share on closing date. Issuance of options under stock plans Issuance of options under stock plan [Member] Represents the information on issuance of options under stock plan. Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] SVB loan payable, current portion Secured Debt, Current Total assets Assets Debt Disclosure [Abstract] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Income Statement Location [Axis] Income Statement Location [Axis] Expiration period of agreement Collaborative Arrangement, Expiration Period Represents the agreement expiration term after first commercial sale. Assumptions on the date of grant to estimate the fair value of the stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accrued expenses Total Accrued Liabilities, Current Credit Concentration Risk Credit Concentration Risk [Member] Less SVB loan payable, current portion Long-Term Debt, Current Maturities Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Stockholders' Equity Note [Abstract] Accrued employee compensation and benefits Employee-related Liabilities, Current Beginning balance Ending balance Temporary Equity, Carrying Amount, Attributable to Parent Amount that will be eligible to disburse per tranche Debt Instrument, Unused Borrowing Capacity, Amount per Tranche Debt Instrument, Unused Borrowing Capacity, Amount per Tranche Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Schedule of Assumptions Used to Estimate Fair Value of Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Finance lease obligation, net of current portion Finance Lease, Liability, Noncurrent Operating lease obligation Increase (Decrease) in Operating Lease Liability Related Party Transaction [Line Items] Related Party Transaction [Line Items] Accelerated vesting ending period Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting Ending Period Represents the end of involuntary termination term after effective date of corporate transaction. Short-term Investments Short-Term Investments [Member] Award Type [Domain] Award Type [Domain] Expected weighted average period compensation costs to be recognized (years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Gain on PPP loan forgiveness Gain on PPP loan forgiveness Gain (Loss) on Extinguishment of Debt Weighted average remaining contractual term, vested and exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term AHAC Founders AHAC Founders [Member] AHAC Founders Computer equipment Computer Equipment [Member] Maximum contingent earnout (in shares) Reverse Recapitalization, Contingent Consideration, Liability, Shares The maximum aggregate number of shares of combined entity that equity holders of acquiring entity are entitled to upon occurrence of triggering events. Entity Registrant Name Entity Registrant Name Closing stock price to trigger contingent earnout shares (in dollars per share) Reverse Recapitalization, Contingent Consideration, Liability, Per Share Reverse Recapitalization, Contingent Consideration, Liability, Per Share The Merger and related PIPE financing, net of transaction costs and acquired liabilities (in shares) New Humacyte shares issued to PIPE Investors (in shares) Stock Issued During Period, Shares, New Issues Merger Agreement Merger Agreement [Member] Merger Agreement Estimated dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Software Software Development [Member] Entity Address, City or Town Entity Address, City or Town Accelerated vesting commencement period Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting Commencement Period Represents the commencement of involuntary termination term prior to effective date of corporate transaction. Operating expenses: Operating Expenses [Abstract] Expected term (years) Measurement Input, Expected Term [Member] Tubular Prostheses Patent Rights Tubular Prostheses Patent Rights [Member] Tubular Prostheses Patent Rights SVB Loan payable SVB Loan Payable [Member] Represents information pertaining to SVB loan payable. Grant revenue Revenue Not from Contract with Customer Minimum Minimum [Member] Distribution agreement, termination period Distribution Agreement, Termination Period Distribution Agreement, Termination Period Issuance of warrants in conjunction with debt Issuance of Stock Warrants in Conjunction with Debt Represents the issuance of stock warrants in conjunction with debt noncash investing or financing activities. Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Warrants exercised, minimum percent of outstanding shares, to receive cash Warrants Exercised, Minimum Percent Of Outstanding Shares, To Receive Cash Warrants Exercised, Minimum Percent Of Outstanding Shares, To Receive Cash Amount of loan drawn Proceeds from Issuance of Secured Debt Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Deferred payroll tax Accrued Payroll Taxes, Current Research and development Research and Development Expense Purchase of short-term investments (certificates of deposit) Payments to Acquire Short-Term Investments Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing Stock Issued During Period Value Conversion Merger And Related Pipe Financing Stock Issued During Period Value Conversion Merger And Related Pipe Financing Paycheck Protection Program Paycheck Protection Program [Member] Represents the information pertaining to Paycheck Protection Program. Effective tax rate Effective Income Tax Rate Reconciliation, Percent Grant Revenue Revenue From Grants [Member] Revenue From Grants Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Number of equity incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans The number of plans in share-based compensation arrangement. Number of shares, vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Reverse Recapitalization Business Combination Disclosure [Text Block] Other income (expense), net: Other Nonoperating Income (Expense) [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Prime Rate Prime Rate [Member] Concentration risk, percentage Concentration Risk, Percentage Number of tranches Debt Instrument, Number of Tranches The number of tranches of loan release in a loan agreement. Weighted average expected share price volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Summary Of Common Stock Reserved For Future Issuances Schedule of Common Stock Reserved For Future Issuance [Table Text Block] The tabular disclosure of common stock were reserved for future issuance. Income Taxes Income Tax Disclosure [Text Block] SVB loan payable, net of current portion Secured Long-Term Debt, Noncurrent Warrants, exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Cash paid for interest on SVB loan Interest Paid, Excluding Capitalized Interest, Operating Activities Number of contingent earnout shares per tranche (in shares) Reverse Recapitalization, Contingent Consideration, Liability, Shares Per Tranche The number of shares of combined entity per tranche that equity holders of acquiring entity are entitled to upon occurrence of triggering events. Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic Decellularized Tissue Engineering Patent Rights Decellularized Tissue Engineering Patent Rights [Member] Decellularized Tissue Engineering Patent Rights Common Stock Warrants Warrants And Rights Outstanding, Policy [Policy Text Block] Warrants And Rights Outstanding, Policy Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Stock Option Plan, 2005 Stock Option Plan, 2005 [Member] Represents 2005 Stock Option plan. Dividends, common stock Dividends, Common Stock Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Entity Interactive Data Current Entity Interactive Data Current Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Share accepting a tender offer entitles warrants to receive cash (as a percent) Class of Warrant or Right, Redemption Threshold The percentage of outstanding shares that accept a tender or exchange offer made that triggers entitles holders to receive cash for all warrants. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Summary of Changes in Fair Value of Level 3 Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Cash equivalents (money market funds) Money Market Funds [Member] Accumulated Deficit Retained Earnings [Member] Unrecognized stock-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Common Stock Common Stock [Member] Summary of Stock-Based Compensation Expense and Remaining Unrecognized Costs Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Number of reportable segment Number of Reportable Segments Number of shares remaining available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Contingent Earnout Liability Business Combination, Contingent Consideration, Liability Class of Stock [Axis] Class of Stock [Axis] Statement [Table] Statement [Table] Cash, cash equivalents, and short-term investments Cash, Cash Equivalents, and Short-Term Investments Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Document Quarterly Report Document Quarterly Report Public Warrants Public Warrants [Member] Represents the information pertaining to Public Warrants. Assets assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Furniture and fixtures Furniture and Fixtures [Member] Current assets Assets, Current [Abstract] Number of trading days Reverse Recapitalization, Contingent Consideration, Liability, Stock Price Trigger, Number Of Trading Days The number of days that volume-weighted average closing sale price of stock within 30 day period that triggers the earnout shares of combined entity for former holders of acquiree stocks Operating lease obligation, net of current portion Operating Lease, Liability, Noncurrent Omnibus Incentive Plan, 2015 Omnibus Incentive Plan, 2015 [Member] Represents 2015 Omnibus Incentive Plan. Schedule Of Assumptions Used In The Valuations Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Final payment amount of SVB loan payable Debt Instrument, Final Payment Amount Final payment amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Debt Instrument, Prepayment Fee, Period [Axis] Debt Instrument, Prepayment Fee, Period [Axis] Debt Instrument, Prepayment Fee, Period Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Proceeds from PIPE Financing Proceeds from Issuance of Private Placement Recurring Fair Value, Recurring [Member] Weighted average exercise price, vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party Transactions Related Party Transactions Disclosure [Text Block] Segments Segment Reporting, Policy [Policy Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Expected term (years) Warrants and Rights Outstanding, Term Payment of finance lease principal Finance Lease, Principal Payments Term Loan Agreement Term Loan Agreement [Member] Represents the information pertaining to term loan agreement. Legacy Humacyte common stock conversion ratio to common stock Recapitalization Exchange Ratio The conversion ratio of the acquiree's common stock to the combined entity's common stock. Total other income (expense), net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Change in fair value of Contingent Earnout Liability Change in fair value of Contingent Earnout Liability Change in fair value of Contingent Earnout Liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Long-Term Incentive Plan, 2021 Long-Term Incentive Plan, 2021 [Member] Represents the 2021 Long-Term Incentive Plan. Weighted average exercise price, vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report AHAC AHAC [Member] AHAC Local Phone Number Local Phone Number Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating losses Operating Income (Loss) Debt Instrument, Prepayment Fee, Period Two Debt Instrument, Prepayment Fee, Period Two [Member] Debt Instrument, Prepayment Fee, Period Two Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Milestone payments Collaborative Arrangement, Milestone Payments Represents the amount of milestone payments upon achievement of certain regulatory milestones. Document Information [Table] Document Information [Table] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding License expenses License Expenses [Member] Represents the information pertaining to License expenses. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Less redemption of AHAC shares (in shares) Stock Repurchased During Period, Shares Number of consecutive trading days Reverse Recapitalization, Contingent Consideration, Liability, Stock Price Trigger, Number of Consecutive Trading Day Period The period over which the number of days that volume-weighted average closing sale price of stock that triggers the earnout shares of combined entity for former holders of acquiree stocks. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax expense or benefit Income Tax Expense (Benefit) Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Government Contracts Concentration Risk Government Contracts Concentration Risk [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Number of vote per common share held Common Stock, Number of Votes Per Unit Of Shares Held Represents the number of vote per common share held. Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average expected share price volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Outstanding principal and interest collateralized Debt Instrument, Percent of Collateral Amount in Outstanding Principal and Interest Percent of amount to be collateralized in outstanding principal and interest. Expected term of options (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing Temporary Equity Stock Issued During Period Value Conversion Merger And Related Pipe Financing Temporary Equity Stock Issued During Period Value Conversion Merger And Related Pipe Financing Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Accounts Receivable Accounts Receivable [Member] Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares) Stock Issued During Period, Shares, Conversion, Merger and Related PIPE Financing The number of stock issued during the period for conversion of common stock in connection with the Merger and related PIPE financing. Schedule of Reverse Recapitalization [Line Items] Schedule of Reverse Recapitalization [Line Items] Schedule of Reverse Recapitalization [Line Items] Common stock, $0.0001 par value; 250,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 103,098,768 and 103,003,646 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Summary of securities that could potentially dilute net loss per share in the future that were not included in the computation of diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Aggregate intrinsic value, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Liabilities: Financial Liabilities Fair Value Disclosure [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Private Placement Private Placement [Member] Preferred stock, shares designated (in shares) Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Public warrants assumed upon the Merger, net of transaction costs Adjustments to Additional Paid in Capital, Warrant Issued Warrants, measurement input Warrants and Rights Outstanding, Measurement Input Market price of public stock Current stock price Measurement Input, Share Price [Member] Current liabilities Liabilities, Current [Abstract] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Common stock, shares issued (in shares) Common stock issued (in shares) Common Stock, Shares, Issued Private placement warrant liability acquired as part of the Merger Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Contingent Consideration Liability recognized upon the closing of the reverse recapitalization Reverse Recapitalization, Contingent Consideration, Liability Recognized Amount of contingent consideration liability recognized upon the closing of the reverse recapitalization. Weighted average remaining contractual term, vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Concentration Risk [Line Items] Concentration Risk [Line Items] Purchase of property and equipment in accounts payable Capital Expenditures Incurred but Not yet Paid Proceeds from SVB loan Proceeds from Bank Debt Common stock warrant liabilities Private Placement Warrants liability Warrants and Rights Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Finance lease obligation, current portion Finance Lease, Liability, Current Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Exercise price Measurement Input, Exercise Price [Member] Capital Shares Reserved for Future Issuance [Domain] Capital Shares Reserved for Future Issuance [Domain] Information on capital stock reserved for future issuance. Transaction costs expensed (less than) Professional Fees Maximum loan facility amount Debt Instrument, Face Amount Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., [Member] Represents the information pertaining to Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.,. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Construction in progress Construction in Progress [Member] Payment of transaction costs related to Merger Payments of Merger Related Costs, Financing Activities Entity Current Reporting Status Entity Current Reporting Status Assumption Of Publicly Traded Securities Assumption Of Publicly Traded Securities [Member] Assumption Of Publicly Traded Securities Future minimum payments of principal and estimated payments of interest Long-Term Debt, Fiscal Year Maturity [Abstract] Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Number of shares, vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Purchase price of common stock, percent of closing trading price Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Common Shareholders Common Shareholders [Member] Common Shareholders Counterparty Name [Axis] Counterparty Name [Axis] Summary of Related Party Expenses Schedule of Related Party Transactions [Table Text Block] Outstanding awards (in shares) Options outstanding, beginning of period (in shares) Options outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Net premium associated with accretion of final payment and other debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Change in fair value included in other income (expense), net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Exercise of options under stock plan Options Share-Based Payment Arrangement, Option [Member] Weighted average expected share price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Transaction costs Transaction Costs for Raising Capital Amount of transaction costs for raising capital. Advance notice period Debt Instrument, Advance Notice Period N/A Proceeds from the exercise of stock options Stock Issued During Period, Value, Stock Options Exercised SVB loan payable, current and noncurrent Long-Term Debt Balance Sheet Location [Axis] Balance Sheet Location [Axis] Price per share (in dollars per share) Sale of Stock, Price Per Share Common stock, shares authorized (in shares) Common stock, authorized (in shares) Common Stock, Shares Authorized Contingent Earnout Liability Business Combination, Contingent Consideration, Liability, Noncurrent Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Statement of Comprehensive Income [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Annual increase in available shares Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Annual Increase, Percent The annual increase of shares reserve for the share-based compensation plans as percent of the lesser of the number of shares of the entity's common stock outstanding on calendar year end of the preceding year and a number of shares of common stock determined by the Company's board of directors. Regulatory Milestone Regulatory Milestone [Member] Regulatory Milestone Accrued external research, development and manufacturing costs Accrued External Research Development And Manufacturing Costs, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research, development, and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Maximum annual maintenance fee, less than Collaborative Arrangement, Maximum Annual Maintenance Fee Represents the amount of maximum annual maintenance fee. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Schedule Of Activity Of Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity (Deficit) Stockholders' Equity Note Disclosure [Text Block] Non-cash operating lease costs Operating Lease, Right-of-Use Asset, Amortization Expense Line of Credit Facility [Table] Line of Credit Facility [Table] Contingent Consideration Tranches [Domain] Contingent Consideration Tranches [Domain] Contingent consideration tranches number. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Amortization of SVB debt discount Amortization of Debt Discount (Premium) Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of Reverse Recapitalization [Table] Schedule of Reverse Recapitalization [Table] Schedule of Reverse Recapitalization [Table] Short-term investments Short-Term Investments Conversion of stock (in shares) Conversion of Stock, Shares Issued Conversion of redeemable convertible preferred stock into common stock in connection with the reverse capitalization Conversion of Stock, Amount Converted Debt Instrument [Line Items] Debt Instrument [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Stock [Line Items] Class of Stock [Line Items] Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 [Member] Information pertaining to redeemable warrants exercisable for common stock. Final payment fee percentage Debt Instrument, Final Payment Fee, Percent Represents the percentage of final payment fee. Expected share price volatility Measurement Input, Price Volatility [Member] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Small-Diameter Vessels Patent Rights Small-Diameter Vessels Patent Rights [Member] Small-Diameter Vessels Patent Rights Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] 2022 (remainder) Long-Term Debt, Maturity, Remainder of Fiscal Year Proceeds from Merger and PIPE financing, net of offering costs paid Proceeds From Reverse Recapitalization, Net Of Offering Costs Paid The cash inflow associated with the amount received from a reverse recapitalization, net of offering costs paid. Contingent Earnout Liability recognized upon closing of the reverse recapitalization Adjustments To Additional Paid In Capital Contingent Consideration Liability Recognized Adjustments To Additional Paid In Capital Contingent Consideration Liability Recognized Aggregate purchase price Sale of Stock, Consideration Received on Transaction Tranche two Contingent Consideration Tranche Two [Member] Represents the information pertaining to contingent consideration tranche two. Accounts payable Accounts Payable, Current Aggregate intrinsic value, vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Warrants to purchase common stock Warrant [Member] Entity Filer Category Entity Filer Category Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Accrued Liabilities, Current [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Expense Supplemental disclosure of noncash activities: Noncash Investing and Financing Items [Abstract] Commitments and contingencies (Note 11) Commitments and Contingencies Security Exchange Name Security Exchange Name Options outstanding, beginning of period (in dollars per share) Options outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Issuance of common stock upon reverse recapitalization and PIPE Financing (in shares) Stock Issued During Period, Shares, Reverse Recapitalization Stock Issued During Period, Shares, Reverse Recapitalization Preferred stock, $0.0001 par value; 20,000,000 shares designated as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021 Preferred Stock, Value, Issued Capital Shares Reserved for Future Issuance [Axis] Capital Shares Reserved for Future Issuance [Axis] The table relating to information on capital stock reserved for future issuance. Payment of liabilities assumed in Merger Payments for Merger Related Costs Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative General and Administrative Expense [Member] Unpaid transaction costs in connection with Merger Unpaid Transaction Costs In Connection With Merger Amount of unpaid transaction costs in connection with Merger. Reserved common stock for future issuances (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cash and Cash Equivalents Cash and Cash Equivalents [Member] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Certificates of deposit Certificates of Deposit, at Carrying Value Debt Instrument, Prepayment Fee, Period Three Debt Instrument, Prepayment Fee, Period Three [Member] Debt Instrument, Prepayment Fee, Period Three Stock-based Compensation Share-Based Payment Arrangement [Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Total liabilities and stockholders’ equity Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Debt issuance costs Amortization of Debt Issuance Costs Related Party [Axis] Related Party [Axis] Warrants exercised (in shares) Number of Warrants Exercised Number of warrants exercised. Organization, Consolidation and Presentation of Financial Statements [Abstract] Contingent Earnout Liability recognized upon the closing of the reverse recapitalization Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Tranche one Contingent Consideration Tranche One [Member] Represents the information pertaining to contingent consideration tranche one. Current Fiscal Year End Date Current Fiscal Year End Date Net loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Payment of deferred offering costs Payments of Stock Issuance Costs Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Change in fair value of common stock warrant liabilities Change in fair value of common stock warrant liabilities Fair Value Adjustment of Warrants Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Exercisable warrants upon funding of additional tranche (in shares) Class of Warrant or Right, Exercisable Upon Funding of Additional Tranche Number of warrants that becomes exercisable upon borrowing an additional loan tranche in a loan agreement. Reverse Recapitalization [Abstract] Reverse Recapitalization Entity Ex Transition Period Entity Ex Transition Period Contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Entity Address, Address Line One Entity Address, Address Line One New Humacyte shares issued in Merger to Legacy Humacyte stockholders (in shares) Stock Converted, Reverse Recapitalization Stock Converted, Reverse Recapitalization Product and Service [Axis] Product and Service [Axis] Schedule of Common Stock Outstanding Immediately Following the Consummation of the Merger Schedule of Common Stock Outstanding Immediately Following the Consummation of the Merger [Table Text Block] Tabular disclosure of common stock outstanding immediately following the consummation of the Merger. Class of Stock [Domain] Class of Stock [Domain] Fair Value Disclosures [Abstract] Interest expense Interest Expense Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Summary of SVB Loan Payable and Net Discount or Premium Balances Schedule of Long-Term Debt Instruments [Table Text Block] Commercial Milestone Commercial Milestone [Member] Commercial Milestone Entity Tax Identification Number Entity Tax Identification Number Asset Acquisition [Line Items] Asset Acquisition [Line Items] Changes in the fair value of the Level 3 financial instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued Liabilities Accrued Liabilities [Member] Measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Interest income Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Entity [Domain] Entity [Domain] Duke University Duke University [Member] Represents the pertaining information of duke university. City Area Code City Area Code Accrued professional fees Accrued Professional Fees, Current General and administrative General and Administrative Expense ASSETS Assets [Abstract] Common stock reserved for Contingent Earnout Shares Common stock reserved for Contingent Consideration Shares [Member] Represents the information pertaining to common stock reserved for Contingent Consideration Shares. Accrued Expenses Accrued Liabilities Disclosure [Text Block] The entire disclosure for Accrued Liabilities Disclosure of financial statements disclosure. Shares available for grant under ESPP Shares available for grant under ESPP [Member] Represents the information pertaining to shares available for grant under ESPP. Statement of Stockholders' Equity [Abstract] Termination period Collaborative Arrangement, Termination Period Represents the threshold notice period required to terminate the agreement. Sale of Stock [Axis] Sale of Stock [Axis] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Total financial liabilities Financial Liabilities Fair Value Disclosure Net Loss per Share Attributable to Common Stockholders Earnings Per Share, Policy [Policy Text Block] 2023 Long-Term Debt, Maturity, Year One Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Warrants (in shares) Class of Warrant or Right, Outstanding Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Prepayment fee Debt Instrument, Prepayment Fee, Percent Debt Instrument, Prepayment Fee, Percent Issuance of warrants in conjunction with debt Adjustments to Additional Paid in Capital, Warrant Issued In Conjunction With Debt Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants in conjunction with allocation of proceeds of debt securities issued with detachable stock purchase warrants. EX-101.PRE 10 huma-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
9 Months Ended
Sep. 30, 2022
Nov. 04, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-39532  
Entity Registrant Name Humacyte, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-1763759  
Entity Address, Address Line One 2525 East North Carolina Highway 54  
Entity Address, City or Town Durham,  
Entity Address, State or Province NC  
Entity Address, Postal Zip Code 27713  
City Area Code 919  
Local Phone Number 313-9633  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   103,118,461
Entity Central Index Key 0001818382  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Common Stock    
Document Information [Line Items]    
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol HUMA  
Security Exchange Name NASDAQ  
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50    
Document Information [Line Items]    
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50  
Trading Symbol HUMAW  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 163,731 $ 217,502
Short-term investments 8,000 8,000
Accounts receivable 31 176
Prepaid expenses and other current assets 2,850 3,662
Total current assets 174,612 229,340
Finance lease right-of-use assets, net 19,888 21,432
Operating lease right-of-use assets, net 693 727
Property and equipment, net 31,026 35,034
Total assets 226,219 286,533
Current liabilities    
Accounts payable 3,255 2,094
Accrued expenses 7,959 6,757
SVB loan payable, current portion 4,286 0
Finance lease obligation, current portion 2,185 1,981
Deferred payroll tax 173 173
Operating lease obligation, current portion 48 45
Total current liabilities 17,906 11,050
Contingent Earnout Liability 45,011 103,660
SVB loan payable, net of current portion 24,286 27,361
Finance lease obligation, net of current portion 19,442 21,109
Operating lease obligation, net of current portion 645 682
Common stock warrant liabilities 257 497
Total liabilities 107,547 164,359
Commitments and contingencies (Note 11)
Stockholders’ equity    
Preferred stock, $0.0001 par value; 20,000,000 shares designated as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021 0 0
Common stock, $0.0001 par value; 250,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 103,098,768 and 103,003,646 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 10 10
Additional paid-in capital 541,480 536,737
Accumulated deficit (422,818) (414,573)
Total stockholders' equity 118,672 122,174
Total liabilities and stockholders’ equity $ 226,219 $ 286,533
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares designated (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 103,098,768 103,003,646
Common stock, shares outstanding (in shares) 103,098,768 103,003,646
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Grant revenue $ 31 $ 241 $ 1,565 $ 1,086
Operating expenses:        
Research and development 17,337 15,386 48,303 45,091
General and administrative 6,188 5,398 17,050 15,576
Total operating expenses 23,525 20,784 65,353 60,667
Loss from operations (23,494) (20,543) (63,788) (59,581)
Other income (expense), net:        
Interest income 883 3 1,215 6
Change in fair value of Contingent Earnout Liability (962) (9,768) 58,649 (9,768)
Change in fair value of common stock warrant liabilities (67) (2) 240 (2)
Gain on PPP loan forgiveness 0 0 0 3,284
Interest expense (1,641) (1,204) (4,561) (2,952)
Transaction costs expensed 0 (49) 0 (49)
Total other income (expense), net (1,787) (11,020) 55,543 (9,481)
Net loss (25,281) (31,563) (8,245) (69,062)
Comprehensive loss $ (25,281) $ (31,563) $ (8,245) $ (69,062)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.25) $ (0.72) $ (0.08) $ (3.69)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.25) $ (0.72) $ (0.08) $ (3.69)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) 103,031,980 43,950,856 103,014,009 18,728,471
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) 103,031,980 43,950,856 103,014,009 18,728,471
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020 69,613,562      
Beginning balance at Dec. 31, 2020 $ 420,989      
Ending balance (in shares) at Mar. 31, 2021 69,613,562      
Ending balance at Mar. 31, 2021 $ 420,989      
Beginning balance (in shares) at Dec. 31, 2020   5,822,396    
Beginning balance at Dec. 31, 2020 (350,317) $ 1 $ 37,778 $ (388,096)
Equity        
Proceeds from the exercise of stock options (in shares)   116,149    
Proceeds from the exercise of stock options 206   206  
Stock-based compensation 2,528   2,528  
Issuance of warrants in conjunction with debt 2,360   2,360  
Net income (loss) (20,301)     (20,301)
Ending balance (in shares) at Mar. 31, 2021   5,938,545    
Ending balance at Mar. 31, 2021 $ (365,524) $ 1 42,872 (408,397)
Beginning balance (in shares) at Dec. 31, 2020 69,613,562      
Beginning balance at Dec. 31, 2020 $ 420,989      
Ending balance (in shares) at Sep. 30, 2021 0      
Ending balance at Sep. 30, 2021 $ 0      
Beginning balance (in shares) at Dec. 31, 2020   5,822,396    
Beginning balance at Dec. 31, 2020 (350,317) $ 1 37,778 (388,096)
Equity        
Net income (loss) (69,062)      
Ending balance (in shares) at Sep. 30, 2021   103,003,384    
Ending balance at Sep. 30, 2021 $ 75,861 $ 10 533,009 (457,158)
Beginning balance (in shares) at Mar. 31, 2021 69,613,562      
Beginning balance at Mar. 31, 2021 $ 420,989      
Ending balance (in shares) at Jun. 30, 2021 69,613,562      
Ending balance at Jun. 30, 2021 $ 420,989      
Beginning balance (in shares) at Mar. 31, 2021   5,938,545    
Beginning balance at Mar. 31, 2021 (365,524) $ 1 42,872 (408,397)
Equity        
Proceeds from the exercise of stock options (in shares)   5,204    
Proceeds from the exercise of stock options 30   30  
Stock-based compensation 2,930   2,930  
Net income (loss) (17,198)     (17,198)
Ending balance (in shares) at Jun. 30, 2021   5,943,749    
Ending balance at Jun. 30, 2021 $ (379,762) $ 1 45,832 (425,595)
Redeemable convertible preferred Stock        
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares) (69,613,562)      
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing $ (420,989)      
Ending balance (in shares) at Sep. 30, 2021 0      
Ending balance at Sep. 30, 2021 $ 0      
Equity        
Proceeds from the exercise of stock options (in shares)   99,624    
Proceeds from the exercise of stock options 360   360  
Stock-based compensation 1,877   1,877  
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares)   69,613,562    
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing 420,989 $ 7 420,982  
The Merger and related PIPE financing, net of transaction costs and acquired liabilities (in shares)   27,346,449    
The Merger and related PIPE financing, net of transaction costs and acquired liabilities 209,480 $ 2 209,478  
Public warrants assumed upon the Merger, net of transaction costs 13,912   13,912  
Contingent Earnout Liability recognized upon closing of the reverse recapitalization (159,432)   (159,432)  
Net income (loss) (31,563)     (31,563)
Ending balance (in shares) at Sep. 30, 2021   103,003,384    
Ending balance at Sep. 30, 2021 $ 75,861 $ 10 533,009 (457,158)
Equity        
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares) 69,613,562      
The Merger and related PIPE financing, net of transaction costs and acquired liabilities (in shares) 17,500,000      
Ending balance (in shares) at Aug. 26, 2021 103,003,384      
Beginning balance (in shares) at Dec. 31, 2021 0      
Beginning balance at Dec. 31, 2021 $ 0      
Ending balance (in shares) at Mar. 31, 2022 0      
Ending balance at Mar. 31, 2022 $ 0      
Beginning balance (in shares) at Dec. 31, 2021 103,003,646 103,003,646    
Beginning balance at Dec. 31, 2021 $ 122,174 $ 10 536,737 (414,573)
Equity        
Proceeds from the exercise of stock options (in shares)   926    
Proceeds from the exercise of stock options 1   1  
Stock-based compensation 1,547   1,547  
Net income (loss) (19,832)     (19,832)
Ending balance (in shares) at Mar. 31, 2022   103,004,572    
Ending balance at Mar. 31, 2022 $ 103,890 $ 10 538,285 (434,405)
Beginning balance (in shares) at Dec. 31, 2021 0      
Beginning balance at Dec. 31, 2021 $ 0      
Ending balance (in shares) at Sep. 30, 2022 0      
Ending balance at Sep. 30, 2022 $ 0      
Beginning balance (in shares) at Dec. 31, 2021 103,003,646 103,003,646    
Beginning balance at Dec. 31, 2021 $ 122,174 $ 10 536,737 (414,573)
Equity        
Proceeds from the exercise of stock options (in shares) 95,122      
Net income (loss) $ (8,245)      
Ending balance (in shares) at Sep. 30, 2022 103,098,768 103,098,768    
Ending balance at Sep. 30, 2022 $ 118,672 $ 10 541,480 (422,818)
Beginning balance (in shares) at Mar. 31, 2022 0      
Beginning balance at Mar. 31, 2022 $ 0      
Ending balance (in shares) at Jun. 30, 2022 0      
Ending balance at Jun. 30, 2022 $ 0      
Beginning balance (in shares) at Mar. 31, 2022   103,004,572    
Beginning balance at Mar. 31, 2022 103,890 $ 10 538,285 (434,405)
Equity        
Proceeds from the exercise of stock options (in shares)   2,231    
Proceeds from the exercise of stock options 11   11  
Stock-based compensation 1,491   1,491  
Net income (loss) 36,868     36,868
Ending balance (in shares) at Jun. 30, 2022   103,006,803    
Ending balance at Jun. 30, 2022 $ 142,260 $ 10 539,787 (397,537)
Ending balance (in shares) at Sep. 30, 2022 0      
Ending balance at Sep. 30, 2022 $ 0      
Equity        
Proceeds from the exercise of stock options (in shares)   91,965    
Proceeds from the exercise of stock options 217   217  
Stock-based compensation 1,476   1,476  
Net income (loss) $ (25,281)     (25,281)
Ending balance (in shares) at Sep. 30, 2022 103,098,768 103,098,768    
Ending balance at Sep. 30, 2022 $ 118,672 $ 10 $ 541,480 $ (422,818)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Cash flows from operating activities              
Net loss $ (25,281,000) $ (19,832,000) $ (31,563,000) $ (20,301,000) $ (8,245,000) $ (69,062,000)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation expense 1,500,000   1,500,000   4,552,000 4,650,000  
Stock-based compensation expense         4,514,000 7,335,000  
Change in fair value of Contingent Earnout Liability 962,000   9,768,000   (58,649,000) 9,768,000  
Change in fair value of common stock warrant liabilities 67,000   2,000   (240,000) 2,000  
Amortization expense         1,544,000 1,545,000  
Non-cash operating lease costs         34,000 31,000  
Amortization of SVB debt discount         1,211,000 628,000  
Accrued interest on PPP loan obligation         0 11,000  
Gain on PPP loan forgiveness 0   0   0 (3,284,000)  
Payment of liabilities assumed in Merger         0 (12,363,000)  
Changes in operating assets and liabilities:              
Accounts receivable         145,000 (127,000)  
Prepaid expenses and other current assets         812,000 (2,002,000)  
Accounts payable         984,000 757,000  
Accrued expenses         1,202,000 2,401,000  
Operating lease obligation         (34,000) (32,000)  
Net cash used in operating activities         (52,170,000) (59,742,000)  
Cash flows from investing activities              
Purchase of short-term investments (certificates of deposit)         (8,000,000) 0  
Proceeds from maturity of short-term investments (certificates of deposit)         8,000,000 0  
Purchase of property and equipment         (367,000) (175,000)  
Net cash used in investing activities         (367,000) (175,000)  
Cash flows from financing activities              
Proceeds from the exercise of stock options         229,000 596,000  
Payment of finance lease principal         (1,463,000) (1,277,000)  
Proceeds from Merger and PIPE financing, net of offering costs paid         0 242,400,000  
Payment of transaction costs related to Merger         0 (941,000)  
Proceeds from SVB loan         0 19,659,000  
Payment of deferred offering costs         0 0  
Net cash (used in) provided by financing activities         (1,234,000) 260,437,000  
Net (decrease) increase in cash and cash equivalents         (53,771,000) 200,520,000  
Cash and cash equivalents at the beginning of the period   $ 217,502,000   $ 39,929,000 217,502,000 39,929,000 $ 39,929,000
Cash and cash equivalents at the end of the period $ 163,731,000   $ 240,449,000   163,731,000 240,449,000 $ 217,502,000
Supplemental disclosure              
Cash paid for interest on SVB loan         1,867,000 642,000  
Supplemental disclosure of noncash activities:              
Purchase of property and equipment in accounts payable         198,000 0  
Issuance of warrants in conjunction with debt         0 2,360,000  
Unpaid liabilities assumed in connection with Merger         0 2,228,000  
Unpaid transaction costs in connection with Merger         0 3,004,000  
Conversion of redeemable convertible preferred stock into common stock in connection with the reverse capitalization         0 420,989,000  
Contingent Consideration Liability recognized upon the closing of the reverse recapitalization         $ 0 $ 159,432,000  
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Description of Business
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Organization
Humacyte, Inc. and subsidiary (the “Company”) is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company is leveraging its technology platform to develop proprietary product candidates for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
On August 26, 2021 (the Closing Date), Alpha Healthcare Acquisition Corp. (AHAC) consummated a merger pursuant to a Business Combination Agreement, dated as of February 17, 2021 (the “Merger Agreement”), by and among Humacyte, Inc., a Delaware Corporation (“Legacy Humacyte”), AHAC and Hunter Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly owned subsidiary of AHAC. As contemplated by the Merger Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte continuing as the surviving corporation and as a wholly owned subsidiary of AHAC (such transactions, the “Merger,” and, collectively with the other transactions described in the Merger Agreement, the “Reverse Recapitalization”). On the Closing Date, AHAC changed its name to Humacyte, Inc. (“New Humacyte”) and Legacy Humacyte changed its name to Humacyte Global, Inc. The Merger is accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and under this method of accounting, AHAC is treated as the acquired company for financial reporting purposes and Legacy Humacyte is treated as the acquirer. Operations prior to the Merger are those of Legacy Humacyte.
Refer to Note 3 — Reverse Recapitalization for further details of the Merger.
Liquidity and Going Concern
Since its inception in 2004, the Company has generated no product revenue and has incurred operating losses and negative cash flows from operations in each year. To date, the Company has financed its operations primarily through the sale of equity securities and convertible debt, proceeds from the Reverse Recapitalization, borrowings under loan facilities and, to a lesser extent, through governmental and other grants. At September 30, 2022 and December 31, 2021, the Company had an accumulated deficit of $422.8 million and $414.6 million, respectively. The Companys operating losses were $63.8 million and $59.6 million for the nine months ended September 30, 2022 and 2021, respectively. Net cash flows used in operating activities were $52.2 million and $59.7 million during the nine months ended September 30, 2022 and 2021, respectively. Substantially all of the Companys operating losses resulted from costs incurred in connection with the Companys research and development programs and from general and administrative costs associated with the Companys operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates.
As of September 30, 2022, the Company had cash and cash equivalents and short-term investments of $171.7 million. The Company believes its combined cash and cash equivalents and short-term investments on hand will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, for at least 12 months from the issuance date of these interim financial statements.
Impact of COVID-19
The COVID-19 pandemic has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in-place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on the Companys business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Companys business and operations are uncertain. The COVID-19 pandemic may affect the Companys ability to initiate and complete preclinical studies, delay its clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on its business and operations. The pandemic has already caused significant disruptions in the financial markets and may continue to cause such disruptions, which could impact the Companys ability to raise additional funds to support its operations. Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Companys business and operations.
To date, there have been no material financial impacts or impairment losses in the carrying values of the Companys assets as a result of the pandemic and the Company is not aware of any specific related event or circumstance that would require it to revise the estimates reflected in these financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact the Companys business, results of operations and financial condition, including current and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, the emergence of new virus variants, and the duration and intensity of the related economic impact of the pandemic.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The Company has prepared the accompanying financial statements in conformity with U.S. GAAP. The Companys condensed consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement. Operations prior to the Merger are those of Legacy Humacyte.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in the financial statements include stock-based compensation costs, right-of-use assets, accruals for research and development activities, contingent earnout liability, fair value of common stock warrants, redeemable convertible preferred stock and income taxes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
Unaudited Interim Condensed Consolidated Financial Statements
The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements and, in managements opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Companys financial position as of September 30, 2022 and its results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or any other period. The December 31, 2021 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.
Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 and the related notes included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022 (the “Annual Report”), which provides a more complete discussion of the Company’s accounting policies and certain other information. There have been no significant changes to the significant accounting policies disclosed in Note 2 of the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in the Companys Annual Report.
Segments
The Company operates and manages its business as one reportable and operating segment. The Company is developing proprietary, bioengineered, acellular human tissues, advanced tissue constructs and organ systems that are designed to be used in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The Companys chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments consisting of certificates of deposit (“CDs”). Total cash balances exceeded insured balances by the Federal Deposit Insurance Corporation (“FDIC”) as of September 30, 2022 and December 31, 2021. The Company has cash equivalents that are invested in highly rated money market funds that are invested only in obligations of the U.S. government and its agencies.
As of both September 30, 2022 and December 31, 2021, the Company had approximately $10.0 million in CDs. These cash deposits are deposited at a bank that is a member of the Certificate of Deposit Account Registry Service (“CDARS”), in which large deposits are divided into smaller amounts and placed with other FDIC insured banks which are also members of the CDARS network. Those members issue CDs in amounts under $250,000, so that the entire deposit balance is eligible for FDIC insurance. As of both September 30, 2022 and December 31, 2021, the Company classified $2.0 million of its certificates of deposit as cash and cash equivalents and $8.0 million of its certificates of deposit as short-term investments on its condensed consolidated balance sheets.
During the three and nine months ended September 30, 2022 and 2021, 100% of the Company’s total revenue relates to an award it received from the Department of Defense (“DoD”) in August 2017. As of September 30, 2022 and December 31, 2021, 100% of the Company’s accounts receivable relates to the DoD grant.
Net Loss per Share Attributable to Common Stockholders
Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive.
The potential shares of common stock that were excluded from the computation of diluted net loss per share for each period because including them would have had an antidilutive effect were as follows:
Three and Nine Months Ended
September 30,
20222021
Exercise of options under stock plan6,722,422 6,399,888 
Warrants to purchase common stock5,588,506 5,465,204 
The 15,000,000 Contingent Earnout Shares, as defined in Note 3, are excluded from the anti-dilutive table for all periods presented, as such shares are contingently issuable until the share price of the Company exceeds specified thresholds that have not yet been achieved, or upon the occurrence of a change in control.
Other Risks and Uncertainties
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, the success of clinical trials and other studies for its product candidates, including for its ongoing V005 Phase II/III clinical trial and V007 Phase III clinical trial, the regulatory approval and commercialization of its HAVs and other product candidates, the expected size of the target populations for the Companys product candidates, the degree of market acceptance of the HAVs, if approved, the availability of third-party coverage and reimbursement, development by competitors of new technological innovations, the ability to manufacture HAVs and other product candidates in sufficient quantities, expectations regarding the Companys strategic partnerships, dependence on third parties, key personnel and the ability to attract and retain qualified employees, protection of proprietary technology and confidentiality of trade secrets, compliance with governmental regulations, the impact of the COVID-19 pandemic, the Companys implementation and maintenance of effective internal controls, and the ability to secure additional capital to fund operations and the commercial success of its product candidates.
Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Companys commercialization efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales, and the Company may depend on certain strategic relationships to distribute its products, including the Companys strategic partnership with Fresenius Medical Care, to sell, market and distribute its 6 millimeter HAV for certain specified indications outside the United States.
Recently Adopted Accounting Pronouncements
In May 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, “Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). The FASB issued this update to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring after the effective date of the amendments. The Company adopted ASU 2021-04 as of January 1, 2022. The adoption of this ASU had no impact on the Companys financial statements and related disclosures.
In November 2021, the FASB issued ASU No. 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”) to improve financial reporting by requiring annual disclosures that increase the transparency of transactions with a government accounted for by applying a grant or contribution model by analogy, including (i) the types of transactions, (ii) an entity’s accounting for those transactions, and (iii) the effect of those transactions on an entity’s financial statements. ASU 2021-10 is effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021, and an entity can elect to apply the amendments in this guidance prospectively or retrospectively. The Company adopted ASU 2021-10 effective January 1, 2022, and does not expect a material impact to its annual consolidated financial statement disclosures.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Reverse Recapitalization
9 Months Ended
Sep. 30, 2022
Reverse Recapitalization [Abstract]  
Reverse Recapitalization Reverse Recapitalization
On August 26, 2021, Merger Sub, a wholly-owned subsidiary of AHAC, merged with Legacy Humacyte, with Legacy Humacyte surviving as a wholly-owned subsidiary of AHAC. At the effective time of the Merger:
each outstanding share of Legacy Humacyte common stock was converted into approximately 0.26260 shares of New Humacyte’s common stock, par value $0.0001 per share (“Common Stock”);
each outstanding share of preferred stock of Legacy Humacyte was cancelled and converted into the aggregate number of shares of Common Stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately 0.26260; and
each outstanding option or warrant to purchase Legacy Humacyte common stock was converted into an option or warrant, as applicable, to purchase a number of shares of Common Stock equal to the number of shares of Legacy Humacyte common stock subject to such option or warrant multiplied by approximately 0.26260, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.26260;
in each case, rounded down to the nearest whole share.
In addition, upon the closing of the Merger (the “Closing”), 2,500,000 Class B shares of AHAC (the “Founder Shares”) automatically converted into shares of Common Stock on a one-for-one basis.
Former holders of the Legacy Humacyte common stock and Legacy Humacyte preferred stock are eligible to receive up to an aggregate of 15,000,000 additional shares of Common Stock (the “Contingent Earnout Shares”) in the aggregate, comprised of two equal tranches of 7,500,000 shares per tranche if the volume-weighted average closing sale price of the Common Stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period. At the Closing on August 26, 2021, the Company recorded a liability (“Contingent Earnout Liability”) of $159.4 million, based on the estimated fair value of the 15,000,000 Contingent Earnout Shares with a corresponding reduction of additional paid-in capital in the equity section of the Company’s condensed consolidated balance sheet.
Concurrently with the execution of the Merger Agreement, AHAC entered into subscription agreements (the “Subscription Agreements”) with certain investors (the “PIPE Investors”). Pursuant to the Subscription Agreements, the PIPE Investors purchased an aggregate of 17,500,000 shares of Common Stock (the “PIPE Shares”) in a private placement at a price of $10.00 per share for an aggregate purchase price of $175 million (the “PIPE Financing”). The PIPE Financing was consummated in connection with the Closing.
The number of shares of Common Stock outstanding immediately following the consummation of the Merger was:
Shares
Common stock of AHAC, outstanding prior to Merger10,355,000 
Less redemption of AHAC shares(3,008,551)
Common stock of AHAC7,346,449 
AHAC Founder Shares2,500,000 
New Humacyte shares issued to PIPE Investors17,500,000 
Issuance of common stock upon reverse recapitalization and PIPE Financing27,346,449 
New Humacyte shares issued in Merger to Legacy Humacyte stockholders75,656,935 (1)
Total shares of Common Stock immediately after Merger103,003,384 
________________
(1)Includes 69,613,562 shares of Common Stock issued upon conversion of Legacy Humacyte’s redeemable convertible preferred stock.
The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, AHAC was treated as the acquired company for financial reporting purposes and Legacy Humacyte was treated as the acquirer. This determination was primarily based on the fact that subsequent to the Merger, the Legacy Humacyte stockholders held a majority of the voting rights of the combined company, Legacy Humacyte comprised all of the ongoing operations of the combined company, Legacy Humacyte comprised a majority of the governing body of the combined company, and Legacy Humacyte’s senior management comprised all of the senior management of the combined company. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Humacyte issuing shares for the net assets of AHAC, accompanied by a recapitalization. The net assets of AHAC were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the Merger are those of Legacy Humacyte.
In connection with the Merger, the Company received $242.4 million in proceeds from the Merger and related PIPE Financing. The Company incurred $3.9 million of transaction costs, consisting of banking, legal, and other professional fees, of which $3.9 million was recorded as a reduction of proceeds to additional paid-in capital, and less than $0.1 million related to the Private Placement Warrants, which are classified as liabilities in the condensed consolidated balance sheets, was expensed in the condensed consolidated statements of operations and comprehensive loss during the three months ended September 30, 2021. All transaction costs were paid as of December 31, 2021. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Of the $15.2 million of liabilities assumed from AHAC, $0.1 million was included in accrued expenses as of December 31, 2021, and there were no unpaid liabilities as of September 30, 2022.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) 820, Fair Value Measurement and Disclosures, establishes a hierarchy whereby inputs to valuation techniques used in measuring fair value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy based on reliability of inputs, as follows:
Level 1 — Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.
Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.
The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company.
The Company’s assets and liabilities that were measured at fair value on a recurring basis were as follows:
($ in thousands)
Fair Value Measured as of September 30, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents (money market funds)$160,370 $— $— $160,370 
Cash equivalents (certificates of deposit)— 2,014 — 2,014 
Short-term investments (certificates of deposit)— 8,000 — 8,000 
Total financial assets$160,370 $10,014 $— $170,384 
Liabilities:
Contingent Earnout Liability$— $— $45,011 $45,011 
Private Placement Warrants liability— — 257 257 
Total financial liabilities$— $— $45,268 $45,268 
($ in thousands)
Fair Value Measured as of December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents (money market funds)$208,821 $— $— $208,821 
Cash equivalents (certificates of deposit)— 2,000 — 2,000 
Short-term investments (certificates of deposit)— 8,000 — 8,000 
Total financial assets$208,821 $10,000 $— $218,821 
Liabilities:
Contingent Earnout Liability$— $— $103,660 $103,660 
Private Placement Warrants liability— — 497 497 
Total financial liabilities$— $— $104,157 $104,157 
The following tables present a summary of the changes in the fair value of the Company’s Level 3 financial instruments:
($ in thousands)Contingent Earnout Liability
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Fair value as of beginning of period$(44,049)$— $(103,660)$— 
Contingent Earnout Liability recognized upon the closing of the reverse recapitalization— (159,432)— (159,432)
Change in fair value included in other income (expense), net(962)(9,768)58,649 (9,768)
Fair value as of end of period$(45,011)$(169,200)$(45,011)$(169,200)
Private Placement Warrants
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
Fair value as of beginning of period$(190)$— $(497)$— 
Private placement warrant liability acquired as part of the Merger— (553)— (553)
Change in fair value included in other income (expense), net(67)(2)240 (2)
Fair value as of end of period$(257)$(555)$(257)$(555)
The fair value of the Contingent Earnout Liability and Private Placement Warrants (as defined in Note 8 — Stockholders’ Equity (Deficit)) liability are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy.
In determining the fair value of the Contingent Earnout Liability, the Company used the Monte Carlo simulation value model using a distribution of potential outcomes on a monthly basis over a 10-year period prioritizing the most reliable information available. The assumptions utilized in the calculation were based on the achievement of certain stock price milestones, including the current Common Stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8 — Stockholders’ Equity (Deficit)). Contingent earnout payments involve certain assumptions requiring significant judgment and actual results can differ from assumed and estimated amounts.
In determining the fair value of the Private Placement Warrants liability, the Company used the Monte Carlo simulation valuation model to estimate the fair value utilizing assumptions including the current Company stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8 — Stockholders’ Equity (Deficit)).
The Company’s money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheets, which approximates their fair value based on Level 2 inputs. The carrying values of other receivables, accounts payable and accrued expenses as of September 30, 2022 and December 31, 2021 approximated their fair values due to the short-term nature of these items.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment, Net
9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net Property and Equipment, Net
Property and equipment, net consist of the following:
($ in thousands)September 30,
2022
December 31,
2021
Scientific equipment(1)
$27,926 $27,641 
Computer equipment232 155 
Software335 335 
Furniture and fixtures1,000 988 
Leasehold improvements26,355 26,355 
Construction in progress170 — 
56,018 55,474 
Accumulated depreciation(24,992)(20,440)
Property and equipment, net$31,026 $35,034 
___________________________
(1)As of December 31, 2021, includes $3.6 million related to scientific equipment not depreciated until being placed in service during the third quarter of 2022.
Depreciation expense totaled $1.5 million and $4.6 million for the three and nine months ended September 30, 2022, respectively, and $1.5 million and $4.7 million for the three and nine months ended September 30, 2021, respectively. All long-lived assets are maintained in the United States.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses
9 Months Ended
Sep. 30, 2022
Accrued Liabilities, Current [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consisted of the following:
($ in thousands)September 30,
2022
December 31,
2021
Accrued external research, development and manufacturing costs$2,673 $2,520 
Accrued employee compensation and benefits5,023 3,943 
Accrued professional fees263 294 
Total$7,959 $6,757 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Debt Debt
On March 30, 2021, the Company entered into a term loan agreement with Silicon Valley Bank (“SVB”) and SVB Innovation Credit Fund VIII, L.P., as amended in June 2021 and September 2021 (the “Loan Agreement”), which provides a term loan facility of up to $50.0 million with a maturity date of March 1, 2025. The Companys obligations under the Loan Agreement are secured by substantially all of its assets except for its intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. If a minimum liquidity amount is not maintained, 50% of the outstanding principal and interest will become cash collateralized. As of September 30, 2022, the Company was in compliance with all covenants. The Company may use the proceeds of borrowings under the Loan Agreement as working capital and to fund its general business requirements.
The Loan Agreement provides that the term loans will be distributed in tranches. The initial term loan tranche of $20.0 million was drawn on March 31, 2021, and on October 13, 2021, the Company borrowed an additional $10.0 million under the Loan Agreement. Borrowings under the Loan Agreement are accounted for net of issuance costs which are being accreted to interest expense over the term of the loan using the effective interest method. As of September 30, 2022, two subsequent $10.0 million term loan tranches will be eligible to be drawn at the request of the Company during specified draw periods prior to May 15, 2023, the first tranche subject to submission by the Company of its first Biologics License Application (“BLA”) to the FDA for its HAV prior to March 31, 2023, and the second tranche subject to the first approval from the FDA of any BLA for the HAV prior to March 31, 2023 and the Company having borrowed the first remaining tranche.
Borrowings bear interest at the greater of 7.5% or the Wall Street Journal Prime Rate plus 4.25% (10.50% as of September 30, 2022). Interest only payments on the principal amount outstanding are due monthly beginning in the first month after the loan is dispersed. Repayment of principal may begin as soon as July 1, 2023 under the level of borrowing outstanding at September 30, 2022, and no later than April 1, 2024 if the remaining two loan tranches are drawn. The term loans may only be prepaid in full, and such prepayment requires 30 days advance notice and was subject initially to a prepayment fee of 3.00% that was decreased to 2.00% after March 30, 2022 (with a further decrease to 1.00% after March 30, 2023). The Company is not obligated to pay a prepayment fee if the Company makes a prepayment after March 30, 2024.
In connection with the Loan Agreement, the Company granted warrants to the lenders to purchase shares of Common Stock at an exercise price of $10.28 per share, of which 287,704 warrants were immediately exercisable. The warrants are classified within stockholders equity, as the settlement of the warrants is indexed to the Common Stock. The Company recognized the fair value of the warrants immediately exercisable within stockholders equity using a Black-Scholes valuation model at issuance.
At issuance, the Company initially determined that the funding of an additional tranche was not probable, and therefore no value was ascribed to the remaining 123,302 warrants that were only exercisable upon the funding of the first additional tranche. As a result of the Company’s additional $10.0 million borrowings under the Loan Agreement on October 13, 2021, the warrants to purchase the additional 123,302 shares of Common Stock became exercisable at an exercise price of $10.28 per share and the value of the warrants was recorded as of that date. The additional warrants are classified within stockholders’ equity using a Black-Scholes valuation model, as the settlement of the warrants is indexed to the Common Stock.
As of September 30, 2022, the fair value of warrants ($3.3 million), a 5% final payment fee ($1.5 million) and debt issuance costs ($0.3 million) are being accreted to interest expense over the term of the loan using the effective interest method.
SVB loan payable and net discount or premium balances are as follows:
($ in thousands)September 30,
2022
Principal amount of SVB loan payable$30,000 
Final payment amount of SVB loan payable1,500 
Net premium associated with accretion of final payment and other debt issuance costs(2,928)
SVB loan payable, current and noncurrent28,572 
Less SVB loan payable, current portion(4,286)
SVB loan payable, noncurrent portion$24,286 
Future minimum payments of principal on the Companys outstanding variable rate borrowings as of September 30, 2022 are as follows:
Year ending December 31:
($ in thousands)
2022 (remainder)
$— 
20238,571 
202417,143 
20254,286 
Total future payments$30,000 
On April 30, 2020, the Company received loan proceeds in the amount of approximately $3.3 million under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act. All or a portion of this loan and any accrued interest was eligible to be forgiven after a twenty-four week period as long as the borrower used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintained its payroll levels. On May 25, 2021, the PPP loan was forgiven and the Company recognized a gain from loan extinguishment in the amount of $3.3 million during the three months ended June 30, 2021.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit)
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Stockholders' Equity (Deficit) Stockholders Equity (Deficit)
Redeemable Convertible Preferred Stock
Immediately prior to the Merger, Legacy Humacyte had outstanding series A redeemable convertible preferred stock, series B redeemable convertible preferred stock, series C redeemable convertible preferred stock and series D redeemable convertible preferred stock, which are collectively referred to as redeemable convertible preferred stock.
In connection with the Merger, all previously issued and outstanding redeemable convertible preferred stock was converted into an equivalent number of shares of Common Stock of the Company on a one-for-one basis, then multiplied by the exchange ratio pursuant to the Merger Agreement and the amounts were reclassified as additional paid-in capital.
Common Stock
On August 26, 2021, the Merger and related PIPE Financing was consummated and the Company issued 27,346,449 shares of Common Stock for proceeds of $242.4 million. The Company incurred $3.9 million of transaction costs, consisting of banking, legal, and other professional fees. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Immediately following the Merger, there were 103,003,384 shares of Common Stock outstanding with a par value of $0.0001 per share.
As of September 30, 2022, the Companys Second Amended and Restated Certificate of Incorporation authorized the Company to issue 250,000,000 shares of Common Stock. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares then outstanding or reserved for issuance) by the affirmative vote of the holders of a majority of the capital stock of the Company entitled to vote and may require a separate class vote of the Common Stock.
The holders of Common Stock are entitled to receive dividends from time to time as may be declared by the Companys board of directors. Through September 30, 2022, no dividends have been declared.
The holders of Common Stock are entitled to one vote for each share held with respect to all matters voted on by the common stockholders of the Company.
In the event of a reorganization of the Company, after payment to the preferred stockholders of their liquidation preferences, holders of Common Stock are entitled to share ratably in all remaining assets of the Company.
As of September 30, 2022, the Company had reserved Common Stock for future issuances as follows:
September 30,
2022
Common stock reserved for Contingent Earnout Shares15,000,000 
Exercise of options under stock plans6,722,422 
Issuance of options under stock plans7,312,585 
Shares available for grant under ESPP1,030,033 
Warrants to purchase Common Stock5,588,506 
35,653,546 
Preferred Stock
The Companys Second Amended and Restated Certificate of Incorporation provides the Companys board of directors with the authority to issue preferred stock, par value $0.0001 per share, in one more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were 20,000,000 shares designated as preferred stock and none were outstanding as of September 30, 2022 and December 31, 2021.
Warrants
The Company had the following common stock warrants outstanding as of September 30, 2022 and December 31, 2021:
Common Stock Warrants Outstanding
Legacy Humacyte Common Stock Warrants411,006 
Private Placement Warrants177,500 
Public Warrants5,000,000 
Total Common Stock Warrants5,588,506 
See Note 7 — Debt for a discussion of common stock warrants issued in conjunction with the Companys Loan Agreement in 2021 (such warrants, “Legacy Humacyte Common Stock Warrants”). There were no issuances, exercises or expirations of warrants during the nine months ended September 30, 2022. During the nine months ended September 30, 2021 there were 32,961 of warrants exercised that were issued in conjunction with a long-term debt agreement repaid in a prior reporting period. There were no expirations of warrants during the nine months ended September 30, 2021.
In connection with the Merger, the Company assumed 5,000,000 publicly-traded warrants (Public Warrants) and 177,500 private placement warrants issued to AHAC Sponsor LLC (the Sponsor), Oppenheimer & Co. Inc. and Northland Securities, Inc, in connection with AHACs initial public offering (Private Placement Warrants and, together with the Public Warrants, the Common Stock Warrants). The Common Stock Warrants entitle the holder to purchase one share of Common Stock at an exercise price of $11.50 per share. The Company evaluated the Common Stock Warrants to determine the appropriate financial statement classification upon the consummation of the Merger. The Common Stock Warrants are not mandatorily redeemable and are considered to be freestanding instruments as they are separately exercisable into common shares. As such, the Common Stock Warrants were not classified as liabilities under FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company then evaluated the Common Stock Warrants under FASB ASC Topic 815, Derivatives and Hedging.
Public Warrants
The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the Public Warrants may be eligible for a cashless exercise. The Public Warrants may only be exercised for a whole number of shares and will expire five years after the completion of the Merger. The Public Warrants became exercisable 30 days after the completion of the Merger.
The Public Warrants are considered to be “indexed to the Company’s own stock”. The agreement provides that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of the Companys Common Stock, all holders of the Common Stock Warrants (both the Public Warrants and the Private Placement Warrants) would be entitled to receive cash for all of their Common Stock Warrants. As the Company has a single class of Common Stock, a qualifying cash tender offer of more than 50% of the Companys Common Stock will always result in a change in control and would not preclude permanent equity classification of the Public Warrants. Based on this evaluation, the Company concluded that the Public Warrants meet the criteria to be classified within stockholders equity. The Public Warrants were initially recognized as equity on the Closing Date at a fair value of $2.80 per share.
Private Placement Warrants
The Private Placement Warrants are non-redeemable for cash so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
The agreement governing the Common Stock Warrants includes a provision, the application of which could result in a different settlement value for the Private Placement Warrants depending on their holder. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on the Common Stock, the Private Placement Warrants are not considered to be indexed to the Companys own stock and therefore are not classified in stockholders equity. As the Private Placement Warrants meet the definition of a derivative, the Company recorded these warrants as liabilities on the condensed consolidated balance sheet at fair value, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date.
The Private Placement Warrants were initially recognized as a liability on the Closing Date, at a fair value of $0.6 million, and the liability was remeasured to an estimated fair value of $0.5 million as of December 31, 2021. See Note 4 — Fair Value Measurements for a summary of the change in the fair value of the Private Placement Warrants during the three and nine months ended September 30, 2022 and 2021. The remeasurement of the Private Placement Warrant liability to a fair value of $0.3 million as of September 30, 2022 resulted in a non-cash loss of $0.1 million and a non-cash gain of $0.2 million for the three and nine months ended September 30, 2022, respectively, compared to a non-cash loss of less than $0.1 million for each of the three and nine months ended September 30, 2021. The remeasurement of the Private Placement Warrant liability is classified within Change in fair value of common stock warrant liabilities in the condensed consolidated statements of operations and comprehensive loss.
The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model:
September 30,
2022
December 31,
2021
Market price of public stock$3.26$7.25
Exercise price$11.50$11.50
Expected term (years)3.914.65
Expected share price volatility94.5 %61.0 %
Risk-free interest rate4.16 %1.21 %
Estimated dividend yield%%
Contingent Earnout Liability
Following the Closing, former holders of Legacy Humacyte common and preferred shares may receive up to 15,000,000 additional shares of Common Stock in the aggregate, in two equal tranches of 7,500,000 shares of Common Stock per tranche. The first and second tranches are issuable if the closing volume weighted average price (VWAP) per share of Common Stock quoted on Nasdaq (or the exchange on which the shares of Common Stock are then listed) is greater or equal to $15.00 and $20.00, respectively, over any 20 trading days within any 30 consecutive trading day period.
Upon the Closing, the contingent obligation to issue Contingent Earnout Shares was accounted for as a liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the Common Stock. The Contingent Earnout Shares are subsequently remeasured at each reporting date with changes in fair value recorded as a component of other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss. The estimated fair value of the total Contingent Earnout Shares at the Closing on August 26, 2021 was $159.4 million based on a Monte Carlo simulation valuation model using a distribution of potential outcomes on a monthly basis over a ten-year period using the most reliable information available. The estimated fair value of the total Contingent Earnout Shares at December 31, 2021 was $103.7 million.
See Note 4 — Fair Value Measurements for a summary of the change in the fair value of the Contingent Earnout Liability during the three and nine months ended September 30, 2022. The remeasurement of the Contingent Earnout Liability to a fair value of $45.0 million as of September 30, 2022 resulted in a non-cash loss of $1.0 million and a non-cash gain of $58.6 million for the three and nine months ended September 30, 2022, respectively, compared to a non-cash loss of $9.8 million for each of the three and nine months ended September 30, 2021. The remeasurement of the Contingent Earnout Liability is classified within Change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss. The assumptions utilized in the calculations of fair value were based on the achievement of certain stock price milestones, including the current Common Stock price, expected volatility, risk-free rate, expected term and expected dividend yield.
Assumptions used in the valuations are described below:
September 30,
2022
December 31,
2021
Current stock price$3.26$7.25
Expected share price volatility89.0 %85.8 %
Risk-free interest rate3.83 %1.52 %
Estimated dividend yield0.0 %%
Expected term (years)10.0010.00
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Stock-based Compensation
At Closing, the 2021 Long-Term Incentive Plan, (the “2021 Plan”), and the 2021 Employee Stock Purchase Plan, (the “ESPP”), became effective. As of September 30, 2022, 7,312,585 and 1,030,033 shares of Common Stock were available under the 2021 Plan and ESPP, respectively. The 2021 Plan and ESPP provide that on January 1 of each year commencing January 1, 2022, the 2021 Plan and the ESPP reserve will automatically increase in an amount equal to the lesser of (a) 5% and 1%, respectively, of the number of shares of the Companys Common Stock outstanding on December 31 of the preceding year and (b) a number of shares of Common Stock determined by the Companys board of directors. In December 2021, the Company’s board of directors determined that there would be no automatic increase in the number of shares reserved under the 2021 Plan or the ESPP on January 1, 2022.
Under the 2021 Plan, the Company can grant non-statutory stock options (“NSOs”), incentive stock options (“ISOs), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, performance awards and other forms of awards. Under the ESPP, when and if implemented, eligible employees will be permitted to purchase shares of the Company’s Common Stock at the lower of 85% of the closing trading price per share of the Company’s Common Stock on the first day of the offering or 85% of the closing trading price per share on the exercise date, which will occur on the last day of each offering.
Prior to the Closing, Legacy Humacyte had two equity incentive plans, the 2015 Omnibus Incentive Plan, as amended (the “2015 Plan”), and the 2005 Stock Option Plan (the “2005 Plan”). As a result of the Merger, no further awards may be granted under either the 2015 Plan or the 2005 Plan. All awards previously granted and outstanding as of the effective date of the Merger were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2021 Plan or the 2015 Plan that are forfeited, cancelled or reacquired by the Company prior to vesting, that expire or that are paid out in cash rather than shares will become available for grant and issuance under the 2021 Plan. As of September 30, 2022, 5,233,533 and 504,254 shares of Common Stock remain reserved for outstanding options issued under the 2015 Plan and 2005 Plan, respectively.
The Companys stock option plans allow for the grant of awards that the Company believes aid in aligning the interests of award recipients with those of its stockholders. The Companys board of directors or compensation committee determines the specific terms of equity incentive grants, including the exercise price per share and vesting period for option awards. Option awards are granted with an exercise price equal to the fair market value of the Companys Common Stock at the date of grant.
The Company has granted options that include either a service-based or performance-based vesting condition, or both, and a 10-year contractual term. The service-based vesting condition for the plans is generally satisfied over 36 to 48 months from the date of grant. The performance-based vesting conditions are satisfied upon the attainment of certain product development milestones. The Company recognizes stock-based compensation expense based on the grant date fair value of the awards measured using the Black-Scholes option pricing model. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying Common Stock on the date of grant. Forfeitures are accounted for as they occur.
Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur.
Option awards under the Companys option plans generally provide for accelerated vesting of the unvested portions of any option award in the event of an involuntary termination, as such term is defined in the relevant stock option agreement, of a grantees employment during the period that commences 30 days prior to the effective date of a corporate transaction and that ends 12 months following the effective date of such transaction. Additionally, the Companys board of directors may, in its sole discretion, accelerate the vesting of any unvested stock options in the event of a corporate transaction.
The Company estimated the fair value of the stock options on the date of grant using the following assumptions in the Black-Scholes option-pricing model:
Three Months Ended September 30,Nine Months Ended September 30,
2022
2021 (1)
20222021
Estimated dividend yield%— %%
Expected share price volatility (weighted average and range, if applicable)
89.3% (89.2% to 89.4%)
— 
93.3% (89.0% to 100.0%)
91.4% (91.0% to 92.1%)
Risk-free interest rate (weighted average and range, if applicable)
3.58% (3.46% to 3.65%)
— 
2.96% (1.89% to 3.65%)
0.68% (0.62% to 1.02%)
Expected term of options (in years)6.25— 6.256.00
__________________________
(1)The Company did not grant any stock options during the three months ended September 30, 2021.
Fair Value of Common Stock. Prior to the Merger, as the Companys common stock was not publicly traded, the fair value of the shares of its common stock underlying the options was determined by the Companys board of directors with input from management, after considering independent third-party valuation reports. Subsequent to the Merger, the fair value of the Common Stock has been determined based on the closing price of the shares on the Nasdaq market.
Expected Term. The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.
Expected Volatility. The expected volatility was determined based on a blended approach using the historical share volatility of the Company’s Common Stock and that of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company has a limited trading history. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies.
Risk-Free Interest Rate. The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options.
Expected Dividend Yield. The Company has not paid dividends on its Common Stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero.
At September 30, 2022, there were 7,312,585 options remaining available for grant under the 2021 Plan. The Company has sufficient authorized and unissued shares to issue Common Stock in satisfaction of any awards available for grant under the 2021 Plan.
The following tables show a summary of stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021, and remaining unrecognized cost as of September 30, 2022 and December 31, 2021:
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
Research and development$216 $486 $682 $1,837 
General and administrative1,260 1,391 3,832 5,498 
Total$1,476 $1,877 $4,514 $7,335 
($ in thousands)September 30,
2022
December 31,
2021
Unrecognized stock-based compensation cost$10,234 $13,346 
Expected weighted average period compensation costs to be recognized (years)2.02.3
A summary of option activity under the Companys stock option plans during the nine months ended September 30, 2022 is presented below:
Number of SharesWeighted
Average Exercise
Price Per Share
Weighted
Average
Remaining
Contractual Term
(years)
Aggregate
Intrinsic Value
(in thousands)
Options outstanding at December 31, 2021
6,711,192 $7.48 5.3$8,276 
Granted675,077 $5.00 
Exercised(95,122)$2.41 
Forfeited(568,725)$8.69 
Options outstanding at September 30, 2022
6,722,422 $7.20 5.2$1,438 
Vested and exercisable, September 30, 2022
4,408,060 $6.41 3.3$1,438 
Vested and expected to vest, September 30, 2022
6,722,422 $7.20 5.2$1,438 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Companys tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate and, if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. No such adjustment was made as of September 30, 2022. The Companys effective federal tax rate for the three and nine months ended September 30, 2022 and 2021 was 0%, primarily as a result of estimated tax losses for the fiscal year to date offset by the increase in the valuation allowance in the net operating loss carryforwards.
The Company did not record any income tax expense or benefit during the three and nine months ended September 30, 2022 and 2021. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Companys ability to realize these assets. All losses before income taxes arose in the United States.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Patent License Agreements
Duke University
In March 2006, the Company entered into a license agreement with Duke University (“Duke”), which was subsequently amended in 2011, 2014, 2015, 2018, 2019 and January 2022. Under this license agreement, Duke granted the Company a worldwide, exclusive, sublicensable license to certain patents related to decellularized tissue engineering, referred to as the patent rights, as well as a non-exclusive license to use and practice certain know-how related to the patent rights. The relevant licensed patent on decellularization of tissue expired in 2021. The Company has agreed to use commercially reasonable efforts to develop, register, market and sell products utilizing the patent rights, referred to as the licensed products. Any services provided to a third party utilizing licensed products are referred to as licensed services. The Company has also agreed to meet certain benchmarks in its development efforts, including as to development events, clinical trials, regulatory submissions and marketing approval, within specified timeframes. Under the license agreement, Duke retains the right to use the patent rights for its own educational and research purposes, and to provide the patent rights to other non-profit, governmental or higher-learning institutions for non-commercial purposes without paying royalties or other fees.
In connection with the Companys entry into the license agreement, the Company granted equity consideration to Duke in the form of 52,693 shares of the Companys common stock. Under the license agreement, the Company also agreed to pay Duke:
a low single-digit percentage royalty on eligible sales of licensed products and licensed services, plus a low double-digit percentage of any sublicensing revenue;
an annual minimum royalty beginning in 2012, which increases in the calendar year immediately following the first commercial sale of licensed products or licensed services (whichever occurs first); and
an additional amount in license fees, as certain milestones are met.
The license agreement remains effective until the later of (i) the last of the patent rights expires or (ii) four years after the Companys first commercial sale, unless terminated earlier. Either party may terminate the agreement for fraud, willful misconduct or illegal conduct, or uncured material breach. Duke may terminate the agreement if the Company becomes insolvent. Duke may also terminate the license, convert the license into a non-exclusive license or seek assignment of any sublicense if the Company fails to reach diligence milestones within the applicable time period. If the Company abandons any claim, patent or patent application, its rights under the license with respect to such patent rights will be terminated in the territory in which the Company abandons such rights. The Company may terminate the license agreement unilaterally upon three months prior notice to Duke. The Company agrees to indemnify Duke against certain third-party claims. Payments to Duke under the license agreement were immaterial during the periods presented.
Yale University
In February 2014, the Company entered into a license agreement with Yale University (“Yale”) that granted the Company a worldwide license to the patents related to coatings for small-diameter vessels to inhibit clotting. The license granted under the agreement is exclusive in the field of engineered vascular tissues and tissues and extracellular matrix-based implants used for vascular repair, reconstruction and replacement (provided that all uses are vascular tissues within the range of 1 12mm in diameter), except that it is subject to Yales non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.
In August 2019, the Company entered into a license agreement with Yale, that granted the Company a worldwide license to the patents related to Bioartificial Vascular Pancreas (“BVP”). The license granted under the agreement is exclusive in the field of engineered vascular tissues that deliver pancreatic islet cells to patients, except that it is subject to Yales non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.
In August 2019, the Company entered into a license agreement with Yale that granted the Company a worldwide license to the patents related to tubular prostheses. The license granted under the agreement is exclusive in the field of engineered urinary conduits, engineered tracheas/airways, and engineered esophagi, except that it is subject to Yales non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.
The Company has agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. The Company is also obligated to provide Yale periodically an updated and revised copy of its plan for each license, which must indicate progress of its development and commercialization. The Company may also sublicense the Companys rights without Yales prior written consent, but such sublicense is subject to certain conditions.
In connection with its entry into the license agreement, the Company paid Yale upfront cash fees. The Company has also agreed to pay Yale:
annual maintenance fees, increasing between the first anniversary of the agreement until the fifth anniversary for the coating and BVP licenses and until the fourth anniversary for the tubular prostheses license up to a maximum of less than $0.1 million per year;
milestone payments upon achievement of certain regulatory and commercial milestones of $0.2 million and $0.6 million, respectively;
a low single-digit percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and
a low double-digit percentage of sublicensing income.
If the Company or any of its future sublicensees bring a patent challenge against Yale or assists another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties.
The agreements expire on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Yale may terminate the agreements if the Company fails to (i) provide written diligence reports, (ii) provide commercially reasonable diligence plans, (iii) implement the plans in accordance with the obligations under the agreements, or (iv) reach certain research and development milestones within the scheduled timeframe set forth in the agreements; however, any such termination right would be limited in scope to the country to which such failure relates. Yale may also terminate for the Companys non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of the Companys products or insolvency. The Company may terminate the license agreements (i) on 90 days prior written notice to Yale, provided the Company is not in breach of the license agreements and has made all required payments to Yale thereunder and (ii) on written notice to Yale following an uncured material breach. With respect to the license agreements related to small-diameter vessels and BVP, the Companys rights under the license agreements will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, the Company does not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive licenses to non-exclusive licenses if the Company declines to initiate certain infringement or interference proceedings with respect to the licensed patents. The Company has agreed to indemnify Yale against certain third-party claims. Payments to Yale under the license agreement were immaterial during the periods presented.
Legal Matters
The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Companys business, financial condition, results of operations, or cash flows.
Indemnification
To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Companys request in such capacity. The indemnification period covers all pertinent events and occurrences during the directors or officers service. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is not specified in such arrangements; however, the Company has director and officer insurance coverage that is intended to reduce its exposure and enable the Company to recover a portion of any potential future amounts the Company could be required to make. To date, the Company has not incurred any costs as a result of such obligations and has not accrued any liabilities related to such obligations in the condensed consolidated financial statements.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
Fresenius Medical Care investments and distribution agreement
In June 2018, the Company completed a $150 million financing transaction pursuant to which Fresenius Medical Care purchased shares of series D redeemable convertible preferred stock that at the Closing of the Merger converted into 15,812,735 shares of the Companys common stock. In August 2021, Fresenius Medical Care invested $25 million as part of the PIPE Financing and received an additional 2.5 million shares of the Companys common stock.
In addition, the Company entered into a distribution agreement with Fresenius Medical Care in June 2018 which, as amended as of February 16, 2021, granted Fresenius Medical Care and its affiliates exclusive rights to develop outside the United States and European Union (the “EU”) and commercialize outside of the United States the Companys 6 millimeter x 42 centimeter HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter or configuration of the foregoing), for use in vascular creation, repair, replacement or construction, including renal replacement therapy for dialysis access, the treatment of peripheral arterial disease, and the treatment of vascular trauma, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients. Within the United States, Fresenius Medical Care will collaborate with the Company in its commercialization of the product in the field, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic analyses.
The Company is responsible for developing and seeking regulatory approval for the distribution product in the field in the United States. For countries outside the United States, the parties agreed to use commercially reasonable efforts to satisfy certain agreed minimum market entry criteria for the distribution product in the field in such country. For the EU, once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory approval for the distribution product in the field in the applicable country, the Company agreed to use commercially reasonable efforts to obtain such regulatory approval (other than pricing approval), and Fresenius Medical Care agreed to use commercially reasonable efforts to obtain the corresponding pricing approval. For the rest of the world (i.e., outside the United States and the EU), once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory and pricing approval for the distribution product in the field in the applicable country, Fresenius Medical Care agreed to use commercially reasonable efforts to obtain such approvals, and the Company agreed to use commercially reasonable efforts to support Fresenius Medical Care in its efforts.
Under the distribution agreement, the Company grants an exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to commercialize the distribution product in the field outside the United States, subject to the Companys retained rights to carry out its obligations under the distribution agreement. The Company also grants a non-exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to develop the distribution product in accordance with the terms of the distribution agreement. In addition, the Company grants to Fresenius Medical Care, among other things, a perpetual, irrevocable, non-exclusive sublicensable license under the patents and know-how that primarily relate to the distribution product or its manufacture and that were created, conceived or developed solely or jointly by or on behalf of Fresenius Medical Care in the performance of its activities under the distribution agreement.
The distribution agreement provides that the Company will own all know-how and patents that primarily relate to the distribution product or its manufacture that are created, conceived or developed by or on behalf of either party in the performance of activities under the distribution agreement. Ownership of all other know-how, patents, materials and other intellectual property created, conceived or developed during the performance of activities under the distribution agreement will be determined in accordance with U.S. patent laws for determining inventorship.
The Company is obligated to make payments to Fresenius Medical Care based on a share of aggregate net sales by or on behalf of the Company of the distribution product in the United States in the field. Such revenue-share payments will be a percentage of net sales in the low double digits, without regard to the calendar year in which such net sales are attributable, until such time that the Company has paid to Fresenius Medical Care a certain total amount, at which time the revenue-share will decrease to a percentage of net sales in the mid-single digits. The amounts that Fresenius Medical Care will be obligated to pay the Company under the distribution agreement for sales of the distribution product in the field outside of the United States will vary. Fresenius Medical Care agreed to pay the Company initially, on a country-by-country basis for sales outside of the United States, the amount equal to the average cost of manufacturing the Companys distribution product plus a fixed dollar amount per unit. Following a specified period, on a country-by-country basis outside of the United States, Fresenius Medical Care will pay the Company a fixed percentage of net sales for each unit sold in such country, such that the Company will receive more than half of such net sales.
The distribution agreement will generally continue on a country-by-country basis until the later of (a) the tenth anniversary of the launch date of the distribution product in the relevant country or (b) the expiration of the last-to-expire valid claim of specified patents in such country. Each party is permitted to terminate the distribution agreement for insolvency of, or, under certain circumstances, including various cure periods, material breach by the other party. Subject to a cure period, Fresenius Medical Care may also terminate the distribution agreement in its entirety or on a country-by-country basis (i) for certain withdrawals of regulatory approval or (ii) for termination or expiration of any of our in-licenses that is necessary for the exercise of Fresenius Medical Cares rights, or the satisfaction of its obligations, under the distribution agreement. In addition, Fresenius Medical Care may terminate the distribution agreement for convenience on a country-by-country basis upon not less than 12 months written notice to the Company, although Fresenius Medical Care is not permitted to give such notice prior to the end of the second year following launch of the distribution product in such country. Each party is required to indemnify one another for certain third-party claims.
Arrangements with Yale University
The Company’s President and Chief Executive Officer, Laura Niklason M.D., PhD., serves as an Adjunct Professor in Anesthesia at Yale University. As of September 30, 2022 and December 31, 2021, the Company was a party to license agreements with Yale University as described in Note 11 Commitments and Contingencies, above.
The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021:
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
License expenses$— $— $50 $85 
Other16 83 
Total66 168 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements
Basis of Presentation
The Company has prepared the accompanying financial statements in conformity with U.S. GAAP. The Companys condensed consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement. Operations prior to the Merger are those of Legacy Humacyte.
Unaudited Interim Condensed Consolidated Financial Statements
The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements and, in managements opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Companys financial position as of September 30, 2022 and its results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or any other period. The December 31, 2021 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.
Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 and the related notes included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022 (the “Annual Report”), which provides a more complete discussion of the Company’s accounting policies and certain other information. There have been no significant changes to the significant accounting policies disclosed in Note 2 of the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in the Companys Annual Report.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in the financial statements include stock-based compensation costs, right-of-use assets, accruals for research and development activities, contingent earnout liability, fair value of common stock warrants, redeemable convertible preferred stock and income taxes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
Segments
Segments
The Company operates and manages its business as one reportable and operating segment. The Company is developing proprietary, bioengineered, acellular human tissues, advanced tissue constructs and organ systems that are designed to be used in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The Companys chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments consisting of certificates of deposit (“CDs”). Total cash balances exceeded insured balances by the Federal Deposit Insurance Corporation (“FDIC”) as of September 30, 2022 and December 31, 2021. The Company has cash equivalents that are invested in highly rated money market funds that are invested only in obligations of the U.S. government and its agencies.
Net Loss per Share Attributable to Common Stockholders
Net Loss per Share Attributable to Common Stockholders
Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive.
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In May 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, “Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). The FASB issued this update to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring after the effective date of the amendments. The Company adopted ASU 2021-04 as of January 1, 2022. The adoption of this ASU had no impact on the Companys financial statements and related disclosures.
In November 2021, the FASB issued ASU No. 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”) to improve financial reporting by requiring annual disclosures that increase the transparency of transactions with a government accounted for by applying a grant or contribution model by analogy, including (i) the types of transactions, (ii) an entity’s accounting for those transactions, and (iii) the effect of those transactions on an entity’s financial statements. ASU 2021-10 is effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021, and an entity can elect to apply the amendments in this guidance prospectively or retrospectively. The Company adopted ASU 2021-10 effective January 1, 2022, and does not expect a material impact to its annual consolidated financial statement disclosures.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) 820, Fair Value Measurement and Disclosures, establishes a hierarchy whereby inputs to valuation techniques used in measuring fair value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy based on reliability of inputs, as follows:
Level 1 — Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.
Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.
The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company.
Common Stock Warrants
In connection with the Merger, the Company assumed 5,000,000 publicly-traded warrants (Public Warrants) and 177,500 private placement warrants issued to AHAC Sponsor LLC (the Sponsor), Oppenheimer & Co. Inc. and Northland Securities, Inc, in connection with AHACs initial public offering (Private Placement Warrants and, together with the Public Warrants, the Common Stock Warrants). The Common Stock Warrants entitle the holder to purchase one share of Common Stock at an exercise price of $11.50 per share. The Company evaluated the Common Stock Warrants to determine the appropriate financial statement classification upon the consummation of the Merger. The Common Stock Warrants are not mandatorily redeemable and are considered to be freestanding instruments as they are separately exercisable into common shares. As such, the Common Stock Warrants were not classified as liabilities under FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company then evaluated the Common Stock Warrants under FASB ASC Topic 815, Derivatives and Hedging.
Public Warrants
The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the Public Warrants may be eligible for a cashless exercise. The Public Warrants may only be exercised for a whole number of shares and will expire five years after the completion of the Merger. The Public Warrants became exercisable 30 days after the completion of the Merger.
The Public Warrants are considered to be “indexed to the Company’s own stock”. The agreement provides that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of the Companys Common Stock, all holders of the Common Stock Warrants (both the Public Warrants and the Private Placement Warrants) would be entitled to receive cash for all of their Common Stock Warrants. As the Company has a single class of Common Stock, a qualifying cash tender offer of more than 50% of the Companys Common Stock will always result in a change in control and would not preclude permanent equity classification of the Public Warrants. Based on this evaluation, the Company concluded that the Public Warrants meet the criteria to be classified within stockholders equity. The Public Warrants were initially recognized as equity on the Closing Date at a fair value of $2.80 per share.
Private Placement Warrants
The Private Placement Warrants are non-redeemable for cash so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
The agreement governing the Common Stock Warrants includes a provision, the application of which could result in a different settlement value for the Private Placement Warrants depending on their holder. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on the Common Stock, the Private Placement Warrants are not considered to be indexed to the Companys own stock and therefore are not classified in stockholders equity. As the Private Placement Warrants meet the definition of a derivative, the Company recorded these warrants as liabilities on the condensed consolidated balance sheet at fair value, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date.
Contingent Earnout Liability Upon the Closing, the contingent obligation to issue Contingent Earnout Shares was accounted for as a liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the Common Stock. The Contingent Earnout Shares are subsequently remeasured at each reporting date with changes in fair value recorded as a component of other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss.
Stock-Based Compensation The Company recognizes stock-based compensation expense based on the grant date fair value of the awards measured using the Black-Scholes option pricing model. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying Common Stock on the date of grant. Forfeitures are accounted for as they occur. Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur.Fair Value of Common Stock. Prior to the Merger, as the Companys common stock was not publicly traded, the fair value of the shares of its common stock underlying the options was determined by the Companys board of directors with input from management, after considering independent third-party valuation reports. Subsequent to the Merger, the fair value of the Common Stock has been determined based on the closing price of the shares on the Nasdaq market.Expected Term. The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.
Expected Volatility. The expected volatility was determined based on a blended approach using the historical share volatility of the Company’s Common Stock and that of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company has a limited trading history. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies.
Risk-Free Interest Rate. The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options.
Expected Dividend Yield. The Company has not paid dividends on its Common Stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of securities that could potentially dilute net loss per share in the future that were not included in the computation of diluted net loss per share
The potential shares of common stock that were excluded from the computation of diluted net loss per share for each period because including them would have had an antidilutive effect were as follows:
Three and Nine Months Ended
September 30,
20222021
Exercise of options under stock plan6,722,422 6,399,888 
Warrants to purchase common stock5,588,506 5,465,204 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Reverse Recapitalization (Tables)
9 Months Ended
Sep. 30, 2022
Reverse Recapitalization [Abstract]  
Schedule of Common Stock Outstanding Immediately Following the Consummation of the Merger
The number of shares of Common Stock outstanding immediately following the consummation of the Merger was:
Shares
Common stock of AHAC, outstanding prior to Merger10,355,000 
Less redemption of AHAC shares(3,008,551)
Common stock of AHAC7,346,449 
AHAC Founder Shares2,500,000 
New Humacyte shares issued to PIPE Investors17,500,000 
Issuance of common stock upon reverse recapitalization and PIPE Financing27,346,449 
New Humacyte shares issued in Merger to Legacy Humacyte stockholders75,656,935 (1)
Total shares of Common Stock immediately after Merger103,003,384 
________________
(1)Includes 69,613,562 shares of Common Stock issued upon conversion of Legacy Humacyte’s redeemable convertible preferred stock.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis
The Company’s assets and liabilities that were measured at fair value on a recurring basis were as follows:
($ in thousands)
Fair Value Measured as of September 30, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents (money market funds)$160,370 $— $— $160,370 
Cash equivalents (certificates of deposit)— 2,014 — 2,014 
Short-term investments (certificates of deposit)— 8,000 — 8,000 
Total financial assets$160,370 $10,014 $— $170,384 
Liabilities:
Contingent Earnout Liability$— $— $45,011 $45,011 
Private Placement Warrants liability— — 257 257 
Total financial liabilities$— $— $45,268 $45,268 
($ in thousands)
Fair Value Measured as of December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents (money market funds)$208,821 $— $— $208,821 
Cash equivalents (certificates of deposit)— 2,000 — 2,000 
Short-term investments (certificates of deposit)— 8,000 — 8,000 
Total financial assets$208,821 $10,000 $— $218,821 
Liabilities:
Contingent Earnout Liability$— $— $103,660 $103,660 
Private Placement Warrants liability— — 497 497 
Total financial liabilities$— $— $104,157 $104,157 
Summary of Changes in Fair Value of Level 3 Financial Instruments
The following tables present a summary of the changes in the fair value of the Company’s Level 3 financial instruments:
($ in thousands)Contingent Earnout Liability
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Fair value as of beginning of period$(44,049)$— $(103,660)$— 
Contingent Earnout Liability recognized upon the closing of the reverse recapitalization— (159,432)— (159,432)
Change in fair value included in other income (expense), net(962)(9,768)58,649 (9,768)
Fair value as of end of period$(45,011)$(169,200)$(45,011)$(169,200)
Private Placement Warrants
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
Fair value as of beginning of period$(190)$— $(497)$— 
Private placement warrant liability acquired as part of the Merger— (553)— (553)
Change in fair value included in other income (expense), net(67)(2)240 (2)
Fair value as of end of period$(257)$(555)$(257)$(555)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment, Net (Tables)
9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule Of Property And Equipment
Property and equipment, net consist of the following:
($ in thousands)September 30,
2022
December 31,
2021
Scientific equipment(1)
$27,926 $27,641 
Computer equipment232 155 
Software335 335 
Furniture and fixtures1,000 988 
Leasehold improvements26,355 26,355 
Construction in progress170 — 
56,018 55,474 
Accumulated depreciation(24,992)(20,440)
Property and equipment, net$31,026 $35,034 
___________________________
(1)As of December 31, 2021, includes $3.6 million related to scientific equipment not depreciated until being placed in service during the third quarter of 2022.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2022
Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Expenses
Accrued expenses consisted of the following:
($ in thousands)September 30,
2022
December 31,
2021
Accrued external research, development and manufacturing costs$2,673 $2,520 
Accrued employee compensation and benefits5,023 3,943 
Accrued professional fees263 294 
Total$7,959 $6,757 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Tables)
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Summary of SVB Loan Payable and Net Discount or Premium Balances
SVB loan payable and net discount or premium balances are as follows:
($ in thousands)September 30,
2022
Principal amount of SVB loan payable$30,000 
Final payment amount of SVB loan payable1,500 
Net premium associated with accretion of final payment and other debt issuance costs(2,928)
SVB loan payable, current and noncurrent28,572 
Less SVB loan payable, current portion(4,286)
SVB loan payable, noncurrent portion$24,286 
Summary of Future Minimum Payments of Principal
Future minimum payments of principal on the Companys outstanding variable rate borrowings as of September 30, 2022 are as follows:
Year ending December 31:
($ in thousands)
2022 (remainder)
$— 
20238,571 
202417,143 
20254,286 
Total future payments$30,000 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) (Tables)
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Summary Of Common Stock Reserved For Future Issuances
As of September 30, 2022, the Company had reserved Common Stock for future issuances as follows:
September 30,
2022
Common stock reserved for Contingent Earnout Shares15,000,000 
Exercise of options under stock plans6,722,422 
Issuance of options under stock plans7,312,585 
Shares available for grant under ESPP1,030,033 
Warrants to purchase Common Stock5,588,506 
35,653,546 
Schedule Of Activity Of Warrants
The Company had the following common stock warrants outstanding as of September 30, 2022 and December 31, 2021:
Common Stock Warrants Outstanding
Legacy Humacyte Common Stock Warrants411,006 
Private Placement Warrants177,500 
Public Warrants5,000,000 
Total Common Stock Warrants5,588,506 
Schedule Of Assumptions Used In The Valuations
The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model:
September 30,
2022
December 31,
2021
Market price of public stock$3.26$7.25
Exercise price$11.50$11.50
Expected term (years)3.914.65
Expected share price volatility94.5 %61.0 %
Risk-free interest rate4.16 %1.21 %
Estimated dividend yield%%
Assumptions used in the valuations are described below:
September 30,
2022
December 31,
2021
Current stock price$3.26$7.25
Expected share price volatility89.0 %85.8 %
Risk-free interest rate3.83 %1.52 %
Estimated dividend yield0.0 %%
Expected term (years)10.0010.00
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Assumptions Used to Estimate Fair Value of Stock Options
The Company estimated the fair value of the stock options on the date of grant using the following assumptions in the Black-Scholes option-pricing model:
Three Months Ended September 30,Nine Months Ended September 30,
2022
2021 (1)
20222021
Estimated dividend yield%— %%
Expected share price volatility (weighted average and range, if applicable)
89.3% (89.2% to 89.4%)
— 
93.3% (89.0% to 100.0%)
91.4% (91.0% to 92.1%)
Risk-free interest rate (weighted average and range, if applicable)
3.58% (3.46% to 3.65%)
— 
2.96% (1.89% to 3.65%)
0.68% (0.62% to 1.02%)
Expected term of options (in years)6.25— 6.256.00
__________________________
(1)The Company did not grant any stock options during the three months ended September 30, 2021.
Summary of Stock-Based Compensation Expense and Remaining Unrecognized Costs
The following tables show a summary of stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021, and remaining unrecognized cost as of September 30, 2022 and December 31, 2021:
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
Research and development$216 $486 $682 $1,837 
General and administrative1,260 1,391 3,832 5,498 
Total$1,476 $1,877 $4,514 $7,335 
($ in thousands)September 30,
2022
December 31,
2021
Unrecognized stock-based compensation cost$10,234 $13,346 
Expected weighted average period compensation costs to be recognized (years)2.02.3
Summary of Stock Option Activity
A summary of option activity under the Companys stock option plans during the nine months ended September 30, 2022 is presented below:
Number of SharesWeighted
Average Exercise
Price Per Share
Weighted
Average
Remaining
Contractual Term
(years)
Aggregate
Intrinsic Value
(in thousands)
Options outstanding at December 31, 2021
6,711,192 $7.48 5.3$8,276 
Granted675,077 $5.00 
Exercised(95,122)$2.41 
Forfeited(568,725)$8.69 
Options outstanding at September 30, 2022
6,722,422 $7.20 5.2$1,438 
Vested and exercisable, September 30, 2022
4,408,060 $6.41 3.3$1,438 
Vested and expected to vest, September 30, 2022
6,722,422 $7.20 5.2$1,438 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Summary of Related Party Expenses
The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021:
Three Months Ended September 30,Nine Months Ended September 30,
($ in thousands)2022202120222021
License expenses$— $— $50 $85 
Other16 83 
Total66 168 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Description of Business (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Accumulated deficit $ 422,818   $ 422,818   $ 414,573
Operating losses 23,494 $ 20,543 63,788 $ 59,581  
Net cash used in operating activities     52,170 $ 59,742  
Cash, cash equivalents, and short-term investments $ 171,700   $ 171,700    
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Segments (Details)
9 Months Ended
Sep. 30, 2022
segment
Accounting Policies [Abstract]  
Number of reportable segment 1
Number of operating segments 1
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Concentration Risk [Line Items]          
Certificates of deposit $ 10.0   $ 10.0   $ 10.0
Government Contracts Concentration Risk | Revenue Benchmark | Grant Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage 100.00% 100.00% 100.00% 100.00%  
Credit Concentration Risk | Accounts Receivable | Grant Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage     100.00%   100.00%
Cash and Cash Equivalents          
Concentration Risk [Line Items]          
Certificates of deposit $ 2.0   $ 2.0   $ 2.0
Short-term Investments          
Concentration Risk [Line Items]          
Certificates of deposit $ 8.0   $ 8.0   $ 8.0
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Maximum contingent earnout (in shares) 15,000,000 15,000,000 15,000,000 15,000,000
Exercise of options under stock plan        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Securities that were not included in the computation of diluted net loss per share (in shares) 6,722,422 6,399,888 6,722,422 6,399,888
Warrants to purchase common stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Securities that were not included in the computation of diluted net loss per share (in shares) 5,588,506 5,465,204 5,588,506 5,465,204
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Reverse Recapitalization - Narrative (Details)
9 Months Ended 12 Months Ended
Aug. 26, 2021
USD ($)
tranche
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
$ / shares
Asset Acquisition [Line Items]        
Legacy Humacyte common stock conversion ratio to common stock 0.26260      
Common stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001   $ 0.0001
Founder shares conversion ratio 1      
Maximum contingent earnout (in shares) | shares   15,000,000 15,000,000  
Contingent Consideration Liability recognized upon the closing of the reverse recapitalization   $ 0 $ 159,432,000  
Proceeds from Merger and PIPE financing, net of offering costs paid $ 242,400,000 0 242,400,000  
Transaction costs 3,900,000      
Transaction costs recorded in APIC 3,900,000      
Transaction costs expensed (less than) 100,000      
Unpaid liabilities assumed in connection with Merger   $ 0 $ 2,228,000  
AHAC        
Asset Acquisition [Line Items]        
Liabilities assumed 15,200,000      
Assets assumed $ 100,000      
Private Placement        
Asset Acquisition [Line Items]        
Number of shares issued (in shares) | shares 17,500,000      
Price per share (in dollars per share) | $ / shares $ 10.00      
Aggregate purchase price $ 175,000,000      
Accrued Liabilities        
Asset Acquisition [Line Items]        
Unpaid liabilities assumed in connection with Merger       $ 100,000
Earnout Shares        
Asset Acquisition [Line Items]        
Maximum contingent earnout (in shares) | shares 15,000,000      
Number of tranches of contingent earnout shares | tranche 2      
Number of contingent earnout shares per tranche (in shares) | shares 7,500,000      
Number of trading days 20 days      
Number of consecutive trading days 30 days      
Contingent Consideration Liability recognized upon the closing of the reverse recapitalization $ 159,400,000      
Tranche one | Earnout Shares        
Asset Acquisition [Line Items]        
Closing stock price to trigger contingent earnout shares (in dollars per share) | $ / shares $ 15.00      
Tranche two | Earnout Shares        
Asset Acquisition [Line Items]        
Closing stock price to trigger contingent earnout shares (in dollars per share) | $ / shares $ 20.00      
AHAC Founders        
Asset Acquisition [Line Items]        
Founder shares converted to common stock (in shares) | shares 2,500,000      
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Reverse Recapitalization - Common Stock Outstanding Immediately Following the Consummation of the Merger (Details) - shares
Aug. 26, 2021
Sep. 30, 2022
Dec. 31, 2021
Aug. 25, 2021
Schedule of Reverse Recapitalization [Line Items]        
Common stock, shares outstanding (in shares) 103,003,384 103,098,768 103,003,646  
New Humacyte shares issued to PIPE Investors (in shares) 17,500,000      
Issuance of common stock upon reverse recapitalization and PIPE Financing (in shares) 27,346,449      
New Humacyte shares issued in Merger to Legacy Humacyte stockholders (in shares) 75,656,935      
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares) 69,613,562      
Common Shareholders        
Schedule of Reverse Recapitalization [Line Items]        
Shares acquired (in shares) 7,346,449      
AHAC Founders        
Schedule of Reverse Recapitalization [Line Items]        
Shares acquired (in shares) 2,500,000      
AHAC        
Schedule of Reverse Recapitalization [Line Items]        
Common stock, shares outstanding (in shares)       10,355,000
Less redemption of AHAC shares (in shares) (3,008,551)      
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Liabilities:    
Private Placement Warrants liability $ 257 $ 497
Recurring    
Assets:    
Short-term investments (certificates of deposit) 8,000 8,000
Total financial assets 170,384 218,821
Liabilities:    
Contingent Earnout Liability 45,011 103,660
Private Placement Warrants liability 257 497
Total financial liabilities 45,268 104,157
Recurring | Level 1    
Assets:    
Short-term investments (certificates of deposit) 0 0
Total financial assets 160,370 208,821
Liabilities:    
Contingent Earnout Liability 0 0
Private Placement Warrants liability 0 0
Total financial liabilities 0 0
Recurring | Level 2    
Assets:    
Short-term investments (certificates of deposit) 8,000 8,000
Total financial assets 10,014 10,000
Liabilities:    
Contingent Earnout Liability 0 0
Private Placement Warrants liability 0 0
Total financial liabilities 0 0
Recurring | Level 3    
Assets:    
Short-term investments (certificates of deposit) 0 0
Total financial assets 0 0
Liabilities:    
Contingent Earnout Liability 45,011 103,660
Private Placement Warrants liability 257 497
Total financial liabilities 45,268 104,157
Recurring | Cash equivalents (money market funds)    
Assets:    
Cash equivalents 160,370 208,821
Recurring | Cash equivalents (money market funds) | Level 1    
Assets:    
Cash equivalents 160,370 208,821
Recurring | Cash equivalents (money market funds) | Level 2    
Assets:    
Cash equivalents 0 0
Recurring | Cash equivalents (money market funds) | Level 3    
Assets:    
Cash equivalents 0 0
Recurring | Cash equivalents (certificates of deposit)    
Assets:    
Cash equivalents 2,014 2,000
Recurring | Cash equivalents (certificates of deposit) | Level 1    
Assets:    
Cash equivalents 0 0
Recurring | Cash equivalents (certificates of deposit) | Level 2    
Assets:    
Cash equivalents 2,014 2,000
Recurring | Cash equivalents (certificates of deposit) | Level 3    
Assets:    
Cash equivalents $ 0 $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Changes in Fair Value of Level 3 Financial Instruments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Contingent Earnout Liability        
Changes in the fair value of the Level 3 financial instruments        
Beginning balance $ (44,049) $ 0 $ (103,660) $ 0
Contingent Earnout Liability recognized upon the closing of the reverse recapitalization 0 (159,432) 0 (159,432)
Change in fair value included in other income (expense), net (962) (9,768) 58,649 (9,768)
Ending balance (45,011) (169,200) (45,011) (169,200)
Private Placement Warrants        
Changes in the fair value of the Level 3 financial instruments        
Beginning balance (190) 0 (497) 0
Private placement warrant liability acquired as part of the Merger 0 (553) 0 (553)
Change in fair value included in other income (expense), net (67) (2) 240 (2)
Ending balance $ (257) $ (555) $ (257) $ (555)
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Narrative (Details) - Expected term (years) - yr
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Measurement input 10.00 10.00
Contingent Earnout Liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Measurement input 10  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment, Net (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 56,018   $ 56,018   $ 55,474
Accumulated depreciation (24,992)   (24,992)   (20,440)
Property and equipment, net 31,026   31,026   35,034
Depreciation expense 1,500 $ 1,500 4,552 $ 4,650  
Scientific equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 27,926   27,926   27,641
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 232   232   155
Software          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 335   335   335
Furniture and fixtures          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 1,000   1,000   988
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 26,355   26,355   26,355
Construction in progress          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 170   $ 170   0
Scientific equipment, not placed into service          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross         $ 3,600
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Accrued Liabilities, Current [Abstract]    
Accrued external research, development and manufacturing costs $ 2,673 $ 2,520
Accrued employee compensation and benefits 5,023 3,943
Accrued professional fees 263 294
Total $ 7,959 $ 6,757
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Term Loan (Details)
3 Months Ended 9 Months Ended
Oct. 13, 2021
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
Apr. 30, 2020
USD ($)
Sep. 30, 2022
USD ($)
tranche
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
tranche
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Aug. 26, 2021
$ / shares
Mar. 30, 2021
USD ($)
$ / shares
shares
Line of Credit Facility [Line Items]                      
Warrants, exercise price (in dollars per share) | $ / shares                   $ 11.50  
Common stock warrant liabilities       $ 257,000     $ 257,000   $ 497,000    
Gain on PPP loan forgiveness       $ 0 $ 0   $ 0 $ 3,284,000      
Term Loan Agreement                      
Line of Credit Facility [Line Items]                      
Amount of loan drawn $ 10,000,000 $ 20,000,000                  
Number of tranches | tranche       2     2        
Amount that will be eligible to disburse per tranche       $ 10,000,000     $ 10,000,000        
Minimum fixed rate on variable rate       7.50%     7.50%        
Advance notice period             30 days        
Common stock warrant liabilities       $ 3,300,000     $ 3,300,000        
Final payment fee percentage             5.00%        
Final payment amount of SVB loan payable       $ 1,500,000     $ 1,500,000        
Debt issuance costs             $ 300,000        
Term Loan Agreement | Debt Instrument, Prepayment Fee, Period One                      
Line of Credit Facility [Line Items]                      
Prepayment fee             3.00%        
Term Loan Agreement | Debt Instrument, Prepayment Fee, Period Two                      
Line of Credit Facility [Line Items]                      
Prepayment fee             2.00%        
Term Loan Agreement | Debt Instrument, Prepayment Fee, Period Three                      
Line of Credit Facility [Line Items]                      
Prepayment fee             1.00%        
Term Loan Agreement | Warrants to purchase common stock                      
Line of Credit Facility [Line Items]                      
Warrants, exercise price (in dollars per share) | $ / shares $ 10.28                   $ 10.28
Warrants immediately exercisable (in shares) | shares                     287,704
Exercisable warrants upon funding of additional tranche (in shares) | shares 123,302                   123,302
Term Loan Agreement | Prime Rate                      
Line of Credit Facility [Line Items]                      
Basis spread on variable rate             4.25%        
Effective interest rate       10.50%     10.50%        
Term Loan Agreement | Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.,                      
Line of Credit Facility [Line Items]                      
Maximum loan facility amount                     $ 50,000,000
Outstanding principal and interest collateralized             50.00%        
Paycheck Protection Program                      
Line of Credit Facility [Line Items]                      
Proceeds from debt instruments     $ 3,300,000                
Gain on PPP loan forgiveness           $ 3,300,000          
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - SVB Loan Payable and Net Discount or Premium Balances (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Debt Instrument [Line Items]  
Principal amount of SVB loan payable $ 30,000
SVB Loan payable  
Debt Instrument [Line Items]  
Principal amount of SVB loan payable 30,000
Final payment amount of SVB loan payable 1,500
Net premium associated with accretion of final payment and other debt issuance costs (2,928)
SVB loan payable, current and noncurrent 28,572
Less SVB loan payable, current portion (4,286)
SVB loan payable, noncurrent portion $ 24,286
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Future Minimum Payments of Principal (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Future minimum payments of principal and estimated payments of interest  
2022 (remainder) $ 0
2023 8,571
2024 17,143
2025 4,286
Total future payments $ 30,000
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Common Stock (Details)
9 Months Ended
Aug. 26, 2021
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
Vote
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Jun. 30, 2022
shares
Mar. 31, 2022
shares
Dec. 31, 2021
$ / shares
shares
Jun. 30, 2021
shares
Mar. 31, 2021
shares
Dec. 31, 2020
shares
Business Acquisition [Line Items]                  
Issuance of common stock upon reverse recapitalization and PIPE Financing (in shares) | shares 27,346,449                
Proceeds from Merger and PIPE financing, net of offering costs paid | $ $ 242,400,000 $ 0 $ 242,400,000            
Transaction costs | $ $ 3,900,000                
Common stock, shares outstanding (in shares) | shares 103,003,384 103,098,768       103,003,646      
Common stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001       $ 0.0001      
Common stock, authorized (in shares) | shares   250,000,000       250,000,000      
Dividends, common stock | $   $ 0              
Number of vote per common share held | Vote   1              
AHAC                  
Business Acquisition [Line Items]                  
Liabilities assumed | $ $ 15,200,000                
Assets assumed | $ $ 100,000                
Common Stock                  
Business Acquisition [Line Items]                  
Issuance of common stock upon reverse recapitalization and PIPE Financing (in shares) | shares 27,346,449                
Common stock, shares outstanding (in shares) | shares   103,098,768 103,003,384 103,006,803 103,004,572 103,003,646 5,943,749 5,938,545 5,822,396
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Common stock for future issuances (Details)
Sep. 30, 2022
shares
Class of Stock [Line Items]  
Reserved common stock for future issuances (in shares) 35,653,546
Common stock reserved for Contingent Earnout Shares  
Class of Stock [Line Items]  
Reserved common stock for future issuances (in shares) 15,000,000
Exercise of options under stock plan  
Class of Stock [Line Items]  
Reserved common stock for future issuances (in shares) 6,722,422
Issuance of options under stock plans  
Class of Stock [Line Items]  
Reserved common stock for future issuances (in shares) 7,312,585
Shares available for grant under ESPP  
Class of Stock [Line Items]  
Reserved common stock for future issuances (in shares) 1,030,033
Warrants to purchase common stock  
Class of Stock [Line Items]  
Reserved common stock for future issuances (in shares) 5,588,506
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Preferred Stock (Details) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Stockholders' Equity Note [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares outstanding (in shares) 0 0
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Warrants (Details) - shares
Sep. 30, 2022
Dec. 31, 2021
Class of Warrant or Right [Line Items]    
Warrants (in shares) 5,588,506 5,588,506
Humacyte, Inc.    
Class of Warrant or Right [Line Items]    
Warrants (in shares) 411,006 411,006
Private Placement Warrants    
Class of Warrant or Right [Line Items]    
Warrants (in shares) 177,500 177,500
Public Warrants    
Class of Warrant or Right [Line Items]    
Warrants (in shares) 5,000,000 5,000,000
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Warrants Narrative (Details) - $ / shares
9 Months Ended
Aug. 26, 2021
Sep. 30, 2022
Sep. 30, 2021
Class of Warrant or Right [Line Items]      
Warrants exercised (in shares)   0 32,961
Warrants, exercise price (in dollars per share) $ 11.50    
Merger Agreement | Warrants to purchase common stock | Assumption Of Publicly Traded Securities | Public Warrants      
Class of Warrant or Right [Line Items]      
Number of securities issued or issuable (in shares) 5,000,000    
Merger Agreement | Warrants to purchase common stock | Private Placement | Private Placement Warrants      
Class of Warrant or Right [Line Items]      
Number of securities issued or issuable (in shares) 177,500    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Public Warrants (Details)
Aug. 26, 2021
$ / shares
Class of Warrant or Right [Line Items]  
Share accepting a tender offer entitles warrants to receive cash (as a percent) 50.00%
Warrants exercised, minimum percent of outstanding shares, to receive cash 50.00%
Public Warrants  
Class of Warrant or Right [Line Items]  
Expected term (years) 5 years
Number of days warrants become exercisable after the completion of merger 30 days
Fair Value per share on Closing Date (in dollars per share) $ 2.80
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Private Placement Warrants (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Aug. 26, 2021
USD ($)
Class of Warrant or Right [Line Items]            
Common stock warrant liabilities $ 257   $ 257   $ 497  
Change in fair value of common stock warrant liabilities 67 $ 2 (240) $ 2    
Private Placement Warrants            
Class of Warrant or Right [Line Items]            
Common stock warrant liabilities 300   300   $ 500 $ 600
Change in fair value of common stock warrant liabilities $ 100 $ 100 $ (200) $ 100    
Private Placement Warrants | Market price of public stock            
Class of Warrant or Right [Line Items]            
Warrants, measurement input | $ / shares 3.26   3.26   7.25  
Private Placement Warrants | Exercise price            
Class of Warrant or Right [Line Items]            
Warrants, measurement input | $ / shares 11.50   11.50   11.50  
Private Placement Warrants | Expected term (years)            
Class of Warrant or Right [Line Items]            
Warrants, measurement input | $ / shares 3.91   3.91   4.65  
Private Placement Warrants | Expected share price volatility            
Class of Warrant or Right [Line Items]            
Warrants, measurement input 0.945   0.945   0.610  
Private Placement Warrants | Risk-free interest rate            
Class of Warrant or Right [Line Items]            
Warrants, measurement input 0.0416   0.0416   0.0121  
Private Placement Warrants | Estimated dividend yield            
Class of Warrant or Right [Line Items]            
Warrants, measurement input 0   0   0  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Deficit) - Contingent Earnout Liability (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 26, 2021
USD ($)
yr
tranche
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
yr
shares
Sep. 30, 2021
USD ($)
shares
Sep. 30, 2022
USD ($)
$ / shares
yr
shares
Sep. 30, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
$ / shares
yr
Business Acquisition, Contingent Consideration [Line Items]            
Maximum contingent earnout (in shares) | shares   15,000,000 15,000,000 15,000,000 15,000,000  
Contingent Consideration Liability recognized upon the closing of the reverse recapitalization       $ 0 $ 159,432  
Contingent Earnout Liability   $ 45,011   45,011   $ 103,660
Change in fair value of Contingent Earnout Liability   $ (962) $ (9,768) $ 58,649 $ (9,768)  
Current stock price            
Business Acquisition, Contingent Consideration [Line Items]            
Measurement input | $ / shares   3.26   3.26   7.25
Expected share price volatility            
Business Acquisition, Contingent Consideration [Line Items]            
Measurement input   0.890   0.890   0.858
Risk-free interest rate            
Business Acquisition, Contingent Consideration [Line Items]            
Measurement input   0.0383   0.0383   0.0152
Estimated dividend yield            
Business Acquisition, Contingent Consideration [Line Items]            
Measurement input   0.000   0.000   0
Expected term (years)            
Business Acquisition, Contingent Consideration [Line Items]            
Measurement input | yr   10.00   10.00   10.00
Earnout Shares            
Business Acquisition, Contingent Consideration [Line Items]            
Maximum contingent earnout (in shares) | shares 15,000,000          
Number of tranches of contingent earnout shares | tranche 2          
Number of contingent earnout shares per tranche (in shares) | shares 7,500,000          
Number of trading days 20 days          
Number of consecutive trading days 30 days          
Contingent Consideration Liability recognized upon the closing of the reverse recapitalization $ 159,400          
Earnout Shares | Expected term (years)            
Business Acquisition, Contingent Consideration [Line Items]            
Measurement input | yr 10          
Tranche one | Earnout Shares            
Business Acquisition, Contingent Consideration [Line Items]            
Closing stock price to trigger contingent earnout shares (in dollars per share) | $ / shares $ 15.00          
Tranche two | Earnout Shares            
Business Acquisition, Contingent Consideration [Line Items]            
Closing stock price to trigger contingent earnout shares (in dollars per share) | $ / shares $ 20.00          
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation - Narrative (Details)
3 Months Ended 9 Months Ended
Aug. 25, 2021
plan
Sep. 30, 2022
shares
Sep. 30, 2022
shares
Sep. 30, 2021
Dec. 31, 2021
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of equity incentive plans | plan 2        
Outstanding awards (in shares)   6,722,422 6,722,422   6,711,192
ESPP          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares remaining available for grant (in shares)   1,030,033 1,030,033    
Annual increase in available shares     1.00%    
Purchase price of common stock, percent of closing trading price     85.00%    
Options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Contractual term     10 years    
Accelerated vesting commencement period     30 days    
Accelerated vesting ending period     12 months    
Estimated dividend yield   0.00% 0.00% 0.00%  
Options | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period     36 months    
Options | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period     48 months    
Long-Term Incentive Plan, 2021          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares remaining available for grant (in shares)   7,312,585 7,312,585    
Annual increase in available shares     5.00%    
Long-Term Incentive Plan, 2021 | Options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares remaining available for grant (in shares)   7,312,585 7,312,585    
Omnibus Incentive Plan, 2015          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding awards (in shares)   5,233,533 5,233,533    
Stock Option Plan, 2005          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding awards (in shares)   504,254 504,254    
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) - Options
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Assumptions on the date of grant to estimate the fair value of the stock options      
Estimated dividend yield 0.00% 0.00% 0.00%
Weighted average expected share price volatility 89.30% 93.30% 91.40%
Weighted average expected share price volatility, minimum 89.20% 89.00% 91.00%
Weighted average expected share price volatility, maximum 89.40% 100.00% 92.10%
Risk-free interest rate 3.58% 2.96% 0.68%
Risk-free interest rate, minimum 3.46% 1.89% 0.62%
Risk-free interest rate, maximum 3.65% 3.65% 1.02%
Expected term of options (in years) 6 years 3 months 6 years 3 months 6 years
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 1,476 $ 1,877 $ 4,514 $ 7,335
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 216 486 682 1,837
General and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 1,260 $ 1,391 $ 3,832 $ 5,498
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation - Remaining Unrecognized Costs (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]    
Unrecognized stock-based compensation cost $ 10,234 $ 13,346
Expected weighted average period compensation costs to be recognized (years) 2 years 2 years 3 months 18 days
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation - Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Number of Shares    
Options outstanding, beginning of period (in shares) | shares 6,711,192  
Granted (in shares) | shares 675,077  
Exercised (in shares) | shares (95,122)  
Forfeited (in shares) | shares (568,725)  
Options outstanding, end of period (in shares) | shares 6,722,422 6,711,192
Number of shares, vested and exercisable (in shares) | shares 4,408,060  
Number of shares, vested and expected to vest (in shares) | shares 6,722,422  
Weighted Average Exercise Price Per Share    
Options outstanding, beginning of period (in dollars per share) | $ / shares $ 7.48  
Granted (in dollars per share) | $ / shares 5.00  
Exercised (in dollars per share) | $ / shares 2.41  
Forfeited (in dollars per share) | $ / shares 8.69  
Options outstanding, end of period (in dollars per share) | $ / shares 7.20 $ 7.48
Weighted average exercise price, vested and exercisable (in dollars per share) | $ / shares 6.41  
Weighted average exercise price, vested and expected to vest (in dollars per share) | $ / shares $ 7.20  
Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value    
Weighted average remaining contractual term, outstanding (in years) 5 years 2 months 12 days 5 years 3 months 18 days
Weighted average remaining contractual term, vested and exercisable (in years) 3 years 3 months 18 days  
Weighted average remaining contractual term, vested and expected to vest (in years) 5 years 2 months 12 days  
Aggregate intrinsic value, outstanding | $ $ 1,438 $ 8,276
Aggregate intrinsic value, vested and exercisable | $ 1,438  
Aggregate intrinsic value, vested and expected to vest | $ $ 1,438  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Effective tax rate 0.00% 0.00% 0.00% 0.00%
Income tax expense or benefit $ 0 $ 0 $ 0 $ 0
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details) - License Agreement - USD ($)
$ in Millions
1 Months Ended 9 Months Ended
Aug. 31, 2019
Feb. 28, 2014
Sep. 30, 2022
Duke University | Decellularized Tissue Engineering Patent Rights      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Shares issued under agreement (in shares)     52,693
Expiration period of agreement     4 years
Termination period     3 months
Yale University      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Termination period     90 days
Maximum annual maintenance fee, less than     $ 0.1
Yale University | Small-Diameter Vessels Patent Rights      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Maximum annual maintenance fee, less than   $ 0.1  
Yale University | BVP Patent Rights      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Maximum annual maintenance fee, less than $ 0.1    
Yale University | Tubular Prostheses Patent Rights      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Maximum annual maintenance fee, less than $ 0.1    
Yale University | Regulatory Milestone      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestone payments     0.2
Yale University | Commercial Milestone      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestone payments     $ 0.6
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended
Aug. 26, 2021
Feb. 16, 2021
Aug. 31, 2021
Jun. 30, 2018
Sep. 30, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]            
Common stock issued (in shares)         103,098,768 103,003,646
Fresenius Medical Care            
Related Party Transaction [Line Items]            
Financing transaction       $ 150    
Conversion of stock (in shares) 15,812,735          
Proceeds from PIPE Financing     $ 25      
Common stock issued (in shares)     2,500,000      
Distribution agreement, termination period   12 months        
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Related Party Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Related Party Transaction [Line Items]        
Related party expenses $ 8 $ 2 $ 66 $ 168
License expenses        
Related Party Transaction [Line Items]        
Related party expenses 0 0 50 85
Other        
Related Party Transaction [Line Items]        
Related party expenses $ 8 $ 2 $ 16 $ 83
XML 70 huma-20220930_htm.xml IDEA: XBRL DOCUMENT 0001818382 2022-01-01 2022-09-30 0001818382 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001818382 huma:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150Member 2022-01-01 2022-09-30 0001818382 2022-11-04 0001818382 2022-09-30 0001818382 2021-12-31 0001818382 2022-07-01 2022-09-30 0001818382 2021-07-01 2021-09-30 0001818382 2021-01-01 2021-09-30 0001818382 us-gaap:CommonStockMember 2021-12-31 0001818382 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001818382 us-gaap:RetainedEarningsMember 2021-12-31 0001818382 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001818382 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001818382 2022-01-01 2022-03-31 0001818382 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001818382 2022-03-31 0001818382 us-gaap:CommonStockMember 2022-03-31 0001818382 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001818382 us-gaap:RetainedEarningsMember 2022-03-31 0001818382 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001818382 2022-04-01 2022-06-30 0001818382 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001818382 2022-06-30 0001818382 us-gaap:CommonStockMember 2022-06-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001818382 us-gaap:RetainedEarningsMember 2022-06-30 0001818382 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001818382 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001818382 us-gaap:CommonStockMember 2022-09-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001818382 us-gaap:RetainedEarningsMember 2022-09-30 0001818382 2020-12-31 0001818382 us-gaap:CommonStockMember 2020-12-31 0001818382 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001818382 us-gaap:RetainedEarningsMember 2020-12-31 0001818382 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001818382 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001818382 2021-01-01 2021-03-31 0001818382 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001818382 2021-03-31 0001818382 us-gaap:CommonStockMember 2021-03-31 0001818382 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001818382 us-gaap:RetainedEarningsMember 2021-03-31 0001818382 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001818382 2021-04-01 2021-06-30 0001818382 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001818382 2021-06-30 0001818382 us-gaap:CommonStockMember 2021-06-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001818382 us-gaap:RetainedEarningsMember 2021-06-30 0001818382 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001818382 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001818382 2021-09-30 0001818382 us-gaap:CommonStockMember 2021-09-30 0001818382 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001818382 us-gaap:RetainedEarningsMember 2021-09-30 0001818382 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0001818382 us-gaap:CashAndCashEquivalentsMember 2022-09-30 0001818382 us-gaap:ShortTermInvestmentsMember 2021-12-31 0001818382 us-gaap:ShortTermInvestmentsMember 2022-09-30 0001818382 huma:RevenueFromGrantsMember us-gaap:SalesRevenueNetMember us-gaap:GovernmentContractsConcentrationRiskMember 2021-07-01 2021-09-30 0001818382 huma:RevenueFromGrantsMember us-gaap:SalesRevenueNetMember us-gaap:GovernmentContractsConcentrationRiskMember 2021-01-01 2021-09-30 0001818382 huma:RevenueFromGrantsMember us-gaap:SalesRevenueNetMember us-gaap:GovernmentContractsConcentrationRiskMember 2022-01-01 2022-09-30 0001818382 huma:RevenueFromGrantsMember us-gaap:SalesRevenueNetMember us-gaap:GovernmentContractsConcentrationRiskMember 2022-07-01 2022-09-30 0001818382 huma:RevenueFromGrantsMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2022-01-01 2022-09-30 0001818382 huma:RevenueFromGrantsMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0001818382 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001818382 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001818382 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001818382 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001818382 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001818382 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001818382 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001818382 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001818382 2021-08-26 0001818382 huma:AHACFoundersMember 2021-08-26 2021-08-26 0001818382 huma:EarnoutSharesMember 2021-08-26 0001818382 huma:EarnoutSharesMember huma:ContingentConsiderationTrancheOneMember 2021-08-26 0001818382 huma:EarnoutSharesMember huma:ContingentConsiderationTrancheTwoMember 2021-08-26 0001818382 huma:EarnoutSharesMember 2021-08-26 2021-08-26 0001818382 us-gaap:PrivatePlacementMember 2021-08-26 2021-08-26 0001818382 us-gaap:PrivatePlacementMember 2021-08-26 0001818382 huma:AHACMember 2021-08-25 0001818382 huma:AHACMember 2021-08-26 2021-08-26 0001818382 huma:CommonShareholdersMember 2021-08-26 2021-08-26 0001818382 2021-08-26 2021-08-26 0001818382 huma:AHACMember 2021-08-26 0001818382 us-gaap:AccruedLiabilitiesMember 2021-01-01 2021-12-31 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001818382 huma:ContingentEarnoutLiabilityMember 2022-06-30 0001818382 huma:ContingentEarnoutLiabilityMember 2021-06-30 0001818382 huma:ContingentEarnoutLiabilityMember 2021-12-31 0001818382 huma:ContingentEarnoutLiabilityMember 2020-12-31 0001818382 huma:ContingentEarnoutLiabilityMember 2022-07-01 2022-09-30 0001818382 huma:ContingentEarnoutLiabilityMember 2021-07-01 2021-09-30 0001818382 huma:ContingentEarnoutLiabilityMember 2022-01-01 2022-09-30 0001818382 huma:ContingentEarnoutLiabilityMember 2021-01-01 2021-09-30 0001818382 huma:ContingentEarnoutLiabilityMember 2022-09-30 0001818382 huma:ContingentEarnoutLiabilityMember 2021-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2022-06-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-06-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-12-31 0001818382 huma:PrivatePlacementWarrantsMember 2020-12-31 0001818382 huma:PrivatePlacementWarrantsMember 2022-07-01 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-07-01 2021-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2022-01-01 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-01-01 2021-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-09-30 0001818382 huma:ContingentEarnoutLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001818382 huma:ScientificEquipmentMember 2022-09-30 0001818382 huma:ScientificEquipmentMember 2021-12-31 0001818382 us-gaap:ComputerEquipmentMember 2022-09-30 0001818382 us-gaap:ComputerEquipmentMember 2021-12-31 0001818382 us-gaap:SoftwareDevelopmentMember 2022-09-30 0001818382 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001818382 us-gaap:FurnitureAndFixturesMember 2022-09-30 0001818382 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001818382 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001818382 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001818382 us-gaap:ConstructionInProgressMember 2022-09-30 0001818382 us-gaap:ConstructionInProgressMember 2021-12-31 0001818382 huma:ScientificEquipmentNotPlacedIntoServiceMember 2021-12-31 0001818382 huma:TermLoanAgreementMember huma:SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember 2021-03-30 0001818382 huma:TermLoanAgreementMember huma:SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember 2022-01-01 2022-09-30 0001818382 huma:TermLoanAgreementMember 2021-03-31 2021-03-31 0001818382 huma:TermLoanAgreementMember 2021-10-13 2021-10-13 0001818382 huma:TermLoanAgreementMember 2022-09-30 0001818382 huma:TermLoanAgreementMember us-gaap:PrimeRateMember 2022-01-01 2022-09-30 0001818382 huma:TermLoanAgreementMember us-gaap:PrimeRateMember 2022-09-30 0001818382 huma:TermLoanAgreementMember 2022-01-01 2022-09-30 0001818382 huma:TermLoanAgreementMember huma:DebtInstrumentPrepaymentFeePeriodOneMember 2022-01-01 2022-09-30 0001818382 huma:TermLoanAgreementMember huma:DebtInstrumentPrepaymentFeePeriodTwoMember 2022-01-01 2022-09-30 0001818382 huma:TermLoanAgreementMember huma:DebtInstrumentPrepaymentFeePeriodThreeMember 2022-01-01 2022-09-30 0001818382 us-gaap:WarrantMember huma:TermLoanAgreementMember 2021-03-30 0001818382 us-gaap:WarrantMember huma:TermLoanAgreementMember 2021-10-13 0001818382 huma:SVBLoanPayableMember 2022-09-30 0001818382 huma:PaycheckProtectionProgramMember 2020-04-30 2020-04-30 0001818382 huma:PaycheckProtectionProgramMember 2021-04-01 2021-06-30 0001818382 us-gaap:CommonStockMember 2021-08-26 2021-08-26 0001818382 huma:CommonStockReservedForContingentConsiderationSharesMember 2022-09-30 0001818382 us-gaap:EmployeeStockOptionMember 2022-09-30 0001818382 huma:IssuanceOfOptionsUnderStockPlanMember 2022-09-30 0001818382 huma:SharesAvailableForGrantUnderESPPMember 2022-09-30 0001818382 us-gaap:WarrantMember 2022-09-30 0001818382 huma:HumacyteIncMember 2022-09-30 0001818382 huma:HumacyteIncMember 2021-12-31 0001818382 huma:PrivatePlacementWarrantsMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-12-31 0001818382 huma:PublicWarrantsMember 2022-09-30 0001818382 huma:PublicWarrantsMember 2021-12-31 0001818382 huma:MergerAgreementMember huma:PublicWarrantsMember us-gaap:WarrantMember huma:AssumptionOfPubliclyTradedSecuritiesMember 2021-08-26 2021-08-26 0001818382 huma:MergerAgreementMember huma:PrivatePlacementWarrantsMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2021-08-26 2021-08-26 0001818382 huma:PublicWarrantsMember 2021-08-26 0001818382 huma:PublicWarrantsMember 2021-08-26 2021-08-26 0001818382 huma:PrivatePlacementWarrantsMember 2021-08-26 0001818382 huma:PrivatePlacementWarrantsMember 2022-07-01 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2022-01-01 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-01-01 2021-09-30 0001818382 huma:PrivatePlacementWarrantsMember 2021-07-01 2021-09-30 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 0001818382 huma:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001818382 huma:EarnoutSharesMember us-gaap:MeasurementInputExpectedTermMember 2021-08-26 0001818382 us-gaap:MeasurementInputSharePriceMember 2022-09-30 0001818382 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001818382 us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001818382 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001818382 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001818382 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001818382 us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 0001818382 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001818382 us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001818382 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001818382 huma:LongTermIncentivePlan2021Member 2022-09-30 0001818382 us-gaap:EmployeeStockMember 2022-09-30 0001818382 huma:LongTermIncentivePlan2021Member 2022-01-01 2022-09-30 0001818382 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0001818382 2021-08-25 2021-08-25 0001818382 huma:OmnibusIncentivePlan2015Member 2022-09-30 0001818382 huma:StockOptionPlan2005Member 2022-09-30 0001818382 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001818382 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001818382 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001818382 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001818382 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001818382 us-gaap:EmployeeStockOptionMember huma:LongTermIncentivePlan2021Member 2022-09-30 0001818382 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001818382 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001818382 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001818382 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001818382 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001818382 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001818382 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001818382 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001818382 2021-01-01 2021-12-31 0001818382 huma:DukeUniversityMember huma:DecellularizedTissueEngineeringPatentRightsMember huma:LicenseAgreementMember 2022-01-01 2022-09-30 0001818382 huma:YaleUniversityMember huma:SmallDiameterVesselsPatentRightsMember huma:LicenseAgreementMember 2014-02-01 2014-02-28 0001818382 huma:YaleUniversityMember huma:BVPPatentRightsMember huma:LicenseAgreementMember 2019-08-01 2019-08-31 0001818382 huma:YaleUniversityMember huma:TubularProsthesesPatentRightsMember huma:LicenseAgreementMember 2019-08-01 2019-08-31 0001818382 huma:YaleUniversityMember huma:LicenseAgreementMember 2022-01-01 2022-09-30 0001818382 huma:YaleUniversityMember huma:LicenseAgreementMember huma:RegulatoryMilestoneMember 2022-01-01 2022-09-30 0001818382 huma:YaleUniversityMember huma:LicenseAgreementMember huma:CommercialMilestoneMember 2022-01-01 2022-09-30 0001818382 huma:FreseniusMedicalCareMember 2018-06-01 2018-06-30 0001818382 huma:FreseniusMedicalCareMember 2021-08-26 2021-08-26 0001818382 huma:FreseniusMedicalCareMember 2021-08-01 2021-08-31 0001818382 huma:FreseniusMedicalCareMember 2021-08-31 0001818382 huma:FreseniusMedicalCareMember 2021-02-16 2021-02-16 0001818382 huma:LicenseExpensesMember 2022-07-01 2022-09-30 0001818382 huma:LicenseExpensesMember 2021-07-01 2021-09-30 0001818382 huma:LicenseExpensesMember 2022-01-01 2022-09-30 0001818382 huma:LicenseExpensesMember 2021-01-01 2021-09-30 0001818382 huma:OtherRelatedPartyExpensesMember 2022-07-01 2022-09-30 0001818382 huma:OtherRelatedPartyExpensesMember 2021-07-01 2021-09-30 0001818382 huma:OtherRelatedPartyExpensesMember 2022-01-01 2022-09-30 0001818382 huma:OtherRelatedPartyExpensesMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares huma:segment pure huma:tranche utr:Y huma:Vote huma:plan 0001818382 --12-31 2022 Q3 false 10-Q true 2022-09-30 false 001-39532 Humacyte, Inc. DE 85-1763759 2525 East North Carolina Highway 54 Durham, NC 27713 919 313-9633 Common Stock, par value $0.0001 per share HUMA NASDAQ Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 HUMAW NASDAQ Yes Yes Non-accelerated Filer true true false false 103118461 163731000 217502000 8000000 8000000 31000 176000 2850000 3662000 174612000 229340000 19888000 21432000 693000 727000 31026000 35034000 226219000 286533000 3255000 2094000 7959000 6757000 4286000 0 2185000 1981000 173000 173000 48000 45000 17906000 11050000 45011000 103660000 24286000 27361000 19442000 21109000 645000 682000 257000 497000 107547000 164359000 0.0001 0.0001 20000000 20000000 0 0 0 0 0 0 0.0001 0.0001 250000000 250000000 103098768 103098768 103003646 103003646 10000 10000 541480000 536737000 -422818000 -414573000 118672000 122174000 226219000 286533000 31000 241000 1565000 1086000 17337000 15386000 48303000 45091000 6188000 5398000 17050000 15576000 23525000 20784000 65353000 60667000 -23494000 -20543000 -63788000 -59581000 883000 3000 1215000 6000 962000 9768000 -58649000 9768000 67000 2000 -240000 2000 0 0 0 3284000 1641000 1204000 4561000 2952000 0 49000 0 49000 -1787000 -11020000 55543000 -9481000 -25281000 -25281000 -31563000 -31563000 -8245000 -8245000 -69062000 -69062000 -0.25 -0.25 -0.72 -0.72 -0.08 -0.08 -3.69 -3.69 103031980 103031980 43950856 43950856 103014009 103014009 18728471 18728471 0 0 103003646 10000 536737000 -414573000 122174000 926 1000 1000 1547000 1547000 -19832000 -19832000 0 0 103004572 10000 538285000 -434405000 103890000 2231 11000 11000 1491000 1491000 36868000 36868000 0 0 103006803 10000 539787000 -397537000 142260000 91965 217000 217000 1476000 1476000 -25281000 -25281000 0 0 103098768 10000 541480000 -422818000 118672000 69613562 420989000 5822396 1000 37778000 -388096000 -350317000 116149 206000 206000 2528000 2528000 2360000 2360000 -20301000 -20301000 69613562 420989000 5938545 1000 42872000 -408397000 -365524000 5204 30000 30000 2930000 2930000 -17198000 -17198000 69613562 420989000 5943749 1000 45832000 -425595000 -379762000 -69613562 -420989000 69613562 7000 420982000 420989000 27346449 2000 209478000 209480000 13912000 13912000 159432000 159432000 99624 360000 360000 1877000 1877000 -31563000 -31563000 0 0 103003384 10000 533009000 -457158000 75861000 -8245000 -69062000 4552000 4650000 4514000 7335000 -58649000 9768000 -240000 2000 1544000 1545000 34000 31000 1211000 628000 0 11000 0 3284000 0 12363000 -145000 127000 -812000 2002000 984000 757000 1202000 2401000 -34000 -32000 -52170000 -59742000 8000000 0 8000000 0 367000 175000 -367000 -175000 229000 596000 1463000 1277000 0 242400000 0 941000 0 19659000 0 0 -1234000 260437000 -53771000 200520000 217502000 39929000 163731000 240449000 1867000 642000 198000 0 0 2360000 0 2228000 0 3004000 0 420989000 0 159432000 Organization and Description of Business<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. and subsidiary (the “Company”) is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company is leveraging its technology platform to develop proprietary product candidates for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 26, 2021 (the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Closing Date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Alpha Healthcare Acquisition Corp. (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHAC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) consummated a merger pursuant to a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Business Combination Agreement, dated as of February 17, 2021 (the “Merger Agreement”), by and among Humacyte, Inc., a Delaware Corporation (“Legacy Humacyte”), AHAC and Hunter Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly owned subsidiary of AHAC. As contemplated by the Merger Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte continuing as the surviving corporation and as a wholly owned subsidiary of AHAC (such transactions, the “Merger,” and, collectively with the other transactions described in the Merger Agreement, the “Reverse Recapitalization”). On the Closing Date, AHAC changed its name to Humacyte, Inc. (“New Humacyte”) and Legacy Humacyte changed its name to Humacyte Global, Inc. The Merger is accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and under this method of accounting, AHAC is treated as the acquired company for financial reporting purposes and Legacy Humacyte is treated as the acquirer. Operations prior to the Merger are those of Legacy Humacyte.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 3 — Reverse Recapitalization for further details of the Merger.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception in 2004, the Company has generated no product revenue and has incurred operating losses and negative cash flows from operations in each year. To date, the Company has financed its operations primarily through the sale of equity securities and convertible debt, proceeds from the Reverse Recapitalization, borrowings under loan facilities and, to a lesser extent, through governmental and other grants. At September 30, 2022 and December 31, 2021, the Company had an accumulated deficit of $422.8 million and $414.6 million, respectively. The Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s operating losses were $63.8 million and $59.6 million for the nine months ended September 30, 2022 and 2021, respectively. Net cash flows used in operating activities were $52.2 million and $59.7 million during the nine months ended September 30, 2022 and 2021, respectively. Substantially all of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s operating losses resulted from costs incurred in connection with the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s research and development programs and from general and administrative costs associated with the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company had cash and cash equivalents and short-term investments of $171.7 million. The Company believes its combined cash and cash equivalents and short-term investments on hand will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, for at least 12 months from the issuance date of these interim financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in-place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business and operations are uncertain. The COVID-19 pandemic may affect the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s ability to initiate and complete preclinical studies, delay its clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on its business and operations. The pandemic has already caused significant disruptions in the financial markets and may continue to cause such disruptions, which could impact the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s ability to raise additional funds to support its operations. Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business and operations.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, there have been no material financial impacts or impairment losses in the carrying values of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets as a result of the pandemic and the Company is not aware of any specific related event or circumstance that would require it to revise the estimates reflected in these financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business, results of operations and financial condition, including current and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, the emergence of new virus variants, and the duration and intensity of the related economic impact of the pandemic.</span></div> -422800000 -414600000 -63800000 -59600000 -52200000 -59700000 171700000 Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying financial statements in conformity with U.S. GAAP. The Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s condensed consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement. Operations prior to the Merger are those of Legacy Humacyte.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in the financial statements include stock-based compensation costs, right-of-use assets, accruals for research and development activities, contingent earnout liability, fair value of common stock warrants, redeemable convertible preferred stock and income taxes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements and, in management</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s financial position as of September 30, 2022 and its results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or any other period. The December 31, 2021 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 and the related notes included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022 (the “Annual Report”), which provides a more complete discussion of the Company’s accounting policies and certain other information. There have been no significant changes to the significant accounting policies disclosed in Note 2 of the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as one reportable and operating segment. The Company is developing proprietary, bioengineered, acellular human tissues, advanced tissue constructs and organ systems that are designed to be used in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments consisting of certificates of deposit (“CDs”). Total cash balances exceeded insured balances by the Federal Deposit Insurance Corporation (“FDIC”) as of September 30, 2022 and December 31, 2021. The Company has cash equivalents that are invested in highly rated money market funds that are invested only in obligations of the U.S. government and its agencies.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022 and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 31, 2021, the Company had approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.0 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in CDs. These cash deposits are deposited at a bank that is a member of the Certificate of Deposit Account Registry Service (“CDARS”), in which large deposits are divided into smaller amounts and placed with other FDIC insured banks which are also members of the CDARS network. Those members issue CDs in amounts under $250,000, so that the entire deposit balance is eligible for FDIC insurance. As of both </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022 and December 31, 2021, t</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company classified </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of its certificates of deposit as cash and cash equivalents and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.0 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of its certificates of deposit as short-term investments on its condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022 and 2021, 100% of the Company’s total revenue relates to an award it received from the Department of Defense (“DoD”) in August 2017. As of September 30, 2022 and December 31, 2021, 100% of the Company’s accounts receivable relates to the DoD grant.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential shares of common stock that were excluded from the computation of diluted net loss per share for each period because including them would have had an antidilutive effect were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options under stock plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,399,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,465,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 15,000,000 Contingent Earnout Shares, as defined in Note 3, are excluded from the anti-dilutive table for all periods presented, as such shares are contingently issuable until the share price of the Company exceeds specified thresholds that have not yet been achieved, or upon the occurrence of a change in control.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, the success of clinical trials and other studies for its product candidates, including for its ongoing V005 Phase II/III clinical trial and V007 Phase III clinical trial, the regulatory approval and commercialization of its HAVs and other product candidates,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the expected size of the target populations for the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s product candidates, the degree of market acceptance of the HAVs, if approved, the availability of third-party coverage and reimbursement, development by competitors of new technological innovations, the ability to manufacture HAVs and other product candidates in sufficient quantities, expectations regarding the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s strategic partnerships, dependence on third parties, key personnel and the ability to attract and retain qualified employees, protection of proprietary technology and confidentiality of trade secrets, compliance with governmental regulations, the impact of the COVID-19 pandemic, the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s implementation and maintenance of effective internal controls, and the ability to secure additional capital to fund operations and the commercial success of its product candidates.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s commercialization efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales, and the Company may depend on certain strategic relationships to distribute its products, including the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s strategic partnership with Fresenius Medical Care, to sell, market and distribute its 6 millimeter HAV for certain specified indications outside the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, “Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). The FASB issued this update to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring after the effective date of the amendments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2021-04 as of January 1, 2022. The adoption of this ASU had no impact on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”) to improve financial reporting by requiring annual disclosures that increase the transparency of transactions with a government accounted for by applying a grant or contribution model by analogy, including (i) the types of transactions, (ii) an entity’s accounting for those transactions, and (iii) the effect of those transactions on an entity’s financial statements. ASU 2021-10 is effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021, and an entity can elect to apply the amendments in this guidance prospectively or retrospectively. The Company adopted ASU 2021-10 effective January 1, 2022, and does not expect a material impact to its annual consolidated financial statement disclosures.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying financial statements in conformity with U.S. GAAP. The Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s condensed consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement. Operations prior to the Merger are those of Legacy Humacyte.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements and, in management</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s financial position as of September 30, 2022 and its results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or any other period. The December 31, 2021 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 and the related notes included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022 (the “Annual Report”), which provides a more complete discussion of the Company’s accounting policies and certain other information. There have been no significant changes to the significant accounting policies disclosed in Note 2 of the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report.</span> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in the financial statements include stock-based compensation costs, right-of-use assets, accruals for research and development activities, contingent earnout liability, fair value of common stock warrants, redeemable convertible preferred stock and income taxes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as one reportable and operating segment. The Company is developing proprietary, bioengineered, acellular human tissues, advanced tissue constructs and organ systems that are designed to be used in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources.</span></div> 1 1 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments consisting of certificates of deposit (“CDs”). Total cash balances exceeded insured balances by the Federal Deposit Insurance Corporation (“FDIC”) as of September 30, 2022 and December 31, 2021. The Company has cash equivalents that are invested in highly rated money market funds that are invested only in obligations of the U.S. government and its agencies.</span></div> 10000000 10000000 2000000 2000000 8000000 8000000 1 1 1 1 1 1 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive.</span></div> <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential shares of common stock that were excluded from the computation of diluted net loss per share for each period because including them would have had an antidilutive effect were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options under stock plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,399,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,465,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6722422 6722422 6399888 6399888 5588506 5588506 5465204 5465204 15000000 15000000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, “Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). The FASB issued this update to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring after the effective date of the amendments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2021-04 as of January 1, 2022. The adoption of this ASU had no impact on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”) to improve financial reporting by requiring annual disclosures that increase the transparency of transactions with a government accounted for by applying a grant or contribution model by analogy, including (i) the types of transactions, (ii) an entity’s accounting for those transactions, and (iii) the effect of those transactions on an entity’s financial statements. ASU 2021-10 is effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021, and an entity can elect to apply the amendments in this guidance prospectively or retrospectively. The Company adopted ASU 2021-10 effective January 1, 2022, and does not expect a material impact to its annual consolidated financial statement disclosures.</span></div> Reverse Recapitalization<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 26, 2021, Merger Sub, a wholly-owned subsidiary of AHAC, merged with Legacy Humacyte, with Legacy Humacyte surviving as a wholly-owned subsidiary of AHAC. At the effective time of the Merger:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each outstanding share of Legacy Humacyte common stock was converted into approximately 0.26260 shares of New Humacyte’s common stock, par value $0.0001 per share (“Common Stock”);</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each outstanding share of preferred stock of Legacy Humacyte was cancelled and converted into the aggregate number of shares of Common Stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately 0.26260; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each outstanding option or warrant to purchase Legacy Humacyte common stock was converted into an option or warrant, as applicable, to purchase a number of shares of Common Stock equal to the number of shares of Legacy Humacyte common stock subject to such option or warrant multiplied by approximately 0.26260, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.26260;</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in each case, rounded down to the nearest whole share.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the closing of the Merger (the “Closing”), 2,500,000 Class B shares of AHAC (the “Founder Shares”) automatically converted into shares of Common Stock on a one-for-one basis.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former holders of the Legacy Humacyte common stock and Legacy Humacyte preferred stock are eligible to receive up to an aggregate of 15,000,000 additional shares of Common Stock (the “Contingent Earnout Shares”) in the aggregate, comprised of two equal tranches of 7,500,000 shares per tranche if the volume-weighted average closing sale price of the Common Stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period. At the Closing on August 26, 2021, the Company recorded a liability (“Contingent Earnout Liability”) of $159.4 million, based on the estimated fair value of the 15,000,000 Contingent Earnout Shares with a corresponding reduction of additional paid-in capital in the equity section of the Company’s condensed consolidated balance sheet.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, AHAC entered into subscription agreements (the “Subscription Agreements”) with certain investors (the “PIPE Investors”). Pursuant to the Subscription Agreements, the PIPE Investors purchased an aggregate of 17,500,000 shares of Common Stock (the “PIPE Shares”) in a private placement at a price of $10.00 per share for an aggregate purchase price of $175 million (the “PIPE Financing”). The PIPE Financing was consummated in connection with the Closing.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of Common Stock outstanding immediately following the consummation of the Merger was:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock of AHAC, outstanding prior to Merger</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,355,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less redemption of AHAC shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,008,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock of AHAC</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,346,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHAC Founder Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Humacyte shares issued to PIPE Investors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon reverse recapitalization and PIPE Financing</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,346,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Humacyte shares issued in Merger to Legacy Humacyte stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,656,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares of Common Stock immediately after Merger</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,003,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 69,613,562 shares of Common Stock issued upon conversion of Legacy Humacyte’s redeemable convertible preferred stock.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, AHAC was treated as the acquired company for financial reporting purposes and Legacy Humacyte was treated as the acquirer. This determination was primarily based on the fact that subsequent to the Merger, the Legacy Humacyte stockholders held a majority of the voting rights of the combined company, Legacy Humacyte comprised all of the ongoing operations of the combined company, Legacy Humacyte comprised a majority of the governing body of the combined company, and Legacy Humacyte’s senior management comprised all of the senior management of the combined company. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Humacyte issuing shares for the net assets of AHAC, accompanied by a recapitalization. The net assets of AHAC were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the Merger are those of Legacy Humacyte.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company received $242.4 million in proceeds from the Merger and related PIPE Financing. The Company incurred $3.9 million of transaction costs, consisting of banking, legal, and other professional fees, of which $3.9 million was recorded as a reduction of proceeds to additional paid-in capital, and less than $0.1 million related to the Private Placement Warrants, which are classified as liabilities in the condensed consolidated balance sheets, was expensed in the condensed consolidated statements of operations and comprehensive loss during the three months ended September 30, 2021. All transaction costs were paid as of December 31, 2021. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Of the $15.2 million of liabilities assumed from AHAC, $0.1 million was included in accrued expenses as of December 31, 2021, and there were no unpaid liabilities as of September 30, 2022.</span></div> 0.26260 0.0001 0.26260 0.26260 0.26260 2500000 1 1 15000000 2 7500000 15.00 20.00 P20D P30D 159400000 15000000 17500000 10.00 175000000 <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of Common Stock outstanding immediately following the consummation of the Merger was:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock of AHAC, outstanding prior to Merger</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,355,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less redemption of AHAC shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,008,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock of AHAC</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,346,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHAC Founder Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Humacyte shares issued to PIPE Investors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon reverse recapitalization and PIPE Financing</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,346,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Humacyte shares issued in Merger to Legacy Humacyte stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,656,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares of Common Stock immediately after Merger</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,003,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 69,613,562 shares of Common Stock issued upon conversion of Legacy Humacyte’s redeemable convertible preferred stock.</span></div> 10355000 3008551 7346449 2500000 17500000 27346449 75656935 103003384 69613562 242400000 3900000 3900000 100000 15200000 100000 15200000 100000 0 Fair Value Measurements<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a hierarchy whereby inputs to valuation techniques used in measuring fair value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy based on reliability of inputs, as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s assets and liabilities that were measured at fair value on a recurring basis were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured as of September 30, 2022</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (certificates of deposit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (certificates of deposit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Earnout Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Warrants liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured as of December 31, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (certificates of deposit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (certificates of deposit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Earnout Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Warrants liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present a summary of the changes in the fair value of the Company’s Level 3 financial instruments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Earnout Liability</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Earnout Liability recognized upon the closing of the reverse recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,011)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,200)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,011)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,200)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private Placement Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement warrant liability acquired as part of the Merger</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Contingent Earnout Liability and Private Placement Warrants (as defined in Note 8 — Stockholders’ Equity (Deficit)) liability are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of the Contingent Earnout Liability, the Company used the Monte Carlo simulation value model using a distribution of potential outcomes on a monthly basis over a 10-year period prioritizing the most reliable information available. The assumptions utilized in the calculation were based on the achievement of certain stock price milestones, including the current Common Stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8 — Stockholders’ Equity (Deficit)). Contingent earnout payments involve certain assumptions requiring significant judgment and actual results can differ from assumed and estimated amounts.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of the Private Placement Warrants liability, the Company used the Monte Carlo simulation valuation model to estimate the fair value utilizing assumptions including the current Company stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8 — Stockholders’ Equity (Deficit)).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheets, which approximates their fair value based on Level 2 inputs. The carrying values of other receivables, accounts payable and accrued expenses as of September 30, 2022 and December 31, 2021 approximated their fair values due to the short-term nature of these items.</span></div> <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a hierarchy whereby inputs to valuation techniques used in measuring fair value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy based on reliability of inputs, as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company.</span></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s assets and liabilities that were measured at fair value on a recurring basis were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured as of September 30, 2022</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (certificates of deposit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (certificates of deposit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Earnout Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Warrants liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured as of December 31, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (certificates of deposit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (certificates of deposit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Earnout Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Warrants liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 160370000 0 0 160370000 0 2014000 0 2014000 0 8000000 0 8000000 160370000 10014000 0 170384000 0 0 45011000 45011000 0 0 257000 257000 0 0 45268000 45268000 208821000 0 0 208821000 0 2000000 0 2000000 0 8000000 0 8000000 208821000 10000000 0 218821000 0 0 103660000 103660000 0 0 497000 497000 0 0 104157000 104157000 <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present a summary of the changes in the fair value of the Company’s Level 3 financial instruments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Earnout Liability</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Earnout Liability recognized upon the closing of the reverse recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,011)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,200)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,011)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,200)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private Placement Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement warrant liability acquired as part of the Merger</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 44049000 0 103660000 0 0 159432000 0 159432000 -962000 -9768000 58649000 -9768000 45011000 169200000 45011000 169200000 190000 0 497000 0 0 553000 0 553000 -67000 -2000 240000 -2000 257000 555000 257000 555000 10 Property and Equipment, Net<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,034 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December 31, 2021, includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to scientific equipment not depreciated until being placed in service during the third quarter of 2022.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense totaled $1.5 million and $4.6 million for the three and nine months ended September 30, 2022, respectively, and $1.5 million and $4.7 million for the three and nine months ended September 30, 2021, respectively. All long-lived assets are maintained in the United</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States.</span> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,034 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December 31, 2021, includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to scientific equipment not depreciated until being placed in service during the third quarter of 2022.</span></div> 27926000 27641000 232000 155000 335000 335000 1000000 988000 26355000 26355000 170000 0 56018000 55474000 24992000 20440000 31026000 35034000 3600000 1500000 4600000 1500000 4700000 Accrued Expenses<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research, development and manufacturing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research, development and manufacturing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2673000 2520000 5023000 3943000 263000 294000 7959000 6757000 Debt<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2021, the Company entered into a term loan agreement with Silicon Valley Bank (“SVB”) and SVB Innovation Credit Fund VIII, L.P., as amended in June 2021 and September 2021 (the “Loan Agreement”), which provides a term loan facility of up to $50.0 million with a maturity date of March 1, 2025. The Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s obligations under the Loan Agreement are secured by substantially all of its assets except for its intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. If a minimum liquidity amount is not maintained, 50% of the outstanding principal and interest will become cash collateralized. As of September 30, 2022, the Company was in compliance with all covenants. The Company may use the proceeds of borrowings under the Loan Agreement as working capital and to fund its general business requirements. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement provides that the term loans will be distributed in tranches. The initial term loan tranche of $20.0 million was drawn on March 31, 2021, and on October 13, 2021, the Company borrowed an additional $10.0 million under the Loan Agreement. Borrowings under the Loan Agreement are accounted for net of issuance costs which are being accreted to interest expense over the term of the loan using the effective interest method. As of September 30, 2022, two subsequent $10.0 million term loan tranches will be eligible to be drawn at the request of the Company during specified draw periods prior to May 15, 2023, the first tranche subject to submission by the Company of its first Biologics License Application (“BLA”) to the FDA for its HAV prior to March 31, 2023, and the second tranche subject to the first approval from the FDA of any BLA for the HAV prior to March 31, 2023 and the Company having borrowed the first remaining tranche.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings bear interest at the greater of 7.5% or the Wall Street Journal Prime Rate plus 4.25% (10.50% as of September 30, 2022). Interest only payments on the principal amount outstanding are due monthly beginning in the first month after the loan is dispersed. Repayment of principal may begin as soon as July 1, 2023 under the level of borrowing outstanding at September 30, 2022, and no later than April 1, 2024 if the remaining two loan tranches are drawn. The term loans may only be prepaid in full, and such prepayment requires 30 days</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> advance notice and was subject initially to a prepayment fee of 3.00% that was decreased to 2.00% after March 30, 2022 (with a further decrease to 1.00% after March 30, 2023). The Company is not obligated to pay a prepayment fee if the Company makes a prepayment after March 30, 2024.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Loan Agreement, the Company granted warrants to the lenders to purchase shares of Common Stock at an exercise price of $10.28 per share, of which 287,704 warrants were immediately exercisable. The warrants are classified within stockholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity, as the settlement of the warrants is indexed to the Common Stock. The Company recognized the fair value of the warrants immediately exercisable within stockholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity using a Black-Scholes valuation model at issuance.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At issuance, the Company initially determined that the funding of an additional tranche was not probable, and therefore no value was ascribed to the remaining 123,302 warrants that were only exercisable upon the funding of the first additional tranche. As a result of the Company’s additional $10.0 million borrowings under the Loan Agreement on October 13, 2021, the warrants to purchase the additional 123,302 shares of Common Stock became exercisable at an exercise price of $10.28 per share and the value of the warrants was recorded as of that date. The additional warrants are classified within stockholders’ equity using a Black-Scholes valuation model, as the settlement of the warrants is indexed to the Common Stock.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the fair value of warrants ($3.3 million), a 5% final payment fee ($1.5 million) and debt issuance costs ($0.3 million) are being accreted to interest expense over the term of the loan using the effective interest method. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVB loan payable and net discount or premium balances are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of SVB loan payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Final payment amount of SVB loan payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premium associated with accretion of final payment and other debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, current and noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less SVB loan payable, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,286 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments of principal on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s outstanding variable rate borrowings as of September 30, 2022 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Year ending December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, the Company received loan proceeds in the amount of approximately $3.3 million under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act. All or a portion of this loan and any accrued interest was eligible to be forgiven after a twenty-four week period as long as the borrower used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintained its payroll levels. On May 25, 2021, the PPP loan was forgiven and the Company recognized a gain from loan extinguishment in the amount of $3.3 million during the three months ended June 30, 2021.</span></div> 50000000 0.50 20000000 10000000 2 10000000 0.075 0.0425 0.1050 2 P30D 0.0300 0.0200 0.0100 10.28 287704 123302 10000000 123302 10.28 3300000 0.05 1500000 300000 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVB loan payable and net discount or premium balances are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of SVB loan payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Final payment amount of SVB loan payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premium associated with accretion of final payment and other debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, current and noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less SVB loan payable, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,286 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30000000 1500000 2928000 28572000 4286000 24286000 <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments of principal on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s outstanding variable rate borrowings as of September 30, 2022 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Year ending December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 8571000 17143000 4286000 30000000 3300000 3300000 Stockholders<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity (Deficit)</span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the Merger, Legacy Humacyte had outstanding series A redeemable convertible preferred stock, series B redeemable convertible preferred stock, series C redeemable convertible preferred stock and series D redeemable convertible preferred stock, which are collectively referred to as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable convertible preferred stock.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, all previously issued and outstanding redeemable convertible preferred stock was converted into an equivalent number of shares of Common Stock of the Company on a one-for-one basis, then multiplied by the exchange ratio pursuant to the Merger Agreement and the amounts were reclassified as additional paid-in capital.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 26, 2021, the Merger and related PIPE Financing was consummated and the Company issued 27,346,449 shares of Common Stock for proceeds of $242.4 million. The Company incurred $3.9 million of transaction costs, consisting of banking, legal, and other professional fees. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Immediately following the Merger, there were 103,003,384 shares of Common Stock outstanding with a par value of $0.0001 per share. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Second Amended and Restated Certificate of Incorporation authorized the Company to issue 250,000,000 shares of Common Stock. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares then outstanding or reserved for issuance) by the affirmative vote of the holders of a majority of the capital stock of the Company entitled to vote and may require a separate class vote of the Common Stock.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Common Stock are entitled to receive dividends from time to time as may be declared by the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s board of directors. Through September 30, 2022, no dividends have been declared.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Common Stock are entitled to one vote for each share held with respect to all matters voted on by the common stockholders of the Company.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a reorganization of the Company, after payment to the preferred stockholders of their liquidation preferences, holders of Common Stock are entitled to share ratably in all remaining assets of the Company.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company had reserved Common Stock for future issuances as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for Contingent Earnout Shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of options under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,653,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Second Amended and Restated Certificate of Incorporation provides the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s board of directors with the authority to issue preferred stock, par value $0.0001 per share, in one more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were 20,000,000 shares designated as preferred stock and none were outstanding as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following common stock warrants outstanding as of September 30, 2022 and December 31, 2021: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants Outstanding</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legacy Humacyte Common Stock Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Common Stock Warrants</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588,506 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7 — Debt for a discussion of common stock warrants issued in conjunction with the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Loan Agreement in 2021 (such warrants, “Legacy Humacyte Common Stock Warrants”). There were no issuances, exercises or expirations of warrants during the nine months ended September 30, 2022. During the nine months ended September 30, 2021 there were 32,961 of warrants exercised that were issued in conjunction with a long-term debt agreement repaid in a prior reporting period. There were no expirations of warrants during the nine months ended September 30, 2021.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company assumed 5,000,000 publicly-traded warrants (</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public Warrants</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and 177,500 private placement warrants issued to AHAC Sponsor LLC (the </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsor</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Oppenheimer &amp; Co. Inc. and Northland Securities, Inc, in connection with AHAC</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s initial public offering (</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private Placement Warrants</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, together with the Public Warrants, the </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock Warrants</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Common Stock Warrants entitle the holder to purchase one share of Common Stock at an exercise price of $11.50 per share. The Company evaluated the Common Stock Warrants to determine the appropriate financial statement classification upon the consummation of the Merger. The Common Stock Warrants are not mandatorily redeemable and are considered to be freestanding instruments as they are separately exercisable into common shares. As such, the Common Stock Warrants were not classified as liabilities under FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 480”). The Company then evaluated the Common Stock Warrants under FASB ASC Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Warrants</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the Public Warrants may be eligible for a cashless exercise. The Public Warrants may only be exercised for a whole number of shares and will expire five years after the completion of the Merger. The Public Warrants became exercisable 30 days after the completion of the Merger.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Public Warrants are considered to be “indexed to the Company’s own stock”. The agreement provides that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Common Stock, all holders of the Common Stock Warrants (both the Public Warrants and the Private Placement Warrants) would be entitled to receive cash for all of their Common Stock Warrants. As the Company has a single class of Common Stock, a qualifying cash tender offer of more than 50% of the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Common Stock will always result in a change in control and would not preclude permanent equity classification of the Public Warrants. Based on this evaluation, the Company concluded that the Public Warrants meet the criteria to be classified within stockholders</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity. The Public Warrants were initially recognized as equity on the Closing Date at a fair value of $2.80 per share.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Warrants</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement Warrants are non-redeemable for cash so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement governing the Common Stock Warrants includes a provision, the application of which could result in a different settlement value for the Private Placement Warrants depending on their holder. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on the Common Stock, the Private Placement Warrants are not considered to be </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indexed to the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s own stock</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and therefore are not classified in stockholders</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity. As the Private Placement Warrants meet the definition of a derivative, the Company recorded these warrants as liabilities on the condensed consolidated balance sheet at fair value, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement Warrants were initially recognized as a liability on the Closing Date, at a fair value of $0.6 million, and the liability was remeasured to an estimated fair value of $0.5 million as of December 31, 2021. See Note 4 — Fair Value Measurements for a summary of the change in the fair value of the Private Placement Warrants during the three and nine months ended September 30, 2022 and 2021. The remeasurement of the Private Placement Warrant liability to a fair value of $0.3 million as of September 30, 2022 resulted in a non-cash loss of $0.1 million and a non-cash gain of $0.2 million for the three and nine months ended September 30, 2022, respectively, compared to a non-cash loss of less than $0.1 million for each of the three and nine months ended September 30, 2021. The remeasurement of the Private Placement Warrant liability is classified within Change in fair value of common stock warrant liabilities in the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market price of public stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Earnout Liability</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Closing, former holders of Legacy Humacyte common and preferred shares may receive up to 15,000,000 additional shares of Common Stock in the aggregate, in two equal tranches of 7,500,000 shares of Common Stock per tranche. The first and second tranches are issuable if the closing volume weighted average price (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VWAP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) per share of Common Stock quoted on Nasdaq (or the exchange on which the shares of Common Stock are then listed) is greater or equal to $15.00 and $20.00, respectively, over any 20 trading days within any 30 consecutive trading day period.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the Closing, the contingent obligation to issue Contingent Earnout Shares was accounted for as a liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the Common Stock. The Contingent Earnout Shares are subsequently remeasured at each reporting date with changes in fair value recorded as a component of other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss. The estimated fair value of the total Contingent Earnout Shares at the Closing on August 26, 2021 was $159.4 million based on a Monte Carlo simulation valuation model using a distribution of potential outcomes on a monthly basis over a ten-year period using the most reliable information available. The estimated fair value of the total Contingent Earnout Shares at December 31, 2021 was $103.7 million.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4 — Fair Value Measurements for a summary of the change in the fair value of the Contingent Earnout Liability during the three and nine months ended September 30, 2022. The remeasurement of the Contingent Earnout Liability to a fair value of $45.0 million as of September 30, 2022 resulted in a non-cash loss of $1.0 million and a non-cash gain of $58.6 million for the three and nine months ended September 30, 2022, respectively, compared to a non-cash loss of $9.8 million for each of the three and nine months ended September 30, 2021. The remeasurement of the Contingent Earnout Liability is classified within Change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss. The assumptions utilized in the calculations of fair value were based on the achievement of certain stock price milestones, including the current Common Stock price, expected volatility, risk-free rate, expected term and expected dividend yield.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions used in the valuations are described below:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr></table></div> 27346449 242400000 3900000 15200000 100000 103003384 0.0001 250000000 0 1 <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company had reserved Common Stock for future issuances as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for Contingent Earnout Shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of options under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,653,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15000000 6722422 7312585 1030033 5588506 35653546 0.0001 20000000 20000000 0 0 <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following common stock warrants outstanding as of September 30, 2022 and December 31, 2021: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants Outstanding</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legacy Humacyte Common Stock Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Common Stock Warrants</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588,506 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 411006 411006 177500 177500 5000000 5000000 5588506 5588506 0 32961 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company assumed 5,000,000 publicly-traded warrants (</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public Warrants</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and 177,500 private placement warrants issued to AHAC Sponsor LLC (the </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsor</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Oppenheimer &amp; Co. Inc. and Northland Securities, Inc, in connection with AHAC</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s initial public offering (</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private Placement Warrants</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, together with the Public Warrants, the </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock Warrants</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Common Stock Warrants entitle the holder to purchase one share of Common Stock at an exercise price of $11.50 per share. The Company evaluated the Common Stock Warrants to determine the appropriate financial statement classification upon the consummation of the Merger. The Common Stock Warrants are not mandatorily redeemable and are considered to be freestanding instruments as they are separately exercisable into common shares. As such, the Common Stock Warrants were not classified as liabilities under FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 480”). The Company then evaluated the Common Stock Warrants under FASB ASC Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Warrants</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the Public Warrants may be eligible for a cashless exercise. The Public Warrants may only be exercised for a whole number of shares and will expire five years after the completion of the Merger. The Public Warrants became exercisable 30 days after the completion of the Merger.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Public Warrants are considered to be “indexed to the Company’s own stock”. The agreement provides that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Common Stock, all holders of the Common Stock Warrants (both the Public Warrants and the Private Placement Warrants) would be entitled to receive cash for all of their Common Stock Warrants. As the Company has a single class of Common Stock, a qualifying cash tender offer of more than 50% of the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Common Stock will always result in a change in control and would not preclude permanent equity classification of the Public Warrants. Based on this evaluation, the Company concluded that the Public Warrants meet the criteria to be classified within stockholders</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity. The Public Warrants were initially recognized as equity on the Closing Date at a fair value of $2.80 per share.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Warrants</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement Warrants are non-redeemable for cash so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement governing the Common Stock Warrants includes a provision, the application of which could result in a different settlement value for the Private Placement Warrants depending on their holder. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on the Common Stock, the Private Placement Warrants are not considered to be </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indexed to the Company</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s own stock</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and therefore are not classified in stockholders</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span> equity. As the Private Placement Warrants meet the definition of a derivative, the Company recorded these warrants as liabilities on the condensed consolidated balance sheet at fair value, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date. 5000000 177500 11.50 P5Y P30D 0.50 0.50 2.80 600000 500000 300000 100000 -200000 100000 100000 <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market price of public stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions used in the valuations are described below:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr></table></div> 3.26 7.25 11.50 11.50 3.91 4.65 0.945 0.610 0.0416 0.0121 0 0 15000000 2 7500000 15.00 20.00 P20D P30D Upon the Closing, the contingent obligation to issue Contingent Earnout Shares was accounted for as a liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the Common Stock. The Contingent Earnout Shares are subsequently remeasured at each reporting date with changes in fair value recorded as a component of other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss. 159400000 10 103700000 45000000 1000000 -58600000 9800000 9800000 3.26 7.25 0.890 0.858 0.0383 0.0152 0.000 0 10.00 10.00 Stock-based Compensation<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Closing, the 2021 Long-Term Incentive Plan, (the “2021 Plan”), and the 2021 Employee Stock Purchase Plan, (the “ESPP”), became effective. As of September 30, 2022, 7,312,585 and 1,030,033 shares of Common Stock were available under the 2021 Plan and ESPP, respectively. The 2021 Plan and ESPP provide that on January 1 of each year commencing January 1, 2022, the 2021 Plan and the ESPP reserve will automatically increase in an amount equal to the lesser of (a) 5% and 1%, respectively, of the number of shares of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Common Stock outstanding on December 31 of the preceding year and (b) a number of shares of Common Stock determined by the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s board of directors. In December 2021, the Company’s board of directors determined that there would be no automatic increase in the number of shares reserved under the 2021 Plan or the ESPP on January 1, 2022.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 Plan, the Company can grant non-statutory stock options (“NSOs”), incentive stock options (“ISOs), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, performance awards and other forms of awards. Under the ESPP, when and if implemented, eligible employees will be permitted to purchase shares of the Company’s Common Stock at the lower of 85% of the closing trading price per share of the Company’s Common Stock on the first day of the offering or 85% of the closing trading price per share on the exercise date, which will occur on the last day of each offering.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Closing, Legacy Humacyte had two equity incentive plans, the 2015 Omnibus Incentive Plan, as amended (the “2015 Plan”), and the 2005 Stock Option Plan (the “2005 Plan”). As a result of the Merger, no further awards may be granted under either the 2015 Plan or the 2005 Plan. All awards previously granted and outstanding as of the effective date of the Merger were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2021 Plan or the 2015 Plan that are forfeited, cancelled or reacquired by the Company prior to vesting, that expire or that are paid out in cash rather than shares will become available for grant and issuance under the 2021 Plan. As of September 30, 2022, 5,233,533 and 504,254 shares of Common Stock remain reserved for outstanding options issued under the 2015 Plan and 2005 Plan, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s stock option plans allow for the grant of awards that the Company believes aid in aligning the interests of award recipients with those of its stockholders. The Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s board of directors or compensation committee determines the specific terms of equity incentive grants, including the exercise price per share and vesting period for option awards. Option awards are granted with an exercise price equal to the fair market value of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Common Stock at the date of grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted options that include either a service-based or performance-based vesting condition, or both, and a 10-year contractual term. The service-based vesting condition for the plans is generally satisfied over 36 to 48 months from the date of grant. The performance-based vesting conditions are satisfied upon the attainment of certain product development milestones. The Company recognizes stock-based compensation expense based on the grant date fair value of the awards measured using the Black-Scholes option pricing model. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying Common Stock on the date of grant. Forfeitures are accounted for as they occur. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option awards under the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s option plans generally provide for accelerated vesting of the unvested portions of any option award in the event of an involuntary termination, as such term is defined in the relevant stock option agreement, of a grantee</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s employment during the period that commences 30 days prior to the effective date of a corporate transaction and that ends 12 months following the effective date of such transaction. Additionally, the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s board of directors may, in its sole discretion, accelerate the vesting of any unvested stock options in the event of a corporate transaction.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the stock options on the date of grant using the following assumptions in the Black-Scholes option-pricing model:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility (weighted average and range, if applicable)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3% (89.2% to 89.4%)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3% (89.0% to 100.0%)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4% (91.0% to 92.1%)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (weighted average and range, if applicable)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.58% (3.46% to 3.65%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.96% (1.89% to 3.65%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.68% (0.62% to 1.02%)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.00</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company did not grant any stock options during the three months ended September 30, 2021.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fair Value of Common Stock.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, as the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock was not publicly traded, the fair value of the shares of its common stock underlying the options was determined by the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s board of directors with input from management, after considering independent third-party valuation reports. Subsequent to the Merger, the fair value of the Common Stock has been determined based on the closing price of the shares on the Nasdaq market.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility was determined based on a blended approach using the historical share volatility of the Company’s Common Stock and that of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company has a limited trading history. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Dividend Yield.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid dividends on its Common Stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, there were 7,312,585 options remaining available for grant under the 2021 Plan. The Company has sufficient authorized and unissued shares to issue Common Stock in satisfaction of any awards available for grant under the 2021 Plan.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show a summary of stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021, and remaining unrecognized cost as of September 30, 2022 and December 31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,514 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,335 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized stock-based compensation cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted average period compensation costs to be recognized (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s stock option plans during the nine months ended September 30, 2022 is presented below:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average <br/>Remaining <br/>Contractual Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate <br/>Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, September 30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408,060 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7312585 1030033 0.05 0.01 0.85 0.85 2 5233533 504254 P10Y P36M P48M The Company recognizes stock-based compensation expense based on the grant date fair value of the awards measured using the Black-Scholes option pricing model. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying Common Stock on the date of grant. Forfeitures are accounted for as they occur. Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fair Value of Common Stock.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, as the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock was not publicly traded, the fair value of the shares of its common stock underlying the options was determined by the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s board of directors with input from management, after considering independent third-party valuation reports. Subsequent to the Merger, the fair value of the Common Stock has been determined based on the closing price of the shares on the Nasdaq market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility was determined based on a blended approach using the historical share volatility of the Company’s Common Stock and that of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company has a limited trading history. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Dividend Yield.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid dividends on its Common Stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero.</span></div> P30D P12M <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the stock options on the date of grant using the following assumptions in the Black-Scholes option-pricing model:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility (weighted average and range, if applicable)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3% (89.2% to 89.4%)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3% (89.0% to 100.0%)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4% (91.0% to 92.1%)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (weighted average and range, if applicable)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.58% (3.46% to 3.65%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.96% (1.89% to 3.65%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.68% (0.62% to 1.02%)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.00</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company did not grant any stock options during the three months ended September 30, 2021.</span></div> 0 0 0 0.893 0.892 0.894 0.933 0.890 1.000 0.914 0.910 0.921 0.0358 0.0346 0.0365 0.0296 0.0189 0.0365 0.0068 0.0062 0.0102 P6Y3M P6Y3M P6Y 0 7312585 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show a summary of stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021, and remaining unrecognized cost as of September 30, 2022 and December 31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,514 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,335 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized stock-based compensation cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted average period compensation costs to be recognized (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr></table></div> 216000 486000 682000 1837000 1260000 1391000 3832000 5498000 1476000 1877000 4514000 7335000 10234000 13346000 P2Y P2Y3M18D <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s stock option plans during the nine months ended September 30, 2022 is presented below:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average <br/>Remaining <br/>Contractual Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate <br/>Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, September 30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408,060 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722,422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6711192 7.48 P5Y3M18D 8276000 675077 5.00 95122 2.41 568725 8.69 6722422 7.20 P5Y2M12D 1438000 4408060 6.41 P3Y3M18D 1438000 6722422 7.20 P5Y2M12D 1438000 Income Taxes<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate and, if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. No such adjustment was made as of September 30, 2022. The Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s effective federal tax rate for the three and nine months ended September 30, 2022 and 2021 was 0%, primarily as a result of estimated tax losses for the fiscal year to date offset by the increase in the valuation allowance in the net operating loss carryforwards.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any income tax expense or benefit during the three and nine months ended September 30, 2022 and 2021. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s ability to realize these assets. All losses before income taxes arose in the United States.</span></div> 0 0 0 0 0 0 0 0 Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent License Agreements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duke University</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2006, the Company entered into a license agreement with Duke University (“Duke”), which was subsequently amended in 2011, 2014, 2015, 2018, 2019 and January 2022. Under this license agreement, Duke granted the Company a worldwide, exclusive, sublicensable license to certain patents related to decellularized tissue engineering, referred to as the patent rights, as well as a non-exclusive license to use and practice certain know-how related to the patent rights. The relevant licensed patent on decellularization of tissue expired in 2021. The Company has agreed to use commercially reasonable efforts to develop, register, market and sell products utilizing the patent rights, referred to as the licensed products. Any services provided to a third party utilizing licensed products are referred to as licensed services. The Company has also agreed to meet certain benchmarks in its development efforts, including as to development events, clinical trials, regulatory submissions and marketing approval, within specified timeframes. Under the license agreement, Duke retains the right to use the patent rights for its own educational and research purposes, and to provide the patent rights to other non-profit, governmental or higher-learning institutions for non-commercial purposes without paying royalties or other fees.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s entry into the license agreement, the Company granted equity consideration to Duke in the form of 52,693 shares of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock. Under the license agreement, the Company also agreed to pay Duke:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a low single-digit percentage royalty on eligible sales of licensed products and licensed services, plus a low double-digit percentage of any sublicensing revenue;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual minimum royalty beginning in 2012, which increases in the calendar year immediately following the first commercial sale of licensed products or licensed services (whichever occurs first); and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an additional amount in license fees, as certain milestones are met.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreement remains effective until the later of (i) the last of the patent rights expires or (ii) four years after the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s first commercial sale, unless terminated earlier. Either party may terminate the agreement for fraud, willful misconduct or illegal conduct, or uncured material breach. Duke may terminate the agreement if the Company becomes insolvent. Duke may also terminate the license, convert the license into a non-exclusive license or seek assignment of any sublicense if the Company fails to reach diligence milestones within the applicable time period. If the Company abandons any claim, patent or patent application, its rights under the license with respect to such patent rights will be terminated in the territory in which the Company abandons such rights. The Company may terminate the license agreement unilaterally upon three months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior notice to Duke. The Company agrees to indemnify Duke against certain third-party claims. Payments to Duke under the license agreement were immaterial during the periods presented.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Yale University</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, the Company entered into a license agreement with Yale University (“Yale”) that granted the Company a worldwide license to the patents related to coatings for small-diameter vessels to inhibit clotting. The license granted under the agreement is exclusive in the field of engineered vascular tissues and tissues and extracellular matrix-based implants used for vascular repair, reconstruction and replacement (provided that all uses are vascular tissues within the range of 1 </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12mm in diameter), except that it is subject to Yale</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into a license agreement with Yale, that granted the Company a worldwide license to the patents related to Bioartificial Vascular Pancreas (“BVP”). The license granted under the agreement is exclusive in the field of engineered vascular tissues that deliver pancreatic islet cells to patients, except that it is subject to Yale</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into a license agreement with Yale that granted the Company a worldwide license to the patents related to tubular prostheses. The license granted under the agreement is exclusive in the field of engineered urinary conduits, engineered tracheas/airways, and engineered esophagi, except that it is subject to Yale</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. The Company is also obligated to provide Yale periodically an updated and revised copy of its plan for each license, which must indicate progress of its development and commercialization. The Company may also sublicense the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s rights without Yale</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s prior written consent, but such sublicense is subject to certain conditions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its entry into the license agreement, the Company paid Yale upfront cash fees. The Company has also agreed to pay Yale:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual maintenance fees, increasing between the first anniversary of the agreement until the fifth anniversary for the coating and BVP licenses and until the fourth anniversary for the tubular prostheses license up to a maximum of less than $0.1 million per year;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">milestone payments upon achievement of certain regulatory and commercial milestones of $0.2 million and $0.6 million, respectively;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a low single-digit percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a low double-digit percentage of sublicensing income.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company or any of its future sublicensees bring a patent challenge against Yale or assists another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements expire on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Yale may terminate the agreements if the Company fails to (i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide written diligence reports, (ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide commercially reasonable diligence plans, (iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implement the plans in accordance with the obligations under the agreements, or (iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reach certain research and development milestones within the scheduled timeframe set forth in the agreements; however, any such termination right would be limited in scope to the country to which such failure relates. Yale may also terminate for the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s products or insolvency. The Company may terminate the license agreements (i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on 90 days</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior written notice to Yale, provided the Company is not in breach of the license agreements and has made all required payments to Yale thereunder and (ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on written notice to Yale following an uncured material breach. With respect to the license agreements related to small-diameter vessels and BVP, the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s rights under the license agreements will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, the Company does not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive licenses to non-exclusive licenses if the Company declines to initiate certain infringement or interference proceedings with respect to the licensed patents. The Company has agreed to indemnify Yale against certain third-party claims. Payments to Yale under the license agreement were immaterial during the periods presented.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business, financial condition, results of operations, or cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s or officer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s service. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is not specified in such arrangements; however, the Company has director and officer insurance coverage that is intended to reduce its exposure and enable the Company to recover a portion of any potential future amounts the Company could be required to make. To date, the Company has not incurred any costs as a result of such obligations and has not accrued any liabilities related to such obligations in the condensed consolidated financial statements.</span></div> 52693 P4Y P3M 100000 100000 100000 100000 200000 600000 P90D Related Party Transactions<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fresenius Medical Care investments and distribution agreement</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company completed a $150 million financing transaction pursuant to which Fresenius Medical Care purchased shares of series D redeemable convertible preferred stock that at the Closing of the Merger converted into 15,812,735 shares of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock. In August 2021, Fresenius Medical Care invested $25 million as part of the PIPE Financing and received an additional 2.5 million shares of the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company entered into a distribution agreement with Fresenius Medical Care in June 2018 which, as amended as of February 16, 2021, granted Fresenius Medical Care and its affiliates exclusive rights to develop outside the United States and European Union (the “EU”) and commercialize outside of the United States the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s 6 millimeter x 42 centimeter HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter or configuration of the foregoing), for use in vascular creation, repair, replacement or construction, including renal replacement therapy for dialysis access, the treatment of peripheral arterial disease, and the treatment of vascular trauma, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients. Within the United States, Fresenius Medical Care will collaborate with the Company in its commercialization of the product in the field, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic analyses.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for developing and seeking regulatory approval for the distribution product in the field in the United States. For countries outside the United States, the parties agreed to use commercially reasonable efforts to satisfy certain agreed minimum market entry criteria for the distribution product in the field in such country. For the EU, once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory approval for the distribution product in the field in the applicable country, the Company agreed to use commercially reasonable efforts to obtain such regulatory approval (other than pricing approval), and Fresenius Medical Care agreed to use commercially reasonable efforts to obtain the corresponding pricing approval. For the rest of the world (i.e., outside the United States and the EU), once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory and pricing approval for the distribution product in the field in the applicable country, Fresenius Medical Care agreed to use commercially reasonable efforts to obtain such approvals, and the Company agreed to use commercially reasonable efforts to support Fresenius Medical Care in its efforts.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the distribution agreement, the Company grants an exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to commercialize the distribution product in the field outside the United States, subject to the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s retained rights to carry out its obligations under the distribution agreement. The Company also grants a non-exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to develop the distribution product in accordance with the terms of the distribution agreement. In addition, the Company grants to Fresenius Medical Care, among other things, a perpetual, irrevocable, non-exclusive sublicensable license under the patents and know-how that primarily relate to the distribution product or its manufacture and that were created, conceived or developed solely or jointly by or on behalf of Fresenius Medical Care in the performance of its activities under the distribution agreement.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution agreement provides that the Company will own all know-how and patents that primarily relate to the distribution product or its manufacture that are created, conceived or developed by or on behalf of either party in the performance of activities under the distribution agreement. Ownership of all other know-how, patents, materials and other intellectual property created, conceived or developed during the performance of activities under the distribution agreement will be determined in accordance with U.S. patent laws for determining inventorship.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make payments to Fresenius Medical Care based on a share of aggregate net sales by or on behalf of the Company of the distribution product in the United States in the field. Such revenue-share payments will be a percentage of net sales in the low double digits, without regard to the calendar year in which such net sales are attributable, until such time that the Company has paid to Fresenius Medical Care a certain total amount, at which time the revenue-share will decrease to a percentage of net sales in the mid-single digits. The amounts that Fresenius Medical Care will be obligated to pay the Company under the distribution agreement for sales of the distribution product in the field outside of the United States will vary. Fresenius Medical Care agreed to pay the Company initially, on a country-by-country basis for sales outside of the United States, the amount equal to the average cost of manufacturing the Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s distribution product plus a fixed dollar amount per unit. Following a specified period, on a country-by-country basis outside of the United States, Fresenius Medical Care will pay the Company a fixed percentage of net sales for each unit sold in such country, such that the Company will receive more than half of such net sales.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution agreement will generally continue on a country-by-country basis until the later of (a) the tenth anniversary of the launch date of the distribution product in the relevant country or (b) the expiration of the last-to-expire valid claim of specified patents in such country. Each party is permitted to terminate the distribution agreement for insolvency of, or, under certain circumstances, including various cure periods, material breach by the other party. Subject to a cure period, Fresenius Medical Care may also terminate the distribution agreement in its entirety or on a country-by-country basis (i) for certain withdrawals of regulatory approval or (ii) for termination or expiration of any of our in-licenses that is necessary for the exercise of Fresenius Medical Care</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s rights, or the satisfaction of its obligations, under the distribution agreement. In addition, Fresenius Medical Care may terminate the distribution agreement for convenience on a country-by-country basis upon not less than 12 months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> written notice to the Company, although Fresenius Medical Care is not permitted to give such notice prior to the end of the second year following launch of the distribution product in such country. Each party is required to indemnify one another for certain third-party claims.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with Yale University</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s President and Chief Executive Officer, Laura Niklason M.D., PhD., serves as an Adjunct Professor in Anesthesia at Yale University. As of September 30, 2022 and December 31, 2021, the Company was a party to license agreements with Yale University as described in Note 11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Commitments and Contingencies, above. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">($ in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License expenses</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">85 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">168 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 150000000 15812735 25000000 2500000 P12M <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">($ in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License expenses</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">85 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">168 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 50000 85000 8000 2000 16000 83000 8000 2000 66000 168000 EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

^9.@O%R6VC[)HZ.=3D2,?)*U MV6AR71>\V.>?@'F]C71GXQ4]*O".-SZ) H_0@-(C\J+>Y\C*BUZ2MV&*GUU9 MGV_8,T#,D(52K%YS._YCL=1& 5[^/.2\DQT?EHTY=*X;EO/+$22)YFK+1_,W MK\(T>'O$\KBW/#XF?7X'.5FT)2=R118:$JG!O=+D*[IB)+G61@!2.?G A"+? M6-E:4KO)Y(LC/N33<:WW&VZQP>IGPCL-H YF5ZAFNU.#,]JJDIU=@".<+- D M(%A#C UIM:C7CEV64!3PBPV<$8[IJF2 3/!8 @P[B6>-$CG25[+@Y3FYWRC. M]^!& "R&5TNN+&(^@RO'UA%1^ C).#P=?%WW;A9B*PI>%^19\+(@ 3DA;UYE M-*1O[1C_UT\-U!B@U0@L@C9RLI4E)%(IS#,9/]K: 1LRQ64.L) GL6;1\2* ML*8I18[I=DJRF1^=D#&\Z GN* SBD]->Y2S:+0=V.0P"&)V260AD9 PO-S^C M?@C3MT(_G*TP1J(V'/!H0"WLQ:]8%/E)!J(C/TZMZ,A/DX%%U)_!_#CTL]EP M.?!3Y(*7\P,,HS#=APJLJ1 2.Z2,8=>?.5/ZE*0^37KQ]B/U@X#\]>+/[MT0 MI(4H2"U-AS>S47 MHU-KMQFW'%LJFOFU5CR7ZUK\8^FU.9C"Q[7?[V6;L:4=X HNL%T_1LOTH!OD M0\MX9YFH\[+%('5)FDL(6>W(:RU+4=BDT09>6$NUVV/ F(L\>H:"%=]@8]]R M4DJMP30UV TDJC%QCV\+M82X/YZ#;Q^Q=ABQ'"(&]<4&_K"(]SSO9D.WW_]# M81F_=B&2K085>EA;?HQNH4$PE6^L%07?PA&IL1WH-:%A"L\XPV>:47B&7A9- MR4=>0S!+R\$*.! (;%5XL@$"F@;PC&8AB8"8DL2+9QFYEP884$ \39V@Z12% M>TD8PWOJ15'RL\'[_NS%: ^1+V+&!A[4!1Z-4$\8>5&<_B@!/]4@@(F0!X1H M+"!+3@9*QUVMH'X _^A(?J9]?J:_E)]=NR0+/#9"%3^4FL@P^O"=F[S<_Z0U)N&H1?.$+=3/\Y(XD

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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 253 296 1 false 85 0 false 9 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.humacyte.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Description of Business Sheet http://www.humacyte.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 0000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.humacyte.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Reverse Recapitalization Sheet http://www.humacyte.com/role/ReverseRecapitalization Reverse Recapitalization Notes 9 false false R10.htm 0000010 - Disclosure - Fair Value Measurements Sheet http://www.humacyte.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 0000011 - Disclosure - Property and Equipment, Net Sheet http://www.humacyte.com/role/PropertyandEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 0000012 - Disclosure - Accrued Expenses Sheet http://www.humacyte.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 0000013 - Disclosure - Debt Sheet http://www.humacyte.com/role/Debt Debt Notes 13 false false R14.htm 0000014 - Disclosure - Stockholders' Equity (Deficit) Sheet http://www.humacyte.com/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 14 false false R15.htm 0000015 - Disclosure - Stock-based Compensation Sheet http://www.humacyte.com/role/StockbasedCompensation Stock-based Compensation Notes 15 false false R16.htm 0000016 - Disclosure - Income Taxes Sheet http://www.humacyte.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 0000017 - Disclosure - Commitments and Contingencies Sheet http://www.humacyte.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 0000018 - Disclosure - Related Party Transactions Sheet http://www.humacyte.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 0000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.humacyte.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 0000020 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.humacyte.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 0000021 - Disclosure - Reverse Recapitalization (Tables) Sheet http://www.humacyte.com/role/ReverseRecapitalizationTables Reverse Recapitalization (Tables) Tables http://www.humacyte.com/role/ReverseRecapitalization 21 false false R22.htm 0000022 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.humacyte.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.humacyte.com/role/FairValueMeasurements 22 false false R23.htm 0000023 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.humacyte.com/role/PropertyandEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.humacyte.com/role/PropertyandEquipmentNet 23 false false R24.htm 0000024 - Disclosure - Accrued Expenses (Tables) Sheet http://www.humacyte.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.humacyte.com/role/AccruedExpenses 24 false false R25.htm 0000025 - Disclosure - Debt (Tables) Sheet http://www.humacyte.com/role/DebtTables Debt (Tables) Tables http://www.humacyte.com/role/Debt 25 false false R26.htm 0000026 - Disclosure - Stockholders' Equity (Deficit) (Tables) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitTables Stockholders' Equity (Deficit) (Tables) Tables http://www.humacyte.com/role/StockholdersEquityDeficit 26 false false R27.htm 0000027 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.humacyte.com/role/StockbasedCompensationTables Stock-based Compensation (Tables) Tables http://www.humacyte.com/role/StockbasedCompensation 27 false false R28.htm 0000028 - Disclosure - Related Party Transactions (Tables) Sheet http://www.humacyte.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.humacyte.com/role/RelatedPartyTransactions 28 false false R29.htm 0000029 - Disclosure - Organization and Description of Business (Details) Sheet http://www.humacyte.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.humacyte.com/role/OrganizationandDescriptionofBusiness 29 false false R30.htm 0000030 - Disclosure - Summary of Significant Accounting Policies - Segments (Details) Sheet http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails Summary of Significant Accounting Policies - Segments (Details) Details 30 false false R31.htm 0000031 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) Sheet http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) Details 31 false false R32.htm 0000032 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation (Details) Sheet http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation (Details) Details 32 false false R33.htm 0000033 - Disclosure - Reverse Recapitalization - Narrative (Details) Sheet http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails Reverse Recapitalization - Narrative (Details) Details 33 false false R34.htm 0000034 - Disclosure - Reverse Recapitalization - Common Stock Outstanding Immediately Following the Consummation of the Merger (Details) Sheet http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails Reverse Recapitalization - Common Stock Outstanding Immediately Following the Consummation of the Merger (Details) Details 34 false false R35.htm 0000035 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 35 false false R36.htm 0000036 - Disclosure - Fair Value Measurements - Changes in Fair Value of Level 3 Financial Instruments (Details) Sheet http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails Fair Value Measurements - Changes in Fair Value of Level 3 Financial Instruments (Details) Details 36 false false R37.htm 0000037 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 37 false false R38.htm 0000038 - Disclosure - Property and Equipment, Net (Details) Sheet http://www.humacyte.com/role/PropertyandEquipmentNetDetails Property and Equipment, Net (Details) Details http://www.humacyte.com/role/PropertyandEquipmentNetTables 38 false false R39.htm 0000039 - Disclosure - Accrued Expenses (Details) Sheet http://www.humacyte.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.humacyte.com/role/AccruedExpensesTables 39 false false R40.htm 0000040 - Disclosure - Debt - Term Loan (Details) Sheet http://www.humacyte.com/role/DebtTermLoanDetails Debt - Term Loan (Details) Details 40 false false R41.htm 0000041 - Disclosure - Debt - SVB Loan Payable and Net Discount or Premium Balances (Details) Sheet http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails Debt - SVB Loan Payable and Net Discount or Premium Balances (Details) Details 41 false false R42.htm 0000042 - Disclosure - Debt - Future Minimum Payments of Principal (Details) Sheet http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails Debt - Future Minimum Payments of Principal (Details) Details 42 false false R43.htm 0000043 - Disclosure - Stockholders' Equity (Deficit) - Common Stock (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails Stockholders' Equity (Deficit) - Common Stock (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 43 false false R44.htm 0000044 - Disclosure - Stockholders' Equity (Deficit) - Common stock for future issuances (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails Stockholders' Equity (Deficit) - Common stock for future issuances (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 44 false false R45.htm 0000045 - Disclosure - Stockholders' Equity (Deficit) - Preferred Stock (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitPreferredStockDetails Stockholders' Equity (Deficit) - Preferred Stock (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 45 false false R46.htm 0000046 - Disclosure - Stockholders' Equity (Deficit) - Warrants (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails Stockholders' Equity (Deficit) - Warrants (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 46 false false R47.htm 0000047 - Disclosure - Stockholders' Equity (Deficit) - Warrants Narrative (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails Stockholders' Equity (Deficit) - Warrants Narrative (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 47 false false R48.htm 0000048 - Disclosure - Stockholders' Equity (Deficit) - Public Warrants (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails Stockholders' Equity (Deficit) - Public Warrants (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 48 false false R49.htm 0000049 - Disclosure - Stockholders' Equity (Deficit) - Private Placement Warrants (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails Stockholders' Equity (Deficit) - Private Placement Warrants (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 49 false false R50.htm 0000050 - Disclosure - Stockholders' Equity (Deficit) - Contingent Earnout Liability (Details) Sheet http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails Stockholders' Equity (Deficit) - Contingent Earnout Liability (Details) Details http://www.humacyte.com/role/StockholdersEquityDeficitTables 50 false false R51.htm 0000051 - Disclosure - Stock-based Compensation - Narrative (Details) Sheet http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails Stock-based Compensation - Narrative (Details) Details 51 false false R52.htm 0000052 - Disclosure - Stock-based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) Sheet http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails Stock-based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) Details 52 false false R53.htm 0000053 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails Stock-based Compensation - Stock-Based Compensation Expense (Details) Details 53 false false R54.htm 0000054 - Disclosure - Stock-based Compensation - Remaining Unrecognized Costs (Details) Sheet http://www.humacyte.com/role/StockbasedCompensationRemainingUnrecognizedCostsDetails Stock-based Compensation - Remaining Unrecognized Costs (Details) Details 54 false false R55.htm 0000055 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) Sheet http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock Option Activity (Details) Details 55 false false R56.htm 0000056 - Disclosure - Income Taxes (Details) Sheet http://www.humacyte.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.humacyte.com/role/IncomeTaxes 56 false false R57.htm 0000057 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.humacyte.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.humacyte.com/role/CommitmentsandContingencies 57 false false R58.htm 0000058 - Disclosure - Related Party Transactions - Narrative (Details) Sheet http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions - Narrative (Details) Details 58 false false R59.htm 0000059 - Disclosure - Related Party Transactions - Related Party Expenses (Details) Sheet http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails Related Party Transactions - Related Party Expenses (Details) Details 59 false false All Reports Book All Reports huma-20220930.htm huma-20220930.xsd huma-20220930_cal.xml huma-20220930_def.xml huma-20220930_lab.xml huma-20220930_pre.xml huma-20220930x10qxex311.htm huma-20220930x10qxex312.htm huma-20220930x10qxex321.htm huma-20220930x10qxex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "huma-20220930.htm": { "axisCustom": 4, "axisStandard": 29, "contextCount": 253, "dts": { "calculationLink": { "local": [ "huma-20220930_cal.xml" ] }, "definitionLink": { "local": [ "huma-20220930_def.xml" ] }, "inline": { "local": [ "huma-20220930.htm" ] }, "labelLink": { "local": [ "huma-20220930_lab.xml" ] }, "presentationLink": { "local": [ "huma-20220930_pre.xml" ] }, "schema": { "local": [ "huma-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 518, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 54, "keyStandard": 242, "memberCustom": 41, "memberStandard": 36, "nsprefix": "huma", "nsuri": "http://www.humacyte.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.humacyte.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Fair Value Measurements", "role": "http://www.humacyte.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Property and Equipment, Net", "role": "http://www.humacyte.com/role/PropertyandEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "huma:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Accrued Expenses", "role": "http://www.humacyte.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "huma:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Debt", "role": "http://www.humacyte.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Stockholders' Equity (Deficit)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficit", "shortName": "Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Stock-based Compensation", "role": "http://www.humacyte.com/role/StockbasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Income Taxes", "role": "http://www.humacyte.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Commitments and Contingencies", "role": "http://www.humacyte.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Related Party Transactions", "role": "http://www.humacyte.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "huma:ScheduleOfCommonStockOutstandingImmediatelyFollowingConsummationOfMergerTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Reverse Recapitalization (Tables)", "role": "http://www.humacyte.com/role/ReverseRecapitalizationTables", "shortName": "Reverse Recapitalization (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "huma:ScheduleOfCommonStockOutstandingImmediatelyFollowingConsummationOfMergerTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.humacyte.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.humacyte.com/role/PropertyandEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.humacyte.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Debt (Tables)", "role": "http://www.humacyte.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "huma:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Stockholders' Equity (Deficit) (Tables)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitTables", "shortName": "Stockholders' Equity (Deficit) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "huma:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Stock-based Compensation (Tables)", "role": "http://www.humacyte.com/role/StockbasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.humacyte.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Organization and Description of Business (Details)", "role": "http://www.humacyte.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)", "role": "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails", "shortName": "Summary of Significant Accounting Policies - Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:CertificatesOfDepositAtCarryingValue", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CertificatesOfDepositAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)", "role": "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails", "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i2a86e6e61ff2429098acc93248daf5f8_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CertificatesOfDepositAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:ReverseRecapitalizationContingentConsiderationLiabilityShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation (Details)", "role": "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails", "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ibb9ed75b2ea946f492cf95d9f0520efb_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i486abbdd7e3c4625ae9faa11abb26aa9_I20210826", "decimals": "5", "first": true, "lang": "en-US", "name": "huma:RecapitalizationExchangeRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Reverse Recapitalization - Narrative (Details)", "role": "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "shortName": "Reverse Recapitalization - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i486abbdd7e3c4625ae9faa11abb26aa9_I20210826", "decimals": "5", "first": true, "lang": "en-US", "name": "huma:RecapitalizationExchangeRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "huma:ScheduleOfCommonStockOutstandingImmediatelyFollowingConsummationOfMergerTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i486abbdd7e3c4625ae9faa11abb26aa9_I20210826", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Reverse Recapitalization - Common Stock Outstanding Immediately Following the Consummation of the Merger (Details)", "role": "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "shortName": "Reverse Recapitalization - Common Stock Outstanding Immediately Following the Consummation of the Merger (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "huma:ScheduleOfCommonStockOutstandingImmediatelyFollowingConsummationOfMergerTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i1cf5053604eb433bba87d89a146ffcd2_D20210826-20210826", "decimals": "INF", "lang": "en-US", "name": "huma:StockConvertedReverseRecapitalization", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i3a7e184a9dad496d985a120ccc393739_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i9fa16bf44aa04c3b855924f947fa0161_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Fair Value Measurements - Changes in Fair Value of Level 3 Financial Instruments (Details)", "role": "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails", "shortName": "Fair Value Measurements - Changes in Fair Value of Level 3 Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i9fa16bf44aa04c3b855924f947fa0161_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie0bf10b1e33c4335a79a7236d3c6351f_I20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unitRef": "y", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i26d1b72b7fd343b2a2d36e4830fcef69_I20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "y", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Property and Equipment, Net (Details)", "role": "http://www.humacyte.com/role/PropertyandEquipmentNetDetails", "shortName": "Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i2a86e6e61ff2429098acc93248daf5f8_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "huma:AccruedExternalResearchDevelopmentAndManufacturingCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Accrued Expenses (Details)", "role": "http://www.humacyte.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "huma:AccruedExternalResearchDevelopmentAndManufacturingCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "huma:WarrantsAndRightsOutstandingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i486abbdd7e3c4625ae9faa11abb26aa9_I20210826", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Debt - Term Loan (Details)", "role": "http://www.humacyte.com/role/DebtTermLoanDetails", "shortName": "Debt - Term Loan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i90cc476504f64b2d8fa5277e9b9d41df_D20211013-20211013", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Debt - SVB Loan Payable and Net Discount or Premium Balances (Details)", "role": "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails", "shortName": "Debt - SVB Loan Payable and Net Discount or Premium Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i4a1b6bbf8add4ae682286bcacbdfb478_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Debt - Future Minimum Payments of Principal (Details)", "role": "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails", "shortName": "Debt - Future Minimum Payments of Principal (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "huma:ScheduleOfCommonStockOutstandingImmediatelyFollowingConsummationOfMergerTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i1cf5053604eb433bba87d89a146ffcd2_D20210826-20210826", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:StockIssuedDuringPeriodSharesReverseRecapitalization", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Stockholders' Equity (Deficit) - Common Stock (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails", "shortName": "Stockholders' Equity (Deficit) - Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DividendsCommonStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "huma:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Stockholders' Equity (Deficit) - Common stock for future issuances (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails", "shortName": "Stockholders' Equity (Deficit) - Common stock for future issuances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "huma:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Stockholders' Equity (Deficit) - Preferred Stock (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitPreferredStockDetails", "shortName": "Stockholders' Equity (Deficit) - Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:ClassOfWarrantOrRightOutstanding", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Stockholders' Equity (Deficit) - Warrants (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails", "shortName": "Stockholders' Equity (Deficit) - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ClassOfWarrantOrRightOutstanding", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:NumberOfWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Stockholders' Equity (Deficit) - Warrants Narrative (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails", "shortName": "Stockholders' Equity (Deficit) - Warrants Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:NumberOfWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "huma:WarrantsAndRightsOutstandingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i486abbdd7e3c4625ae9faa11abb26aa9_I20210826", "decimals": "2", "first": true, "lang": "en-US", "name": "huma:ClassOfWarrantOrRightRedemptionThreshold", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Stockholders' Equity (Deficit) - Public Warrants (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails", "shortName": "Stockholders' Equity (Deficit) - Public Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "huma:WarrantsAndRightsOutstandingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i486abbdd7e3c4625ae9faa11abb26aa9_I20210826", "decimals": "2", "first": true, "lang": "en-US", "name": "huma:ClassOfWarrantOrRightRedemptionThreshold", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Stockholders' Equity (Deficit) - Private Placement Warrants (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails", "shortName": "Stockholders' Equity (Deficit) - Private Placement Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iec0ade5294ec4ee1be339dfd94a16d28_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i08064a3bee68409e8796d771c21ce63f_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i06afe5f0962e4451b6636d75eaa4f755_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:ReverseRecapitalizationContingentConsiderationLiabilityShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Stockholders' Equity (Deficit) - Contingent Earnout Liability (Details)", "role": "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "shortName": "Stockholders' Equity (Deficit) - Contingent Earnout Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i52dc4cd560914913aba23de200cebf5e_I20211231", "decimals": "2", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "icd54e0adb5f641c08177e69184cba77e_D20210825-20210825", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Stock-based Compensation - Narrative (Details)", "role": "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails", "shortName": "Stock-based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "icd54e0adb5f641c08177e69184cba77e_D20210825-20210825", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i34cc746170d04b338b07d23a7241d113_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Stock-based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)", "role": "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails", "shortName": "Stock-based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i34cc746170d04b338b07d23a7241d113_D20220701-20220930", "decimals": "3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)", "role": "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Stock-based Compensation - Remaining Unrecognized Costs (Details)", "role": "http://www.humacyte.com/role/StockbasedCompensationRemainingUnrecognizedCostsDetails", "shortName": "Stock-based Compensation - Remaining Unrecognized Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i2a86e6e61ff2429098acc93248daf5f8_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)", "role": "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails", "shortName": "Stock-based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Income Taxes (Details)", "role": "http://www.humacyte.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i7f2287cc4d1a4a50947e52d043d2290d_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:CollaborativeArrangementSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.humacyte.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "i7f2287cc4d1a4a50947e52d043d2290d_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "huma:CollaborativeArrangementSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "ie988ee28556847dcb0b1cf0c99784a1f_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Related Party Transactions - Narrative (Details)", "role": "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails", "shortName": "Related Party Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id933297d1a8a4da9a2f580fc0cb83b7b_D20180601-20180630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Related Party Transactions - Related Party Expenses (Details)", "role": "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails", "shortName": "Related Party Transactions - Related Party Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "iba16e5b3c919458fa052a7a6f1fff768_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Organization and Description of Business", "role": "http://www.humacyte.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.humacyte.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Reverse Recapitalization", "role": "http://www.humacyte.com/role/ReverseRecapitalization", "shortName": "Reverse Recapitalization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "huma-20220930.htm", "contextRef": "id582258d91a74202a306bc3bfb3ef6b5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 85, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "huma_AHACFoundersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AHAC Founders", "label": "AHAC Founders [Member]", "terseLabel": "AHAC Founders" } } }, "localname": "AHACFoundersMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_AHACMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AHAC", "label": "AHAC [Member]", "terseLabel": "AHAC" } } }, "localname": "AHACMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "domainItemType" }, "huma_AccruedExternalResearchDevelopmentAndManufacturingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/AccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research, development, and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued External Research Development And Manufacturing Costs, Current", "terseLabel": "Accrued external research, development and manufacturing costs" } } }, "localname": "AccruedExternalResearchDevelopmentAndManufacturingCostsCurrent", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "huma_AccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for Accrued Liabilities Disclosure of financial statements disclosure.", "label": "Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "huma_AdjustmentsToAdditionalPaidInCapitalContingentConsiderationLiabilityRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital Contingent Consideration Liability Recognized", "label": "Adjustments To Additional Paid In Capital Contingent Consideration Liability Recognized", "negatedTerseLabel": "Contingent Earnout Liability recognized upon closing of the reverse recapitalization" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalContingentConsiderationLiabilityRecognized", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "huma_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConjunctionWithDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants in conjunction with allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued In Conjunction With Debt", "terseLabel": "Issuance of warrants in conjunction with debt" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConjunctionWithDebt", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "huma_AssumptionOfPubliclyTradedSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumption Of Publicly Traded Securities", "label": "Assumption Of Publicly Traded Securities [Member]", "terseLabel": "Assumption Of Publicly Traded Securities" } } }, "localname": "AssumptionOfPubliclyTradedSecuritiesMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_BVPPatentRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BVP Patent Rights", "label": "BVP Patent Rights [Member]", "terseLabel": "BVP Patent Rights" } } }, "localname": "BVPPatentRightsMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_CapitalSharesReservedForFutureIssuanceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The table relating to information on capital stock reserved for future issuance.", "label": "Capital Shares Reserved for Future Issuance [Axis]", "terseLabel": "Capital Shares Reserved for Future Issuance [Axis]" } } }, "localname": "CapitalSharesReservedForFutureIssuanceAxis", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "stringItemType" }, "huma_CapitalSharesReservedForFutureIssuanceDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information on capital stock reserved for future issuance.", "label": "Capital Shares Reserved for Future Issuance [Domain]", "terseLabel": "Capital Shares Reserved for Future Issuance [Domain]" } } }, "localname": "CapitalSharesReservedForFutureIssuanceDomain", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "domainItemType" }, "huma_ClassOfWarrantOrRightExercisableUponFundingOfAdditionalTranche": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants that becomes exercisable upon borrowing an additional loan tranche in a loan agreement.", "label": "Class of Warrant or Right, Exercisable Upon Funding of Additional Tranche", "terseLabel": "Exercisable warrants upon funding of additional tranche (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisableUponFundingOfAdditionalTranche", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "sharesItemType" }, "huma_ClassOfWarrantOrRightRedemptionThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of outstanding shares that accept a tender or exchange offer made that triggers entitles holders to receive cash for all warrants.", "label": "Class of Warrant or Right, Redemption Threshold", "terseLabel": "Share accepting a tender offer entitles warrants to receive cash (as a percent)" } } }, "localname": "ClassOfWarrantOrRightRedemptionThreshold", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails" ], "xbrltype": "percentItemType" }, "huma_ClassOfWarrantOrRightWarrantsExercisableImmediately": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants immediately exercisable.", "label": "Class of Warrant or Right, Warrants Exercisable Immediately", "terseLabel": "Warrants immediately exercisable (in shares)" } } }, "localname": "ClassOfWarrantOrRightWarrantsExercisableImmediately", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "sharesItemType" }, "huma_CollaborativeArrangementExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the agreement expiration term after first commercial sale.", "label": "Collaborative Arrangement, Expiration Period", "terseLabel": "Expiration period of agreement" } } }, "localname": "CollaborativeArrangementExpirationPeriod", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "huma_CollaborativeArrangementMaximumAnnualMaintenanceFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of maximum annual maintenance fee.", "label": "Collaborative Arrangement, Maximum Annual Maintenance Fee", "terseLabel": "Maximum annual maintenance fee, less than" } } }, "localname": "CollaborativeArrangementMaximumAnnualMaintenanceFee", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "huma_CollaborativeArrangementMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payments upon achievement of certain regulatory milestones.", "label": "Collaborative Arrangement, Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "CollaborativeArrangementMilestonePayments", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "huma_CollaborativeArrangementMilestonePaymentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestone Payments", "label": "Collaborative Arrangement, Milestone Payments [Axis]", "terseLabel": "Collaborative Arrangement, Milestone Payments [Axis]" } } }, "localname": "CollaborativeArrangementMilestonePaymentsAxis", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "huma_CollaborativeArrangementMilestonePaymentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestone Payments [Domain]", "label": "Collaborative Arrangement, Milestone Payments [Domain]", "terseLabel": "Collaborative Arrangement, Milestone Payments [Domain]" } } }, "localname": "CollaborativeArrangementMilestonePaymentsDomain", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_CollaborativeArrangementSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares issued in connection with License agreement.", "label": "Collaborative Arrangement, Shares Issued", "terseLabel": "Shares issued under agreement (in shares)" } } }, "localname": "CollaborativeArrangementSharesIssued", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "huma_CollaborativeArrangementTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold notice period required to terminate the agreement.", "label": "Collaborative Arrangement, Termination Period", "terseLabel": "Termination period" } } }, "localname": "CollaborativeArrangementTerminationPeriod", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "huma_CommercialMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Milestone", "label": "Commercial Milestone [Member]", "terseLabel": "Commercial Milestone" } } }, "localname": "CommercialMilestoneMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_CommonShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Shareholders", "label": "Common Shareholders [Member]", "terseLabel": "Common Shareholders" } } }, "localname": "CommonShareholdersMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails" ], "xbrltype": "domainItemType" }, "huma_CommonStockNumberOfVotesPerUnitOfSharesHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of vote per common share held.", "label": "Common Stock, Number of Votes Per Unit Of Shares Held", "terseLabel": "Number of vote per common share held" } } }, "localname": "CommonStockNumberOfVotesPerUnitOfSharesHeld", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "integerItemType" }, "huma_CommonStockReservedForContingentConsiderationSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock reserved for Contingent Consideration Shares.", "label": "Common stock reserved for Contingent Consideration Shares [Member]", "terseLabel": "Common stock reserved for Contingent Earnout Shares" } } }, "localname": "CommonStockReservedForContingentConsiderationSharesMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "domainItemType" }, "huma_ContingentConsiderationTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contingent consideration tranche one.", "label": "Contingent Consideration Tranche One [Member]", "terseLabel": "Tranche one" } } }, "localname": "ContingentConsiderationTrancheOneMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "domainItemType" }, "huma_ContingentConsiderationTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contingent consideration tranche two.", "label": "Contingent Consideration Tranche Two [Member]", "terseLabel": "Tranche two" } } }, "localname": "ContingentConsiderationTrancheTwoMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "domainItemType" }, "huma_ContingentConsiderationTranchesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the contingent consideration tranches number.", "label": "Contingent Consideration Tranches [Axis]", "terseLabel": "Contingent Consideration Tranches [Axis]" } } }, "localname": "ContingentConsiderationTranchesAxis", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "stringItemType" }, "huma_ContingentConsiderationTranchesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration tranches number.", "label": "Contingent Consideration Tranches [Domain]", "terseLabel": "Contingent Consideration Tranches [Domain]" } } }, "localname": "ContingentConsiderationTranchesDomain", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "domainItemType" }, "huma_ContingentEarnoutLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contingent earnout liability.", "label": "Contingent Earnout Liability [Member]", "terseLabel": "Contingent Earnout Liability", "verboseLabel": "Contingent Earnout Liability" } } }, "localname": "ContingentEarnoutLiabilityMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails", "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_DebtInstrumentAdvanceNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Debt Instrument, Advance Notice Period", "terseLabel": "Advance notice period" } } }, "localname": "DebtInstrumentAdvanceNoticePeriod", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "durationItemType" }, "huma_DebtInstrumentFinalPaymentAmount": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Final payment amount, before unamortized (discount) premium and debt issuance costs, of long-term debt.", "label": "Debt Instrument, Final Payment Amount", "terseLabel": "Final payment amount of SVB loan payable" } } }, "localname": "DebtInstrumentFinalPaymentAmount", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails", "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "huma_DebtInstrumentFinalPaymentFeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of final payment fee.", "label": "Debt Instrument, Final Payment Fee, Percent", "terseLabel": "Final payment fee percentage" } } }, "localname": "DebtInstrumentFinalPaymentFeePercent", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "percentItemType" }, "huma_DebtInstrumentInterestRateMinimumFixedRateOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Rate, Minimum Fixed Rate On Variable Rate", "label": "Debt Instrument, Interest Rate, Minimum Fixed Rate On Variable Rate", "terseLabel": "Minimum fixed rate on variable rate" } } }, "localname": "DebtInstrumentInterestRateMinimumFixedRateOnVariableRate", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "percentItemType" }, "huma_DebtInstrumentNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of tranches of loan release in a loan agreement.", "label": "Debt Instrument, Number of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "DebtInstrumentNumberOfTranches", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "integerItemType" }, "huma_DebtInstrumentPercentOfCollateralAmountInOutstandingPrincipalAndInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of amount to be collateralized in outstanding principal and interest.", "label": "Debt Instrument, Percent of Collateral Amount in Outstanding Principal and Interest", "terseLabel": "Outstanding principal and interest collateralized" } } }, "localname": "DebtInstrumentPercentOfCollateralAmountInOutstandingPrincipalAndInterest", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "percentItemType" }, "huma_DebtInstrumentPrepaymentFeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Percent", "label": "Debt Instrument, Prepayment Fee, Percent", "terseLabel": "Prepayment fee" } } }, "localname": "DebtInstrumentPrepaymentFeePercent", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "percentItemType" }, "huma_DebtInstrumentPrepaymentFeePeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Period", "label": "Debt Instrument, Prepayment Fee, Period [Axis]", "terseLabel": "Debt Instrument, Prepayment Fee, Period [Axis]" } } }, "localname": "DebtInstrumentPrepaymentFeePeriodAxis", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "stringItemType" }, "huma_DebtInstrumentPrepaymentFeePeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Period [Domain]", "label": "Debt Instrument, Prepayment Fee, Period [Domain]", "terseLabel": "Debt Instrument, Prepayment Fee, Period [Domain]" } } }, "localname": "DebtInstrumentPrepaymentFeePeriodDomain", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "huma_DebtInstrumentPrepaymentFeePeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Period One", "label": "Debt Instrument, Prepayment Fee, Period One [Member]", "terseLabel": "Debt Instrument, Prepayment Fee, Period One" } } }, "localname": "DebtInstrumentPrepaymentFeePeriodOneMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "huma_DebtInstrumentPrepaymentFeePeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Period Three", "label": "Debt Instrument, Prepayment Fee, Period Three [Member]", "terseLabel": "Debt Instrument, Prepayment Fee, Period Three" } } }, "localname": "DebtInstrumentPrepaymentFeePeriodThreeMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "huma_DebtInstrumentPrepaymentFeePeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Period Two", "label": "Debt Instrument, Prepayment Fee, Period Two [Member]", "terseLabel": "Debt Instrument, Prepayment Fee, Period Two" } } }, "localname": "DebtInstrumentPrepaymentFeePeriodTwoMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "huma_DebtInstrumentUnusedBorrowingCapacityAmountPerTranche": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Unused Borrowing Capacity, Amount per Tranche", "label": "Debt Instrument, Unused Borrowing Capacity, Amount per Tranche", "terseLabel": "Amount that will be eligible to disburse per tranche" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmountPerTranche", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "huma_DecellularizedTissueEngineeringPatentRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decellularized Tissue Engineering Patent Rights", "label": "Decellularized Tissue Engineering Patent Rights [Member]", "terseLabel": "Decellularized Tissue Engineering Patent Rights" } } }, "localname": "DecellularizedTissueEngineeringPatentRightsMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_DistributionAgreementTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution Agreement, Termination Period", "label": "Distribution Agreement, Termination Period", "terseLabel": "Distribution agreement, termination period" } } }, "localname": "DistributionAgreementTerminationPeriod", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "huma_DukeUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the pertaining information of duke university.", "label": "Duke University [Member]", "terseLabel": "Duke University" } } }, "localname": "DukeUniversityMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_EarnoutSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnout Shares", "label": "Earnout Shares [Member]", "terseLabel": "Earnout Shares" } } }, "localname": "EarnoutSharesMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "domainItemType" }, "huma_FairValuePerShareOnClosingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value per share on closing date.", "label": "Fair Value per Share on Closing Date", "terseLabel": "Fair Value per share on Closing Date (in dollars per share)" } } }, "localname": "FairValuePerShareOnClosingDate", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails" ], "xbrltype": "perShareItemType" }, "huma_FreseniusMedicalCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Fresenius Medical Care.", "label": "Fresenius Medical Care [Member]", "terseLabel": "Fresenius Medical Care" } } }, "localname": "FreseniusMedicalCareMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_HumacyteIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Humacyte, Inc.", "label": "Humacyte, Inc. [Member]", "terseLabel": "Humacyte, Inc." } } }, "localname": "HumacyteIncMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails" ], "xbrltype": "domainItemType" }, "huma_IssuanceOfOptionsUnderStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information on issuance of options under stock plan.", "label": "Issuance of options under stock plan [Member]", "terseLabel": "Issuance of options under stock plans" } } }, "localname": "IssuanceOfOptionsUnderStockPlanMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "domainItemType" }, "huma_IssuanceOfStockWarrantsInConjunctionWithDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the issuance of stock warrants in conjunction with debt noncash investing or financing activities.", "label": "Issuance of Stock Warrants in Conjunction with Debt", "terseLabel": "Issuance of warrants in conjunction with debt" } } }, "localname": "IssuanceOfStockWarrantsInConjunctionWithDebt", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "huma_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the pertaining information to license agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_LicenseExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to License expenses.", "label": "License Expenses [Member]", "terseLabel": "License expenses" } } }, "localname": "LicenseExpensesMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "huma_LongTermIncentivePlan2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2021 Long-Term Incentive Plan.", "label": "Long-Term Incentive Plan, 2021 [Member]", "terseLabel": "Long-Term Incentive Plan, 2021" } } }, "localname": "LongTermIncentivePlan2021Member", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_MergerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger Agreement", "label": "Merger Agreement [Member]", "terseLabel": "Merger Agreement" } } }, "localname": "MergerAgreementMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_NumberOfDaysWarrantsBecomeExercisableAfterCompletionOfMerger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of days warrants become exercisable after the completion of merger.", "label": "Number of Days Warrants Become Exercisable After the Completion of Merger", "terseLabel": "Number of days warrants become exercisable after the completion of merger" } } }, "localname": "NumberOfDaysWarrantsBecomeExercisableAfterCompletionOfMerger", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails" ], "xbrltype": "durationItemType" }, "huma_NumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "Number of Warrants Exercised", "terseLabel": "Warrants exercised (in shares)" } } }, "localname": "NumberOfWarrantsExercised", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "huma_OmnibusIncentivePlan2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents 2015 Omnibus Incentive Plan.", "label": "Omnibus Incentive Plan, 2015 [Member]", "terseLabel": "Omnibus Incentive Plan, 2015" } } }, "localname": "OmnibusIncentivePlan2015Member", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_OtherRelatedPartyExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other research and development expenses.", "label": "Other Related Party Expenses [Member]", "terseLabel": "Other" } } }, "localname": "OtherRelatedPartyExpensesMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "huma_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Paycheck Protection Program.", "label": "Paycheck Protection Program [Member]", "terseLabel": "Paycheck Protection Program" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "huma_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to private placement warrants.", "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_ProceedsFromReverseRecapitalizationNetOfOfferingCostsPaid": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from a reverse recapitalization, net of offering costs paid.", "label": "Proceeds From Reverse Recapitalization, Net Of Offering Costs Paid", "terseLabel": "Proceeds from Merger and PIPE financing, net of offering costs paid" } } }, "localname": "ProceedsFromReverseRecapitalizationNetOfOfferingCostsPaid", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "huma_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Public Warrants.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_RecapitalizationExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The conversion ratio of the acquiree's common stock to the combined entity's common stock.", "label": "Recapitalization Exchange Ratio", "terseLabel": "Legacy Humacyte common stock conversion ratio to common stock" } } }, "localname": "RecapitalizationExchangeRatio", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "pureItemType" }, "huma_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to redeemable warrants exercisable for common stock.", "label": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 [Member]", "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50" } } }, "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150Member", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "huma_RegulatoryMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory Milestone", "label": "Regulatory Milestone [Member]", "terseLabel": "Regulatory Milestone" } } }, "localname": "RegulatoryMilestoneMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_RevenueFromGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Grants", "label": "Revenue From Grants [Member]", "terseLabel": "Grant Revenue" } } }, "localname": "RevenueFromGrantsMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "huma_ReverseRecapitalizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reverse Recapitalization", "label": "Reverse Recapitalization [Abstract]" } } }, "localname": "ReverseRecapitalizationAbstract", "nsuri": "http://www.humacyte.com/20220930", "xbrltype": "stringItemType" }, "huma_ReverseRecapitalizationContingentConsiderationLiabilityNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of tranches of shares of combined entity that equity holders of acquiring entity are entitled to upon occurrence of triggering events.", "label": "Reverse Recapitalization, Contingent Consideration, Liability, Number of Tranches", "terseLabel": "Number of tranches of contingent earnout shares" } } }, "localname": "ReverseRecapitalizationContingentConsiderationLiabilityNumberOfTranches", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "integerItemType" }, "huma_ReverseRecapitalizationContingentConsiderationLiabilityPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reverse Recapitalization, Contingent Consideration, Liability, Per Share", "label": "Reverse Recapitalization, Contingent Consideration, Liability, Per Share", "terseLabel": "Closing stock price to trigger contingent earnout shares (in dollars per share)" } } }, "localname": "ReverseRecapitalizationContingentConsiderationLiabilityPerShare", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "perShareItemType" }, "huma_ReverseRecapitalizationContingentConsiderationLiabilityRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration liability recognized upon the closing of the reverse recapitalization.", "label": "Reverse Recapitalization, Contingent Consideration, Liability Recognized", "terseLabel": "Contingent Consideration Liability recognized upon the closing of the reverse recapitalization" } } }, "localname": "ReverseRecapitalizationContingentConsiderationLiabilityRecognized", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "huma_ReverseRecapitalizationContingentConsiderationLiabilityShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum aggregate number of shares of combined entity that equity holders of acquiring entity are entitled to upon occurrence of triggering events.", "label": "Reverse Recapitalization, Contingent Consideration, Liability, Shares", "terseLabel": "Maximum contingent earnout (in shares)" } } }, "localname": "ReverseRecapitalizationContingentConsiderationLiabilityShares", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "sharesItemType" }, "huma_ReverseRecapitalizationContingentConsiderationLiabilitySharesPerTranche": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares of combined entity per tranche that equity holders of acquiring entity are entitled to upon occurrence of triggering events.", "label": "Reverse Recapitalization, Contingent Consideration, Liability, Shares Per Tranche", "terseLabel": "Number of contingent earnout shares per tranche (in shares)" } } }, "localname": "ReverseRecapitalizationContingentConsiderationLiabilitySharesPerTranche", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "sharesItemType" }, "huma_ReverseRecapitalizationContingentConsiderationLiabilityStockPriceTriggerNumberOfConsecutiveTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period over which the number of days that volume-weighted average closing sale price of stock that triggers the earnout shares of combined entity for former holders of acquiree stocks.", "label": "Reverse Recapitalization, Contingent Consideration, Liability, Stock Price Trigger, Number of Consecutive Trading Day Period", "terseLabel": "Number of consecutive trading days" } } }, "localname": "ReverseRecapitalizationContingentConsiderationLiabilityStockPriceTriggerNumberOfConsecutiveTradingDayPeriod", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "durationItemType" }, "huma_ReverseRecapitalizationContingentConsiderationLiabilityStockPriceTriggerNumberOfTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of days that volume-weighted average closing sale price of stock within 30 day period that triggers the earnout shares of combined entity for former holders of acquiree stocks", "label": "Reverse Recapitalization, Contingent Consideration, Liability, Stock Price Trigger, Number Of Trading Days", "terseLabel": "Number of trading days" } } }, "localname": "ReverseRecapitalizationContingentConsiderationLiabilityStockPriceTriggerNumberOfTradingDays", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "durationItemType" }, "huma_ReverseRecapitalizationFounderSharesConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio of the conversion of founder shares to common stock upon closing of business combination.", "label": "Reverse Recapitalization, Founder Shares Conversion, Ratio", "terseLabel": "Founder shares conversion ratio" } } }, "localname": "ReverseRecapitalizationFounderSharesConversionRatio", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "pureItemType" }, "huma_ReverseRecapitalizationTransactionCostsExpensed": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents costs incurred to effect a reverse recapitalization which have been expensed during the period, including banking, legal, and other professional fees.", "label": "Reverse Recapitalization, Transaction Costs Expensed", "negatedLabel": "Transaction costs expensed" } } }, "localname": "ReverseRecapitalizationTransactionCostsExpensed", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "huma_SVBLoanPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to SVB loan payable.", "label": "SVB Loan Payable [Member]", "terseLabel": "SVB Loan payable" } } }, "localname": "SVBLoanPayableMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "domainItemType" }, "huma_ScheduleOfCommonStockOutstandingImmediatelyFollowingConsummationOfMergerTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of common stock outstanding immediately following the consummation of the Merger.", "label": "Schedule of Common Stock Outstanding Immediately Following the Consummation of the Merger [Table Text Block]", "terseLabel": "Schedule of Common Stock Outstanding Immediately Following the Consummation of the Merger" } } }, "localname": "ScheduleOfCommonStockOutstandingImmediatelyFollowingConsummationOfMergerTableTextBlock", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationTables" ], "xbrltype": "textBlockItemType" }, "huma_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of common stock were reserved for future issuance.", "label": "Schedule of Common Stock Reserved For Future Issuance [Table Text Block]", "terseLabel": "Summary Of Common Stock Reserved For Future Issuances" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "huma_ScheduleOfReverseRecapitalizationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Reverse Recapitalization [Line Items]", "label": "Schedule of Reverse Recapitalization [Line Items]", "terseLabel": "Schedule of Reverse Recapitalization [Line Items]" } } }, "localname": "ScheduleOfReverseRecapitalizationLineItems", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails" ], "xbrltype": "stringItemType" }, "huma_ScheduleOfReverseRecapitalizationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Reverse Recapitalization [Table]", "label": "Schedule of Reverse Recapitalization [Table]", "terseLabel": "Schedule of Reverse Recapitalization [Table]" } } }, "localname": "ScheduleOfReverseRecapitalizationTable", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails" ], "xbrltype": "stringItemType" }, "huma_ScientificEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Scientific Equipment [Member]", "terseLabel": "Scientific equipment" } } }, "localname": "ScientificEquipmentMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "huma_ScientificEquipmentNotPlacedIntoServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scientific Equipment, Not Placed Into Service", "label": "Scientific Equipment, Not Placed Into Service [Member]", "terseLabel": "Scientific equipment, not placed into service" } } }, "localname": "ScientificEquipmentNotPlacedIntoServiceMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "huma_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingCommencementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the commencement of involuntary termination term prior to effective date of corporate transaction.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting Commencement Period", "terseLabel": "Accelerated vesting commencement period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingCommencementPeriod", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "huma_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingEndingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the end of involuntary termination term after effective date of corporate transaction.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting Ending Period", "terseLabel": "Accelerated vesting ending period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingEndingPeriod", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "huma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of plans in share-based compensation arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans", "terseLabel": "Number of equity incentive plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "huma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncreasePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The annual increase of shares reserve for the share-based compensation plans as percent of the lesser of the number of shares of the entity's common stock outstanding on calendar year end of the preceding year and a number of shares of common stock determined by the Company's board of directors.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Annual Increase, Percent", "terseLabel": "Annual increase in available shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncreasePercent", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "huma_SharesAvailableForGrantUnderESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to shares available for grant under ESPP.", "label": "Shares available for grant under ESPP [Member]", "terseLabel": "Shares available for grant under ESPP" } } }, "localname": "SharesAvailableForGrantUnderESPPMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "domainItemType" }, "huma_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.,.", "label": "Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., [Member]", "terseLabel": "Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.," } } }, "localname": "SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "huma_SmallDiameterVesselsPatentRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Small-Diameter Vessels Patent Rights", "label": "Small-Diameter Vessels Patent Rights [Member]", "terseLabel": "Small-Diameter Vessels Patent Rights" } } }, "localname": "SmallDiameterVesselsPatentRightsMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_StockConvertedReverseRecapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Converted, Reverse Recapitalization", "label": "Stock Converted, Reverse Recapitalization", "terseLabel": "New Humacyte shares issued in Merger to Legacy Humacyte stockholders (in shares)" } } }, "localname": "StockConvertedReverseRecapitalization", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails" ], "xbrltype": "sharesItemType" }, "huma_StockIssuedDuringPeriodSharesConversionMergerAndRelatedPipeFinancing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of stock issued during the period for conversion of common stock in connection with the Merger and related PIPE financing.", "label": "Stock Issued During Period, Shares, Conversion, Merger and Related PIPE Financing", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionMergerAndRelatedPipeFinancing", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails" ], "xbrltype": "sharesItemType" }, "huma_StockIssuedDuringPeriodSharesReverseRecapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization", "label": "Stock Issued During Period, Shares, Reverse Recapitalization", "terseLabel": "Issuance of common stock upon reverse recapitalization and PIPE Financing (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "sharesItemType" }, "huma_StockIssuedDuringPeriodValueConversionMergerAndRelatedPipeFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Conversion Merger And Related Pipe Financing", "label": "Stock Issued During Period Value Conversion Merger And Related Pipe Financing", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing" } } }, "localname": "StockIssuedDuringPeriodValueConversionMergerAndRelatedPipeFinancing", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "huma_StockOptionPlan2005Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents 2005 Stock Option plan.", "label": "Stock Option Plan, 2005 [Member]", "terseLabel": "Stock Option Plan, 2005" } } }, "localname": "StockOptionPlan2005Member", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "huma_TemporaryEquityStockIssuedDuringPeriodSharesConversionMergerAndRelatedPipeFinancing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Stock Issued During Period Shares Conversion Merger And Related Pipe Financing", "label": "Temporary Equity Stock Issued During Period Shares Conversion Merger And Related Pipe Financing", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionMergerAndRelatedPipeFinancing", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "huma_TemporaryEquityStockIssuedDuringPeriodValueConversionMergerAndRelatedPipeFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity Stock Issued During Period Value Conversion Merger And Related Pipe Financing", "label": "Temporary Equity Stock Issued During Period Value Conversion Merger And Related Pipe Financing", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionMergerAndRelatedPipeFinancing", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "huma_TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to term loan agreement.", "label": "Term Loan Agreement [Member]", "terseLabel": "Term Loan Agreement" } } }, "localname": "TermLoanAgreementMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "huma_TransactionCostsForRaisingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs for raising capital.", "label": "Transaction Costs for Raising Capital", "terseLabel": "Transaction costs" } } }, "localname": "TransactionCostsForRaisingCapital", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "huma_TubularProsthesesPatentRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tubular Prostheses Patent Rights", "label": "Tubular Prostheses Patent Rights [Member]", "terseLabel": "Tubular Prostheses Patent Rights" } } }, "localname": "TubularProsthesesPatentRightsMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "huma_UnpaidLiabilitiesAssumedInConnectionWithMerger": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unpaid liabilities assumed in connection with Merger.", "label": "Unpaid Liabilities Assumed in Connection with Merger", "terseLabel": "Unpaid liabilities assumed in connection with Merger" } } }, "localname": "UnpaidLiabilitiesAssumedInConnectionWithMerger", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "huma_UnpaidTransactionCostsInConnectionWithMerger": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unpaid transaction costs in connection with Merger.", "label": "Unpaid Transaction Costs In Connection With Merger", "terseLabel": "Unpaid transaction costs in connection with Merger" } } }, "localname": "UnpaidTransactionCostsInConnectionWithMerger", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "huma_WarrantsAndRightsOutstandingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants And Rights Outstanding, Policy", "label": "Warrants And Rights Outstanding, Policy [Policy Text Block]", "terseLabel": "Common Stock Warrants" } } }, "localname": "WarrantsAndRightsOutstandingPolicyPolicyTextBlock", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "huma_WarrantsExercisedMinimumPercentOfOutstandingSharesToReceiveCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Exercised, Minimum Percent Of Outstanding Shares, To Receive Cash", "label": "Warrants Exercised, Minimum Percent Of Outstanding Shares, To Receive Cash", "terseLabel": "Warrants exercised, minimum percent of outstanding shares, to receive cash" } } }, "localname": "WarrantsExercisedMinimumPercentOfOutstandingSharesToReceiveCash", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails" ], "xbrltype": "percentItemType" }, "huma_YaleUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to yale university.", "label": "Yale University [Member]", "terseLabel": "Yale University" } } }, "localname": "YaleUniversityMember", "nsuri": "http://www.humacyte.com/20220930", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r36", "r85", "r86", "r191", "r233" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails", "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r169", "r170", "r171", "r172", "r190", "r232", "r269", "r271", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r472", "r474", "r492", "r493" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r169", "r170", "r171", "r172", "r190", "r232", "r269", "r271", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r472", "r474", "r492", "r493" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r150", "r170", "r171", "r256", "r257", "r429", "r471", "r473" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails", "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r150", "r170", "r171", "r256", "r257", "r429", "r471", "r473" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails", "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r164", "r169", "r170", "r171", "r172", "r190", "r232", "r258", "r269", "r271", "r305", "r306", "r307", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r472", "r474", "r492", "r493" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r164", "r169", "r170", "r171", "r172", "r190", "r232", "r258", "r269", "r271", "r305", "r306", "r307", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r472", "r474", "r492", "r493" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r35", "r36", "r85", "r86", "r191", "r233" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails", "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r417" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r153", "r154" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.humacyte.com/role/AccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/AccruedExpensesDetails", "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current", "terseLabel": "Deferred payroll tax" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.humacyte.com/role/AccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r8", "r160" ], "calculation": { "http://www.humacyte.com/role/PropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r417" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r89", "r90", "r91", "r317", "r318", "r319", "r364" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r273", "r322", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r246", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Transaction costs recorded in APIC" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r186", "r246", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Public warrants assumed upon the Merger, net of transaction costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r55", "r69", "r210", "r394" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of SVB debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r51", "r69", "r210", "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Securities that were not included in the computation of diluted net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Asset Acquisition [Line Items]", "terseLabel": "Asset Acquisition [Line Items]" } } }, "localname": "AssetAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTable": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset acquisition.", "label": "Asset Acquisition [Table]", "terseLabel": "Asset Acquisition [Table]" } } }, "localname": "AssetAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r82", "r136", "r144", "r148", "r156", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r356", "r358", "r385", "r415", "r417", "r442", "r460" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r22", "r82", "r156", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r356", "r358", "r385", "r415", "r417" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r367" ], "calculation": { "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r301", "r304", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails", "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r268", "r270", "r344" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r268", "r270", "r341", "r342", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Number of securities issued or issuable (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r68", "r352" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedLabel": "Change in fair value of Contingent Earnout Liability", "negatedTerseLabel": "Change in fair value of Contingent Earnout Liability", "terseLabel": "Change in fair value of Contingent Earnout Liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r346", "r347", "r350" ], "calculation": { "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent Earnout Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r346", "r348" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "verboseLabel": "Contingent Earnout Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r345", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Reverse Recapitalization" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalization" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Assets assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "terseLabel": "Liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Contingent Earnout Liability" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchase of property and equipment in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r6", "r71" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents, and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r64", "r71", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r64", "r386" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Certificates of Deposit, at Carrying Value", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Cash equivalents (certificates of deposit)" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r13", "r14", "r15", "r79", "r82", "r104", "r105", "r106", "r108", "r110", "r116", "r117", "r118", "r156", "r175", "r179", "r180", "r181", "r184", "r185", "r230", "r231", "r235", "r239", "r246", "r385", "r500" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r254", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants, exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r254", "r275" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r448", "r466" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r166", "r167", "r168", "r173", "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Reserved common stock for future issuances (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r89", "r90", "r364" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/CoverPage", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "verboseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "verboseLabel": "Common stock issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r417" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 250,000,000 shares authorized as of September\u00a030, 2022 and December\u00a031, 2021; 103,098,768 and 103,003,646 shares issued and outstanding as of September\u00a030, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r38", "r40", "r41", "r48", "r450", "r468" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r126", "r127", "r152", "r382", "r383", "r487" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r126", "r127", "r152", "r382", "r383", "r480", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r126", "r127", "r152", "r382", "r383", "r480", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r121", "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r126", "r127", "r152", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r124", "r126", "r127", "r128", "r382", "r384", "r487" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r126", "r127", "r152", "r382", "r383", "r487" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration by Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the reverse capitalization" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r73", "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversion of stock (in shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r78", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r204", "r211", "r212", "r214", "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r81", "r87", "r187", "r188", "r189", "r190", "r191", "r192", "r194", "r200", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r219", "r220", "r221", "r222", "r397", "r443", "r444", "r458" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails", "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r12", "r215", "r444", "r458" ], "calculation": { "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Principal amount of SVB loan payable", "totalLabel": "Total future payments" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails", "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r187", "r219", "r220", "r395", "r397", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Maximum loan facility amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r29", "r218", "r395", "r397" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r30", "r81", "r87", "r187", "r188", "r189", "r190", "r191", "r192", "r194", "r200", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r219", "r220", "r221", "r222", "r397" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails", "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r81", "r87", "r187", "r188", "r189", "r190", "r191", "r192", "r194", "r200", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r219", "r220", "r221", "r222", "r247", "r250", "r251", "r252", "r394", "r395", "r397", "r398", "r456" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r200", "r216", "r219", "r220", "r396" ], "calculation": { "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Net premium associated with accretion of final payment and other debt issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r69", "r158" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r276", "r277", "r311", "r312", "r314", "r324" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r253", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "terseLabel": "Dividends, common stock" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r49", "r94", "r95", "r96", "r97", "r98", "r102", "r104", "r108", "r109", "r110", "r113", "r114", "r365", "r366", "r451", "r469" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r49", "r94", "r95", "r96", "r97", "r98", "r104", "r108", "r109", "r110", "r113", "r114", "r365", "r366", "r451", "r469" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.humacyte.com/role/AccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected weighted average period compensation costs to be recognized (years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationRemainingUnrecognizedCostsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationRemainingUnrecognizedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Exercise of options under stock plan", "verboseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails", "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails", "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r42", "r43", "r44", "r89", "r90", "r91", "r93", "r99", "r101", "r115", "r157", "r246", "r253", "r317", "r318", "r319", "r331", "r332", "r364", "r387", "r388", "r389", "r390", "r391", "r392", "r406", "r475", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r69", "r226" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of common stock warrant liabilities", "terseLabel": "Change in fair value of common stock warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r367", "r368", "r378" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r367", "r368", "r369", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule Of Assumptions Used In The Valuations" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r202", "r219", "r220", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r368", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r376", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails", "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r367", "r368", "r371", "r372", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r202", "r259", "r260", "r265", "r267", "r368", "r418" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r202", "r219", "r220", "r259", "r260", "r265", "r267", "r368", "r419" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r202", "r219", "r220", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r368", "r420" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails", "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Changes in the fair value of the Level 3 financial instruments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r373", "r378" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r373", "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of Level 3 Financial Instruments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value included in other income (expense), net" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "negatedTerseLabel": "Contingent Earnout Liability recognized upon the closing of the reverse recapitalization" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "negatedTerseLabel": "Private placement warrant liability acquired as part of the Merger" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "negatedPeriodEndLabel": "Ending balance", "negatedPeriodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsChangesinFairValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r202", "r219", "r220", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r376", "r379" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r400" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease obligation, current portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r400" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease obligation, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r402", "r404" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payment of finance lease principal" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r399" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease right-of-use assets, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r401", "r403", "r405" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "verboseLabel": "Amortization expense" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r69", "r223", "r224" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain on PPP loan forgiveness", "terseLabel": "Gain on PPP loan forgiveness" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GovernmentContractsConcentrationRiskMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City.", "label": "Government Contracts Concentration Risk [Member]", "terseLabel": "Government Contracts Concentration Risk" } } }, "localname": "GovernmentContractsConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r162", "r165" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r83", "r328", "r329", "r330", "r333", "r335", "r337", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r100", "r101", "r135", "r326", "r334", "r336", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense or benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r68" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r68" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r68", "r404" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease obligation" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Redeemable convertible preferred Stock" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r45", "r134", "r393", "r396", "r452" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r56", "r209", "r221", "r222" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Accrued interest on PPP loan obligation" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r63", "r65", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest on SVB loan" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r53", "r133" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r367" ], "calculation": { "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Short-term investments (certificates of deposit)" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r82", "r145", "r156", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r357", "r358", "r359", "r385", "r415", "r416" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r82", "r156", "r385", "r417", "r445", "r464" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r28", "r82", "r156", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r357", "r358", "r359", "r385", "r415", "r416", "r417" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r24", "r81" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r24", "r81" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r24", "r81" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r12", "r201", "r217", "r219", "r220", "r444", "r462" ], "calculation": { "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "SVB loan payable, current and noncurrent" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Future minimum payments of principal and estimated payments of interest" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Less SVB loan payable, current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r87", "r174", "r206" ], "calculation": { "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r87", "r174", "r206" ], "calculation": { "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r87", "r174", "r206" ], "calculation": { "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r87" ], "calculation": { "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2022 (remainder)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtFutureMinimumPaymentsofPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "SVB loan payable, noncurrent portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtSVBLoanPayableandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Exercise price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Estimated dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected term (years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected share price volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Current stock price", "verboseLabel": "Market price of public stock" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Cash equivalents (money market funds)" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r67", "r70" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r37", "r39", "r44", "r47", "r70", "r82", "r92", "r94", "r95", "r96", "r97", "r100", "r101", "r107", "r136", "r143", "r146", "r147", "r149", "r156", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r366", "r385", "r449", "r467" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income (loss)", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of noncash activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesSegmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r136", "r143", "r146", "r147", "r149" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "negatedLabel": "Operating losses", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.humacyte.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r400" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease obligation, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r400" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease obligation, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r399" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash operating lease costs" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForMergerRelatedCosts": { "auth_ref": [ "r66" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.", "label": "Payments for Merger Related Costs", "negatedTerseLabel": "Payment of liabilities assumed in Merger" } } }, "localname": "PaymentsForMergerRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for financing costs associated with business combinations.", "label": "Payments of Merger Related Costs, Financing Activities", "negatedTerseLabel": "Payment of transaction costs related to Merger" } } }, "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r62" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payment of deferred offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r58" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r59" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedTerseLabel": "Purchase of short-term investments (certificates of deposit)" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r301", "r304", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r301", "r304", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r230" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.humacyte.com/role/StockholdersEquityDeficitPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "verboseLabel": "Preferred stock, shares designated (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.humacyte.com/role/StockholdersEquityDeficitPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r230" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.humacyte.com/role/StockholdersEquityDeficitPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r417" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 shares designated as of September\u00a030, 2022 and December\u00a031, 2021; 0 shares issued and outstanding as of September\u00a030, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromBankDebt": { "auth_ref": [ "r61" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from bank borrowing during the year.", "label": "Proceeds from Bank Debt", "terseLabel": "Proceeds from SVB loan" } } }, "localname": "ProceedsFromBankDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "verboseLabel": "Proceeds from debt instruments" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from PIPE Financing" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Amount of loan drawn" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Financing transaction" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r57", "r59" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "terseLabel": "Proceeds from maturity of short-term investments (certificates of deposit)" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r60", "r316" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r481", "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Transaction costs expensed (less than)" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r163", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r7", "r159" ], "calculation": { "http://www.humacyte.com/role/PropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r161", "r417", "r453", "r465" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.humacyte.com/role/PropertyandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets", "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule Of Property And Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r266", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r266", "r409", "r410", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r409" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "verboseLabel": "Related party expenses" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r266", "r409", "r412", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r407", "r408", "r410", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r325", "r428", "r494" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r253", "r417", "r463", "r478", "r479" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets", "http://www.humacyte.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r89", "r90", "r91", "r93", "r99", "r101", "r157", "r317", "r318", "r319", "r331", "r332", "r364", "r475", "r477" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r46" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "verboseLabel": "Grant revenue" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Aggregate purchase price" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r126", "r152" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of securities that could potentially dilute net loss per share in the future that were not included in the computation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitContingentEarnoutLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r341", "r342", "r344" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r30", "r87", "r219", "r221", "r247", "r250", "r251", "r252", "r394", "r395", "r398", "r456" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Summary of SVB Loan Payable and Net Discount or Premium Balances" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r309", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense and Remaining Unrecognized Costs" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Summary of Future Minimum Payments of Principal" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.humacyte.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Summary of Related Party Expenses" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r272", "r274", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r301", "r304", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails", "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r281", "r296", "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used to Estimate Fair Value of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r13", "r14", "r15", "r79", "r116", "r117", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r239", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r254", "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule Of Activity Of Warrants" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r10", "r443", "r461" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt, Current", "terseLabel": "SVB loan payable, current portion" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r30" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "SVB loan payable, net of current portion" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r137", "r138", "r139", "r140", "r141", "r142", "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Assumptions on the date of grant to estimate the fair value of the stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Estimated dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails", "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Weighted average expected share price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Weighted average expected share price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Weighted average expected share price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails", "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares remaining available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares, vested and exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, vested and exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, end of period (in shares)", "periodStartLabel": "Options outstanding, beginning of period (in shares)", "verboseLabel": "Outstanding awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails", "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, end of period (in dollars per share)", "periodStartLabel": "Options outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of shares, vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r301", "r304", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails", "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r280", "r302", "r303", "r304", "r305", "r308", "r320", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of options (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationAssumptionsUsedtoEstimateFairValueofStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, vested and exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, outstanding (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, vested and expected to vest (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock, percent of closing trading price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r21", "r446", "r447", "r459" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r483", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Short-term Investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r79", "r82", "r104", "r105", "r106", "r108", "r110", "r116", "r117", "r118", "r156", "r175", "r179", "r180", "r181", "r184", "r185", "r230", "r231", "r235", "r239", "r246", "r385", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CoverPage", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r42", "r43", "r44", "r89", "r90", "r91", "r93", "r99", "r101", "r115", "r157", "r246", "r253", "r317", "r318", "r319", "r331", "r332", "r364", "r387", "r388", "r389", "r390", "r391", "r392", "r406", "r475", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r89", "r90", "r91", "r115", "r429" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r14", "r15", "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Founder shares converted to common stock (in shares)", "verboseLabel": "Shares acquired (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r246", "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "New Humacyte shares issued to PIPE Investors (in shares)", "verboseLabel": "The Merger and related PIPE financing, net of transaction costs and acquired liabilities (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r246", "r253", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Proceeds from the exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit", "http://www.humacyte.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r246", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "The Merger and related PIPE financing, net of transaction costs and acquired liabilities" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r33", "r246", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r14", "r15", "r246", "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Less redemption of AHAC shares (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationCommonStockOutstandingImmediatelyFollowingtheConsummationoftheMergerDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r82", "r155", "r156", "r385", "r417" ], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets", "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r80", "r231", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r253", "r255", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r175", "r179", "r180", "r181", "r184", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofChangesinRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CommitmentsandContingenciesDetails", "http://www.humacyte.com/role/ReverseRecapitalizationNarrativeDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r119", "r120", "r122", "r123", "r129", "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/DebtTermLoanDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitCommonstockforfutureissuancesDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitWarrantsNarrativeDetails", "http://www.humacyte.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Common stock warrant liabilities", "verboseLabel": "Private Placement Warrants liability" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedBalanceSheets", "http://www.humacyte.com/role/DebtTermLoanDetails", "http://www.humacyte.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPrivatePlacementWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Expected term (years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/StockholdersEquityDeficitPublicWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r103", "r110" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r102", "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.humacyte.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r495": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r496": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r497": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r498": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r499": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r500": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r501": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r502": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 77 0001818382-22-000180-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001818382-22-000180-xbrl.zip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